var title_f17_25_17808="Erythromelalgia";
var content_f17_25_17808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Erythromelalgia involving the hands in essential thrombocythemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows the presence of erythromelalgia of the hands in a woman with essential thrombocythemia. This condition is associated with burning pain in the feet or hands accompanied by erythema, pallor, or cyanosis, in the presence of palpable pulses, and is common in both essential thrombocythemia and polycythemia vera.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photograph courtesy of Dr. Ayalew Tefferi, Mayo Clinic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17808=[""].join("\n");
var outline_f17_25_17808=null;
var title_f17_25_17809="Paravertebral sympathetic chain";
var content_f17_25_17809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brachial plexus and paravertebral sympathetic chain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram shows the interrelationships of the nerve roots, the sympathetic chain, and the peripheral nerves that can potentially be involved with superior sulcus tumors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17809=[""].join("\n");
var outline_f17_25_17809=null;
var title_f17_25_17810="Autonomic nerve supply to the pancreas";
var content_f17_25_17810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autonomic nerve supply to the pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram of the autonomic nerve supply to the pancreas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Originally published in Skandalakis JE, Gray SW, Rowe JS Jr, et al. Anatomical complications of pancreatic surgery. Contemp Surg 1979; 15:17. Redrawn in Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Reproduced with permission. Copyright &copy; 1979.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17810=[""].join("\n");
var outline_f17_25_17810=null;
var title_f17_25_17811="Inferior epigastric vessels round ligament";
var content_f17_25_17811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Laparoscopic view of inferior epigastric vessels and round ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laparoscopic view of the inferior epigastric vessels, located lateral to the medial umbilical ligaments (obliterated umbilical ligaments), and the round ligament entering the inguinal canal. It is important during placement of the lower abdominal trocars during laparoscopy to avoid the inferior epigastric vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17811=[""].join("\n");
var outline_f17_25_17811=null;
var title_f17_25_17812="Dyphylline: Patient drug information";
var content_f17_25_17812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dyphylline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/11/41139?source=see_link\">",
"     see \"Dyphylline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lufyllin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dyphylline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ulcer disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697357",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you stop smoking, talk with your doctor. How much drug you take may need to be changed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14935204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12406 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17812=[""].join("\n");
var outline_f17_25_17812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012012\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012011\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012016\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012017\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012019\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14935204\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012015\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012020\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012021\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/11/41139?source=related_link\">",
"      Dyphylline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_25_17813="Breast pumps";
var content_f17_25_17813=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Breast pumps (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/25/17813/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/25/17813/contributors\" id=\"au1765\">",
"       Lisa Enger, RN, BSN, IBCLC",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/25/17813/contributors\" id=\"au1788\">",
"       Nancy M Hurst, PhD, RN, IBCLC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/25/17813/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/25/17813/contributors\" id=\"se4702\">",
"       Steven A Abrams, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/25/17813/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/25/17813/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/25/17813?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BREAST PUMP OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     A breast pump is a device that allows a woman to express breast milk from the breasts when it is not possible to breastfeed her infant directly. Many women choose to use a breast pump so that they can continue to provide breast milk while working or if their infant is hospitalized. However, it is not necessary for all women who breastfeed to purchase or use a breast pump.",
"    </p>",
"    <p>",
"     This topic review discusses the use of breast pumps and breast milk storage and preparation. Additional breastfeeding topics are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHOOSING A PUMP",
"     </span>",
"    </p>",
"    <p>",
"     There are a wide variety and quality of breast pumps available, each of which varies in cost, quality, and efficiency; the optimal pump depends upon your needs and how frequently the pump will be used. No one pump is best for every woman. In most situations, you should wait to buy a pump until after your infant is born; this will allow you to determine your and your infant's individual needs.",
"    </p>",
"    <p>",
"     Some of the most common reasons women use a breast pump include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       To stimulate your milk production when you are unable to nurse your infant after birth, if your infant is in the hospital",
"      </li>",
"      <li>",
"       To maintain your milk supply when you are away from your infant (eg, after returning to work)",
"      </li>",
"      <li>",
"       To provide your baby with your breast milk",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Hospital grade electric breast pump",
"     </span>",
"     &nbsp;&mdash;&nbsp;A hospital grade electric breast pump is recommended for women who must initiate and maintain their milk production for extended periods of time, such as those with a premature or hospitalized infant who cannot nurse immediately after delivery [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/1\">",
"      1",
"     </a>",
"     ]. This is the most efficient, easiest, and fastest type of pump, and is the most effective way to maintain an adequate milk supply for an infant's full nutritional needs [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/2\">",
"      2",
"     </a>",
"     ]. Although most women prefer to pump both breasts at the same time (double pump), this machine can be used to pump one breast at a time [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The amount of time it takes to empty both breasts will vary depending upon the woman's experience with the pump, although it generally takes about 10 to 15 minutes after let-down has occurred. A hospital grade pump can be safely used by more than one woman in a hospital and may be rented for home use. Some commercial health insurance plans cover the cost of purchasing or renting a hospital grade breast pump.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Personal electric pump",
"     </span>",
"     &nbsp;&mdash;&nbsp;A smaller, personal electric breast pump is designed for one woman to use several times per day. These pumps are not as effective in establishing and maintaining a woman's milk supply long term (without some direct breastfeeding). Most models allow you to pump one or two breasts at a time. The life expectancy of these pumps is generally about one year, depending upon how frequently the pump is used.",
"    </p>",
"    <p>",
"     Most of the high quality personal pumps are self-contained in a carrying case (as a backpack or shoulder bag) that includes the motor, supplies, and in some cases, a cooler for storing milk. The pump and related equipment are small and light enough to carry on a daily basis and can pump one or both breasts. These pumps work well for the working mother or when traveling. These pumps are intended for use by only one woman; sharing or re-selling of a personal pump is not recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Single-sided pump",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you want to pump occasionally so that you can leave your baby with a caregiver for a few hours, a single-sided breast pump may be adequate [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/4\">",
"      4",
"     </a>",
"     ]. Single pumps are powered by hand, batteries, or electricity. Single breast pumps are not recommended if you need to maintain your milk supply while working or for a premature infant, but are adequate for occasional use. Pumping both breasts with a single-sided pump takes about 20 to 30 minutes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5957464\">",
"     <span class=\"h1\">",
"      COVERAGE OF COSTS IN THE UNITED STATES",
"     </span>",
"    </p>",
"    <p>",
"     As of August 1, 2012, the Affordable Healthcare Act under the Women&rsquo;s Preventive Services: Required Health Plan Coverage Guidelines has expanded to include the following coverage: &ldquo;Comprehensive lactation support and counseling by a trained provider during pregnancy",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     in the post partum period, and the costs for renting breastfeeding equipment in conjunction with each birth. Mothers should contact their insurance providers to verify their coverage. It is currently up to each insurance company to determine the type of pump covered and length of coverage.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HOW TO PUMP",
"     </span>",
"    </p>",
"    <p>",
"     Each of the different types of pumps has specific instructions for use. The following are general recommendations for use of a breast pump.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Wash your hands with soap and water before pumping. It is not necessary to wash the breasts or nipples [",
"       <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/5\">",
"        5",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Ensure that the pump pieces and milk collection containers are clean. Washing with hot soapy water is sufficient; it is not necessary to sterilize the pump or bottles when pumping for a healthy infant. Do not wash the pump tubing because it cannot be dried easily. If moisture or milk is noted in the tubing, contact the manufacturer. It may be necessary to purchase new tubing.",
"      </li>",
"      <li>",
"       Most women prefer to sit while pumping. For electric pumps, set the pump's suction strength to a comfortable level. Pumping should not hurt, even if you have sore or painful nipples. On some pump models, the cycling speed (the number of suction cycles per minute) can be set based on personal preference; some women start with a rapid cycle speed then slow the speed after their milk begins to flow in a steady stream. (See",
"       <a class=\"local\" href=\"#H7\">",
"        'Let-down'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Be sure that the flanges (the cone-shaped pieces that fit over the breasts and nipples) are the appropriate size. When pumping, the nipples should not rub against the tunnels of the flanges. It may be necessary to purchase larger flanges to pump comfortably and stimulate the breasts correctly. Be sure to purchase pump parts that are the same brand as that of the pump. Parts should not be interchanged from different manufacturers.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Let-down",
"     </span>",
"     &nbsp;&mdash;&nbsp;Let-down, also called the milk-ejection reflex, is the term used to describe what happens in the breasts when milk is released from the milk glands into the milk ducts (",
"     <a class=\"graphic graphic_figure graphicRef72583 \" href=\"UTD.htm?8/30/8674\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Let-down is a conditioned response usually brought on by the infant sucking at the breast and stimulating the release of the hormone oxytocin in the mother's brain. This causes cells in the breast to eject the milk. Some women experience let-down at other times, by just thinking about their baby or hearing their baby cry. For women who are dependent on the pump exclusively for breast stimulation (mothers of hospitalized infants), just seeing or hearing the breast pump may cause milk ejection.",
"    </p>",
"    <p>",
"     Let-down usually occurs within the first minute or two of nursing or pumping. Some women feel a sense of heaviness or tingling in the breasts during let-down while other women cannot feel let-down at all.",
"    </p>",
"    <p>",
"     Some women have difficulty with let-down while pumping. In this situation, only drops of milk are seen rather than streams of milk flowing from the nipples. Tips to promote let-down include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Gently massage the breasts before pumping",
"      </li>",
"      <li>",
"       Apply a warm wet cloth to the breasts before pumping",
"      </li>",
"      <li>",
"       Pump in a quiet, darkened room to avoid distractions",
"      </li>",
"      <li>",
"       Look at a picture of the baby or smell the baby's blanket",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Pumping at work",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who return to work after birth and want to continue breastfeeding will need to express their milk several times during their working hours. Pumping will allow you to maintain your milk production and provide your expressed breast milk to your infant while you are separated. Pumping on a schedule similar to their infant's feeding pattern is usually sufficient; for most women, this means pumping two to three times over eight hours. If possible, starting back to work in the middle of the work week will help to ease the transition.",
"    </p>",
"    <p>",
"     It can be challenging to find the time and space to pump, especially for women who do not have a private office. You should discuss your need for a private space with your employer prior to returning to work. It may be helpful to speak with co-workers who have returned to work and pumped to determine if a private space is available. Some employers offer a \"pump room\" or other private area.",
"    </p>",
"    <p>",
"     The Patient Protection and Affordable Care Act signed into law in March 2010 mandates employers to provide &ldquo;reasonable break time for an employee to express breast milk for her nursing child for one year after the child&rsquo;s birth each time such employee has need to express the milk&rdquo;. Provisions by employers for &ldquo;a place other than a bathroom, that is shielded from view and free from intrusion from coworkers and the public, which may be used by an employer to express breast milk&rdquo; is also mandated [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/6\">",
"      6",
"     </a>",
"     ]. A fact sheet outlining the provisions of this act is available online at",
"     <a class=\"external\" href=\"file://op.bna.com/dlrcases.nsf/id/vros-87mrpv/$File/breaktime.pdf\">",
"      file://op.bna.com/dlrcases.nsf/id/vros-87mrpv/$File/breaktime.pdf",
"     </a>",
"     .",
"    </p>",
"    <p>",
"     The United States Center for Disease Control and Prevention has published a number of articles that address the need for support of breastfeeding women who work, citing the health as well as economic benefits of breastfeeding. These articles are available online at",
"     <a class=\"external\" href=\"file://www.cdc.gov/breastfeeding/resources/guide.htm\">",
"      www.cdc.gov/breastfeeding/resources/guide.htm",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Pumping for a premature or ill infant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women whose infants are hospitalized due to prematurity or illness following birth must rely on a breast pump to stimulate their milk production. The first few weeks following delivery are critical in establishing a milk supply that meets the needs of their infants. Several important hormonal and structural changes take place within the breast during this time.",
"    </p>",
"    <p>",
"     The amount of breast stimulation during this time is critical to this process. Women should pump early (within the first six hours after delivery) [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/7\">",
"      7",
"     </a>",
"     ] and frequently (at least eight times per day) for about 15 minutes each time until they are producing about one -half ounce (15 mL) per breast. Thereafter, most women find that pumping six to eight times daily and expressing for about two minutes after milk flow stops is sufficient to maintain an adequate milk supply. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13657?source=see_link\">",
"      \"Breast milk expression for the preterm infant\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     One way that mothers who are pumping for their hospitalized infants can stimulate and increase supply is by &ldquo;hands on pumping&rdquo;. Mothers initiate pumping as soon as possible after delivery. Mothers massage both breasts prior to the start of pumping. They then double pump with massaging and compressing the breasts during pumping as much as possible. Some mothers will use a hands-free pumping device to make this easier. Once the milk flow is reduced to drops, mothers should stop the pump and further massage their breasts. Mothers then finish the session by hand expression into the collection container or using the electric pump with massage to fully empty the breasts. The following is a link to a video demonstrating ways to increase milk production for mothers who are pumping (",
"     <a class=\"external\" href=\"file://newborns.stanford.edu/Breastfeeding/MaxProduction.html\">",
"      Stanford School of medicine: Maximizing milk production with Hands on Pumping",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Although milk volume varies with pumping after premature delivery, it generally increases from 320 mL (about 11 ounces) at the end of the first week to subsequent ranges from 450 to 1200 mL (about 2 to 5 cups) per day. Check with your healthcare provider or lactation consultant on the volume of milk required for your infant and ways to improve your milk supply if needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      STORING BREAST MILK",
"     </span>",
"    </p>",
"    <p>",
"     The temperature at which milk is stored depends upon the intended duration of storage prior to feeding. Breast milk pumped for the healthy child may be safely stored in the refrigerator (up to five days) or freezer (48 hours to 6 months) [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/8,9\">",
"      8,9",
"     </a>",
"     ]. It can even be left at room temperature (approximately 77 to 79&ordm;F or 25 to 27&ordm;C) for up to four hours [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/10,11\">",
"      10,11",
"     </a>",
"     ]. Thawed breast milk can be safely stored in a standard refrigerator for up to 24 hours. Milk that was frozen and then thawed can be refrozen. If your infant is hospitalized, check with the staff on storage guidelines for that facility.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Breast milk storage containers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Breast milk should be placed in a sealed, clean, glass or rigid plastic bottle designed for storing food products. Although plastic breast milk storage bags are not recommended for hospitalized infants due to the loss of some nutrients [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/1\">",
"      1",
"     </a>",
"     ], plastic bags can be used to store breast milk for healthy infants.",
"    </p>",
"    <p>",
"     Milk should be stored in small amounts (one to four ounces) and labeled using permanent ink and a waterproof label. The label should indicate the date the milk was pumped. Milk from different pumping sessions may be combined; the milk should be cooled in the refrigerator before it is combined. Milk that is warm or refrigerated should not be added to frozen milk. The oldest milk should be used first.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      PREPARING PUMPED BREAST MILK FOR FEEDING",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Thawing and warming breast milk",
"     </span>",
"     &nbsp;&mdash;&nbsp;Milk can be warmed gradually to approximately 98&ordm;F (37&ordm;C) in a warm water bath (not to exceed 20 to 30 minutes). One should avoid submerging bottles in water when using the warm water bath method. After warming the milk, the temperature should be tested immediately before it is given to an infant; the milk should feel lukewarm or at room temperature, but never hot. Milk should be gently swirled to redistribute the cream that often rises to the top during refrigeration.",
"    </p>",
"    <p>",
"     Rapid heating or microwaving adversely affects the breast milk's immunologic and nutritional properties. Microwaving also heats milk unevenly, which may potentially burn an infant's mouth [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/12\">",
"      12",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Although freshly pumped breast milk has antibacterial properties, milk stored in a refrigerator for more than a day or two begins to lose this property [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/13-16\">",
"      13-16",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      HOW MUCH MILK SHOULD I OFFER?",
"     </span>",
"    </p>",
"    <p>",
"     Many women who exclusively pump or pump while at work wonder how much breast milk their infant will need at each feeding.",
"    </p>",
"    <p>",
"     The volume of breast milk a baby needs increases with age; infants who are exclusively breastfed require approximately 23 to 24 ounces of breast milk at one month of age and 24 to 30 ounces at six months of age. After six months, most infants begin to consume other foods, and less milk may be needed [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/17\">",
"      17",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     One way to estimate the amount of milk a baby needs for a feeding is to multiply the baby&rsquo;s weight in pounds by 2.5, which will give you the overall volume for 24 hours [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/18\">",
"      18",
"     </a>",
"     ]. You can then divide that by the number of",
"     <span class=\"nowrap\">",
"      feedings/day.",
"     </span>",
"     This is a general guideline with the understanding that some babies will want more and others less, and that the volume at each feeding can vary as well.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Feeding breast milk with a bottle",
"     </span>",
"     &nbsp;&mdash;&nbsp;Babies feed very differently from a bottle compared to the breast. Milk flow from a bottle is fast and the baby usually eats very quickly, sometimes by gulping. Many mothers feel that their infant drinks more milk when he or she is fed with a bottle than when nursed at the breast. It is common to worry that you will not pump enough milk to keep up with this volume.",
"    </p>",
"    <p>",
"     Babies have little control over milk flow from a bottle while they have full control over milk flow from the breast. To minimize this problem, it may help to pace the baby while bottle feeding by taking frequent breaks. Slow flow bottle nipples are available and may help to minimize the differences in flow between bottle and breast feeding. A feeding should take 10 to 15 minutes or more, just like at the breast.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHAT IF I HAVE QUESTIONS?",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider or your child's healthcare provider is the best source of information for questions and concerns related to breastfeeding, pumping, storage of milk, or bottle feeding your infant. Certified lactation consultants, or LCs, are available to mothers and infants at most hospitals as well as privately, and can be an invaluable resource for instruction and troubleshooting for problems. (See",
"     <a class=\"local\" href=\"#H22\">",
"      'Finding a lactation consultant'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366819\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366826\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=see_link\">",
"      Patient information: Breast pumps (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/27/4531?source=see_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=see_link\">",
"      Patient information: When a baby is born premature (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366839\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366851\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43864?source=see_link\">",
"      Maternal nutrition during lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"      Nutrition in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6727?source=see_link\">",
"      Nutritional composition of human milk for full-term infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"      Principles of medication use during lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=see_link\">",
"      Use of psychotropic medications in breastfeeding women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13657?source=see_link\">",
"      Breast milk expression for the preterm infant",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"     <br/>",
"     <br/>",
"     Other breastfeeding resources include:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://newborns.stanford.edu/Breastfeeding/MaxProduction.html\">",
"      Stanford School of medicine: Maximizing milk production with Hands on Pumping",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.bfmed.org/Media/Files/Protocols/Protocol 8 - English revised 2010.pdf\">",
"      Academy of breastfeeding Medicine: Human milk storage",
"     </a>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/breastfeeding\">",
"      www.cdc.gov/breastfeeding",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United States Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://womenshealth.gov/breastfeeding/\">",
"      womenshealth.gov/breastfeeding/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www2.aap.org/healthtopics/breastfeeding.cfm\">",
"      www2.aap.org/healthtopics/breastfeeding.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Working and Pumping",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.workandpump.com/\">",
"      www.workandpump.com",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Finding a lactation consultant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certified lactation consultants, or LCs, are available at most hospitals as well as privately, and can be an invaluable resource for instructions about breastfeeding, pumping, milk storage, and bottle feeding breast milk. The websites listed below have information about finding a lactation consultant or breastfeeding counselor.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       La Leche League",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lalecheleague.org/\">",
"      www.lalecheleague.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Board of Lactation Consultant Examiners",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.iblce.org/\">",
"      www.iblce.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 703-560-7330",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Lactation Consultant Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ilca.org/\">",
"      www.ilca.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 919-861-5577",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Finding a breast pump",
"     </span>",
"     &nbsp;&mdash;&nbsp;Quality breast pumps, both hospital-grade and personal use, are available at various sites (retail stores, pharmacies and hospitals) for rental and purchase. The websites listed below provide information about various models and pricing.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medela Inc.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(www.medela.com)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Ameda, Inc.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(www.ameda.com)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/25/17813/abstract/1-5,8,10,12-17,19,20\">",
"      1-5,8,10,12-17,19,20",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/25/17813?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Hurst NM, Meier PP. Breastfeeding the Preterm Infant. In: Breastfeeding and Human Lactation, 4th ed., Riordan J &amp; Wambach K (Ed), Jones and Bartlett publishers, Boston 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/2\">",
"      Meier PP, Engstrom JL, Hurst NM, et al. A comparison of the efficiency, efficacy, comfort, and convenience of two hospital-grade electric breast pumps for mothers of very low birthweight infants. Breastfeed Med 2008; 3:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/3\">",
"      Becker GE, McCormick FM, Renfrew MJ. Methods of milk expression for lactating women. Cochrane Database Syst Rev 2008; :CD006170.",
"     </a>",
"    </li>",
"    <li>",
"     Lawrence, RA, Lawrence, RM. Breastfeeding: A Guide for the Medical Professional, Mosby, St. Louis, MO 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/5\">",
"      Tully MR. Recommendations for handling of mother's own milk. J Hum Lact 2000; 16:149.",
"     </a>",
"    </li>",
"    <li>",
"     Fact Sheet #73: Break Time for Nursing Mothers under FLSA. file://www.dol.gov/whd/regs/compliance/whdfs73.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/7\">",
"      Parker LA, Sullivan S, Krueger C, et al. Effect of early breast milk expression on milk volume and timing of lactogenesis stage II among mothers of very low birth weight infants: a pilot study. J Perinatol 2012; 32:205.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, F, Tully, MR. Best Practice for Expressing, Storing and Handling Human Milk, 2nd ed, Human Milk Banking Association of North America, Inc., Raleigh, NC 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/9\">",
"      Slutzah M, Codipilly CN, Potak D, et al. Refrigerator storage of expressed human milk in the neonatal intensive care unit. J Pediatr 2010; 156:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/10\">",
"      Hamosh M, Ellis LA, Pollock DR, et al. Breastfeeding and the working mother: effect of time and temperature of short-term storage on proteolysis, lipolysis, and bacterial growth in milk. Pediatrics 1996; 97:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/11\">",
"      Rechtman DJ, Lee ML, Berg H. Effect of environmental conditions on unpasteurized donor human milk. Breastfeed Med 2006; 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/12\">",
"      Quan R, Yang C, Rubinstein S, et al. Effects of microwave radiation on anti-infective factors in human milk. Pediatrics 1992; 89:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/13\">",
"      Igumbor EO, Mukura RD, Makandiramba B, Chihota V. Storage of breast milk: effect of temperature and storage duration on microbial growth. Cent Afr J Med 2000; 46:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/14\">",
"      Ogundele MO. Effects of storage on the physicochemical and antibacterial properties of human milk. Br J Biomed Sci 2002; 59:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/15\">",
"      Silvestre D, L&oacute;pez MC, March L, et al. Bactericidal activity of human milk: stability during storage. Br J Biomed Sci 2006; 63:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/16\">",
"      Mart&iacute;nez-Costa C, Silvestre MD, L&oacute;pez MC, et al. Effects of refrigeration on the bactericidal activity of human milk: a preliminary study. J Pediatr Gastroenterol Nutr 2007; 45:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/17\">",
"      Stuff JE, Garza C, Boutte C, et al. Sources of variance in milk and caloric intakes in breast-fed infants: implications for lactation study design and interpretation. Am J Clin Nutr 1986; 43:361.",
"     </a>",
"    </li>",
"    <li>",
"     Casemore, S. Exclusively Pumping Breast Milk: A Guide to Providing Expressed Breast Milk for Your Baby, 1, Gray Lion Publishing, Ontario 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17813/abstract/19\">",
"      Hayes DK, Prince CB, Espinueva V, et al. Comparison of manual and electric breast pumps among WIC women returning to work or school in Hawaii. Breastfeed Med 2008; 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     How much expressed milk will my baby need? www.kellymom.com/bf/pumping/milkcalc.html (Accessed on May 08, 2009).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_25_17813=[""].join("\n");
var outline_f17_25_17813=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BREAST PUMP OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHOOSING A PUMP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5957464\">",
"           COVERAGE OF COSTS IN THE UNITED STATES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HOW TO PUMP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           STORING BREAST MILK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           PREPARING PUMPED BREAST MILK FOR FEEDING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           HOW MUCH MILK SHOULD I OFFER?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHAT IF I HAVE QUESTIONS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/30/8674\" title=\"figure 1\">",
"           Breastfeeding anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_25_17814="Cervical plexus";
var content_f17_25_17814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Cervical plexus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cervical plexus is composed of the ventral rami of the first four cervical spinal nerves (ie, C1 through C4). The anterior rami of C2 through C4 emerge from the posterior border of the sternocleidomastoid muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17814=[""].join("\n");
var outline_f17_25_17814=null;
var title_f17_25_17815="Ganciclovir and valganciclovir: An overview";
var content_f17_25_17815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ganciclovir and valganciclovir: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/25/17815/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/25/17815/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/25/17815/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/25/17815/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/25/17815/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/25/17815/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/25/17815/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    was the first antiviral agent approved for the treatment of cytomegalovirus (CMV) infection. It is widely used for the treatment of CMV infections among patients with impaired cell-mediated immunity, particularly persons with poorly controlled and advanced",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    and recipients of solid organ and bone marrow transplantation, who are at high risk for invasive CMV disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    , an oral prodrug that is rapidly converted to ganciclovir, also plays a major role in the treatment and prevention of CMV infections in immunocompromised hosts.",
"   </p>",
"   <p>",
"    An overview of the basic pharmacology, pharmacokinetics, and toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    will be discussed here. Treatment of specific clinical syndromes can be found in the appropriate topics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=see_link\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=see_link\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19093?source=see_link\">",
"     \"Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    (9",
"    <strong>",
"     -",
"    </strong>",
"    [(1,3,-dihydroxy-2-propoxy)methyl] guanine, or DHPG) is an acyclic analog of the nucleoside guanosine. The drug is converted intracellularly to ganciclovir 5'-monophosphate by a viral kinase, which is encoded by the cytomegalovirus (CMV) gene UL97 during infection. Subsequently, cellular kinases catalyze the formation of ganciclovir diphosphate and ganciclovir triphosphate, which is present in 10-fold greater concentrations in CMV or herpes simplex virus (HSV)-infected cells than uninfected cells.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    triphosphate is a competitive inhibitor of deoxyguanosine triphosphate incorporation into DNA and preferentially inhibits viral DNA polymerases more than cellular DNA polymerases. In addition, ganciclovir triphosphate serves as a poor substrate for chain elongation, thereby disrupting viral DNA synthesis by a second route [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    are used primarily in treating cytomegalovirus (CMV) infections. In vitro synergy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    has been observed against CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"     \"Foscarnet: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    also inhibits the replication of other herpesviruses in vitro, including herpes simplex virus types 1 and 2 (HSV-1, HSV-2), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), human herpes virus 6 (HHV-6), and herpes simian B virus at clinically achievable concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Ganciclovir is considered the drug of choice for symptomatic herpes simian B virus disease, including central nervous system infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/4\">",
"     4",
"    </a>",
"    ]. However, other antiviral agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    are usually preferred over ganciclovir for treatment of HSV infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/5\">",
"     5",
"    </a>",
"    ]. There are scant data on the use of ganciclovir or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    for the treatment of severe EBV or HHV-6 infections in the immunocompromised host [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H709290675#H709290675\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISMS OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    resistance can occur in patients receiving prolonged therapy with either intravenous ganciclovir or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    . One study of 76 AIDS patients with cytomegalovirus (CMV) retinitis treated initially with ganciclovir reported resistance in 11 percent of patients at six months of treatment and 28 percent at nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the UL97-encoded CMV phosphotransferase have been associated with resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/9\">",
"     9",
"    </a>",
"    ], as have alterations in UL54-encoded viral DNA polymerase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/10\">",
"     10",
"    </a>",
"    ]. It has been postulated that UL97 mutations arise first and confer moderate resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    but not to other CMV antivirals, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    . With continued therapy, DNA polymerase mutations may subsequently appear, leading to high-level resistance to ganciclovir with cross-resistance to cidofovir and, sometimes, resistance to foscarnet [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BASIC PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    is excreted, unmodified, in the urine with a plasma half-life of two to four hours; the intracellular half-life of ganciclovir triphosphate is considerably longer, about 16.5 hours. Clearance is directly correlated to glomerular filtration rate; therefore, dosage adjustment is required in patients with impaired renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Ganciclovir is also available as an oral capsule, but this formulation is rarely used now because of its poor bioavailability.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    , an L-valyl ester of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , is well absorbed after oral administration and rapidly hydrolyzed to ganciclovir in the intestinal wall and liver [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The absolute bioavailability of ganciclovir from valganciclovir tablets (taken with food) is approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/15\">",
"     15",
"    </a>",
"    ]. Systemic exposure of a 900 mg dose of valganciclovir in adults is similar to that attained by a single dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of intravenous ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25347350\">",
"    <span class=\"h1\">",
"     ROUTES OF ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    is given primarily as an intravenous formulation rather than orally because of its poor bioavailability (ie, 6 percent) that is only modestly increased by food [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Intravenous ganciclovir is usually used for induction treatment of severe cytomegalovirus (CMV) disease, such as sight-threatening retinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\", section on 'IV ganciclovir and IV foscarnet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    intraocular implant is also available for the treatment of CMV retinitis. This device releases ganciclovir at a rate of 1 mcg per hour, but requires replacement about every six months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/18\">",
"     18",
"    </a>",
"    ]. This implant was a major advance in the treatment of CMV retinitis because it delivered high intraocular drug levels. Ganciclovir intraocular implants, while avoiding systemic side effects, can be associated with complications of ophthalmologic surgery, such as endophthalmitis and intravitreal bleeding, and may increase the risk of early retinal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/19\">",
"     19",
"    </a>",
"    ]. The use of an implant will also not protect against systemic CMV disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent development of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    was a major advance in the treatment of CMV retinitis, since valganciclovir provides excellent systemic concentrations of drug and the advantage of avoiding catheter-related complications associated with chronic intravenous therapies or the complications associated with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    implant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12196018\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for induction therapy is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours followed by 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    as a single daily infusion for maintenance therapy. The duration of therapy will depend on the host and the severity of disease. Generally speaking, the duration of induction is 14 to 21 days in the HIV-infected host with invasive infection while the induction period is 7 to 14 days in the transplant patient with invasive disease.",
"   </p>",
"   <p>",
"    In patients able to take and absorb oral medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    is a reasonable alternative to intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for both induction and maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/20\">",
"     20",
"    </a>",
"    ], though some experts prefer IV ganciclovir, or ganciclovir intraocular implants plus valganciclovir, for induction therapy of sight-threatening cytomegalovirus (CMV) retinitis.",
"   </p>",
"   <p>",
"    The dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , in adult patients with normal renal function, is 900 mg twice daily for 21 days during induction therapy followed by single daily dosing during maintenance therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\", section on 'Treatment regimens for CMV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4687077\">",
"    <span class=\"h2\">",
"     Bone marrow suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    are both associated with bone marrow suppression, particularly leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/21\">",
"     21",
"    </a>",
"    ]. The frequency and severity of these hematologic abnormalities varies widely in different patient populations.",
"   </p>",
"   <p>",
"    Many potential recipients of these drugs, particularly patients with hematologic malignancies or advanced",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    also have other factors contributing to myelosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/22\">",
"     22",
"    </a>",
"    ]. In fact, disseminated cytomegalovirus (CMV) per se characteristically suppresses bone marrow production, but antiviral therapy usually results in improvement of hematologic parameters. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    should be used with caution in patients with pre-existing cytopenias; neither drug should be used when the absolute neutrophil count is under 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or when the platelet count is under",
"    <span class=\"nowrap\">",
"     25,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematopoietic growth factors (eg, granulocyte-colony stimulating factor, G-CSF or granulocyte macrophage colony-stimulating factor, GM-CSF) are widely used to counter the effects of myelosuppressive drugs, such as chemotherapeutic agents, and can be given to manage neutropenia in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/3,24-29\">",
"     3,24-29",
"    </a>",
"    ]. Hematopoietic growth factors are particularly useful when ongoing anti-CMV treatment is necessary and the disadvantage of switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    is judged to outweigh the risks of myelosuppression. These growth factors are well tolerated and have been shown to facilitate ganciclovir and valganciclovir dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Growth factors also reduce the risk of bacterial infections, which may be secondary to improved neutrophil chemotaxis and phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/28,33,34\">",
"     28,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=see_link&amp;anchor=H4687766#H4687766\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\", section on 'Use of growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4687084\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some placebo-controlled trials, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    has been associated with an increased frequency of elevated serum creatinine; concomitant administration of other medications with well-known nephrotoxicity, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , has been a frequent confounder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/23\">",
"     23",
"    </a>",
"    ]. The mechanism of nephrotoxicity is unknown, and the risk associated with ganciclovir per se appears to be low. Nevertheless, frequent monitoring of renal function is necessary, at least as much to ensure proper dosing as to look for nephrotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4686872\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many potential drug interactions and overlapping toxicities between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and other agents, particularly cytoreductive chemotherapeutics and immunosuppressive drugs commonly administered to transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/35\">",
"     35",
"    </a>",
"    ]. In such cases, increased frequency of laboratory monitoring is advisable and alternative treatment may be necessary.",
"   </p>",
"   <p>",
"    Nephrotoxicity induced by other drugs (for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ) reduces the clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and thereby increases the risk of myelosuppression.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    , especially at high doses such as those used to treat Pneumocystis pneumonia and nocardiosis, can be both myelosuppressive and nephrotoxic, and therefore co-administration of ganciclovir can be problematic. Co-administration of ganciclovir and imipenem may increase the risk of seizures beyond that of imipenem alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25347319\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of bone marrow suppression, patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    should have a complete blood count (CBC) with a differential at least twice a week during induction therapy.",
"   </p>",
"   <p>",
"    In addition, renal function testing such as serum blood urea nitrogen (BUN) and creatinine should be checked at least weekly during induction therapy, since a decline in renal function may require adjusting the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/36\">",
"     36",
"    </a>",
"    ]. The risk of direct nephrotoxicity is low, but patients receiving ganciclovir are often at increased risk for kidney injury related to comorbidities and nephrotoxic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/35\">",
"     35",
"    </a>",
"    ]. More frequent monitoring should be considered in patients at particularly high risk for nephrotoxicity, such as those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , aminoglycosides, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (including liposomal preparations).",
"   </p>",
"   <p>",
"    During maintenance therapy, the frequency of laboratory monitoring can be reduced and should be individualized. At a minimum, serum creatinine and a complete blood count with differential should be checked at least once a month.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     USE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is classified as a pregnancy category C substance, there are no adequate studies of ganciclovir in pregnant women. Women of child-bearing age should be counseled to use effective contraception during treatment. Similarly, men should be advised to practice barrier contraception during and for at least 90 days following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/25/17815/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25346986\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      , a nucleoside analog, disrupts viral DNA synthesis through selective incorporation of ganciclovir triphosphate, which terminates DNA chain elongation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      has been primarily used for treatment of cytomegalovirus (CMV) infections, although it does have in vitro activity against other herpesviruses, such as human herpes virus 6 (HHV-6). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      resistance, which is associated with mutations in CMV phosphotransferase and DNA polymerase, is seen mainly among immunocompromised patients receiving prolonged therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      is excreted, unmodified, in the urine with a plasma half-life of two to four hours. Dosage adjustment is required in patients with impaired renal function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Basic pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      is available intravenously and orally, although the bioavailability of oral ganciclovir is poor. Oral ganciclovir has been essentially replaced by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      , a well-absorbed prodrug that is rapidly converted to ganciclovir. Oral valganciclovir (900 mg) can achieve similar systemic exposure as a standard dose of intravenous ganciclovir (5",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H25347350\">",
"       'Routes of administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A sustained-release intraocular implant has been shown to be effective in the treatment of CMV retinitis, but requires replacement about every six months.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      intraocular implants, while avoiding systemic side effects, can be associated with complications of ophthalmologic surgery, such as endophthalmitis and intravitreal bleeding. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25347350\">",
"       'Routes of administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      are associated with bone marrow suppression, particularly leukopenia, which can usually be managed with hematopoietic growth factors. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      therapy, patients should be monitored for hematologic and renal toxicity. Prior to administration, drug-drug interactions should also be reviewed by the clinician. (See",
"      <a class=\"local\" href=\"#H25347319\">",
"       'Patient monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4686872\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/1\">",
"      Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/2\">",
"      Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990; 39:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/3\">",
"      Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/4\">",
"      Cohen JI, Davenport DS, Stewart JA, et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1). Clin Infect Dis 2002; 35:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/5\">",
"      Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol 2010; 49:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/6\">",
"      Venturi C, Bueno J, Gavalda J, et al. Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant Proc 2009; 41:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/7\">",
"      Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007; 69:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/8\">",
"      Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998; 177:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/9\">",
"      Chou S, Guentzel S, Michels KR, et al. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/10\">",
"      Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66:7146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/11\">",
"      Erice A, Gil-Roda C, P&eacute;rez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/12\">",
"      Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis 1997; 176:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/13\">",
"      Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/14\">",
"      Cvetkovi RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65:859.",
"     </a>",
"    </li>",
"    <li>",
"     Genentech, Inc. Valcyte full prescribing information. file://www.gene.com/gene/products/information/valcyte/pdf/pi.pdf (Accessed on April 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/16\">",
"      Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999; 37:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/17\">",
"      Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/18\">",
"      Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med 1998; 158:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/19\">",
"      Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/20\">",
"      Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/21\">",
"      Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/22\">",
"      Groopman JE. Antiretroviral therapy and immunomodulators in patients with AIDS. Am J Med 1991; 90:18S.",
"     </a>",
"    </li>",
"    <li>",
"     Genentech, Inc., 2010. Cytovene-IV (ganciclovir sodium for injection). file://www.gene.com/gene/products/information/cytovene/pdf/pi.pdf (Accessed on July 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/24\">",
"      Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/25\">",
"      Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/26\">",
"      Davey RT Jr, Davey VJ, Metcalf JA, et al. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991; 164:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/27\">",
"      Walsh C, Wernz JC, Levine A, et al. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 1993; 6:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/28\">",
"      Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/29\">",
"      Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 2000; 30:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/30\">",
"      Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur J Clin Microbiol Infect Dis 1994; 13 Suppl 2:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/31\">",
"      Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991; 9:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/32\">",
"      Ross SD, DiGeorge A, Connelly JE, et al. Safety of GM-CSF in patients with AIDS: a review of the literature. Pharmacotherapy 1998; 18:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/33\">",
"      Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992; 43:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/34\">",
"      Pitrak DL. Filgrastim treatment of HIV-infected patients improves neutrophil function. AIDS 1999; 13 Suppl 2:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/35\">",
"      Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 2010; 67:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/25/17815/abstract/36\">",
"      Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004; 38:1651.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019661s030lbl.pdf (Accessed on July 19, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8342 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17815=[""].join("\n");
var outline_f17_25_17815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25346986\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISMS OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BASIC PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25347350\">",
"      ROUTES OF ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12196018\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4687077\">",
"      Bone marrow suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4687084\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4686872\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25347319\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      USE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25346986\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=related_link\">",
"      AIDS-related cytomegalovirus gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19093?source=related_link\">",
"      Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=related_link\">",
"      Human herpesvirus 6 infection in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=related_link\">",
"      Treatment of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_25_17816="Propofol: Drug information";
var content_f17_25_17816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Propofol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/57/39827?source=see_link\">",
"    see \"Propofol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"    see \"Propofol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diprivan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diprivan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      General Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F214588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage must be individualized based on total body weight and titrated to the desired clinical effect. Wait at least 3-5 minutes between dosage adjustments to clinically assess drug effects. Smaller doses are required when used with narcotics. The following are general dosing guidelines (see &ldquo;Abbreviations&rdquo; section in front section for explanation of ASA-PS classes):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General anesthesia: Note:",
"     </b>",
"     Increase dose in patients with chronic alcoholism (Fassoulaki, 1993); decrease dose with acutely intoxicated (alcoholic) patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Healthy adults, ASA-PS 1 or 2, &lt;55 years: I.V.: 2-2.5 mg/kg (~40 mg every 10 seconds until onset of induction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Debilitated, ASA-PS 3 or 4: Refer to geriatric dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Healthy adults, ASA-PS 1 or 2, &lt;55 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V. infusion: Initial: 100-200 mcg/kg/minute (or 6-12 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) for 10-15 minutes; usual maintenance infusion rate: 50-100 mcg/kg/minute (or 3-6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) to optimize recovery time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V. intermittent bolus: 25-50 mg increments as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Debilitated, ASA-PS 3 or 4: I.V. Infusion: Refer to geriatric dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Monitored anesthesia care sedation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Healthy adults, ASA-PS 1 or 2, &lt;55 years: Slow I.V. infusion: 100-150 mcg/kg/minute (or 6-9 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) for 3-5 minutes",
"     <b>",
"      or",
"     </b>",
"     slow injection: 0.5 mg/kg over 3-5 minutes followed by I.V. infusion of 25-75 mcg/kg/minute (or 1.5-4.5 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"     <b>",
"      or",
"     </b>",
"     incremental bolus doses: 10 mg or 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Debilitated or ASA-PS 3 or 4 patients: Use 80% of healthy adult dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      ICU sedation in intubated mechanically-ventilated patients:",
"     </b>",
"     Avoid rapid bolus injection; individualize dose and titrate to response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion:",
"     </i>",
"     Initial: 5 mcg/kg/minute (or 0.3 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); increase by 5-10 mcg/kg/minute (or 0.3-0.6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) every 5-10 minutes until desired sedation level is achieved; usual maintenance: 5-50 mcg/kg/minute (or 0.3-3  mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); reduce dose after adequate sedation established and adjust to response (eg, evaluate frequently to use minimum dose for sedation). Daily interruption with retitration or a light target level of sedation is recommended to minimize prolonged sedative effects (Barr, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Elderly, debilitated, or ASA-PS 3 or 4 patients: Refer to geriatric dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Postoperative nausea and vomiting (PONV), rescue therapy (unlabeled use; Gan, 2007; Unlugenc, 2004):",
"     </b>",
"     I.V.: 20 mg, may be repeated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Refractory status epilepticus (unlabeled use):",
"     </b>",
"     1-2 mg/kg bolus (optional), then 33-167 mcg/kg/minute (or 2-10 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) (Claassen, 2002; K&auml;lvi&auml;inen, 2007; Meierkord, 2010; Rossetti, 2004); titrate to desired effect (eg, burst suppression on EEG).",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;83 mcg/kg/minute (or &gt;5  mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) may increase the risk of hypotension and propofol-related infusion syndrome (PRIS) especially if used for &gt;48 hours; consider alternative therapies to avoid the risk of PRIS in longer term propofol infusions.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F214606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"      see \"Propofol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage must be individualized based on total body weight and titrated to the desired clinical effect; wait at least 3-5 minutes between dosage adjustments to clinically assess drug effects; smaller doses are required when used with narcotics; the following are general dosing guidelines:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      General anesthesia: Note:",
"     </b>",
"     Increase dose in patients with chronic alcoholism (Fassoulaki, 1993); decrease dose with acutely intoxicated (alcoholic) patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Induction:",
"     </i>",
"     I.V.: Healthy children 3-16 years, ASA-PS 1 or 2: 2.5-3.5 mg/kg over 20-30 seconds; use a lower dose for children ASA-PS 3 or 4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     I.V. infusion: Healthy children 2 months to 16 years, ASA-PS 1 or 2: 125-300 mcg/kg/minute (or 7.5-18 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); after 30 minutes, if clinical signs of light anesthesia are absent, decrease the infusion rate. Children &le;5 years may require larger infusion rates compared to older children.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F214589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General anesthesia: Note:",
"     </b>",
"     Increase dose in patients with chronic alcoholism (Fassoulaki, 1993); decrease dose with acutely intoxicated (alcoholic) patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction:",
"     </i>",
"     Elderly, debilitated, ASA-PS 3 or 4: I.V.: 1-1.5 mg/kg (~20 mg every 10 seconds until onset of induction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     Elderly, debilitated, ASA-PS 3 or 4: I.V. infusion: 50-100 mcg/kg/minute (or 3-6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Monitored anesthesia care sedation:",
"     </b>",
"     Elderly, debilitated, ASA-PS 3 or 4: I.V.: Use 80% of healthy adult dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ICU sedation in intubated mechanically-ventilated patients:",
"     </b>",
"     Avoid rapid bolus injection; individualize dose and titrate to response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion:",
"     </i>",
"     Elderly, debilitated, ASA-PS 3 or 4: Use 80% of healthy adult dose; reduce dose after adequate sedation established and adjust to response (eg, evaluate frequently to use minimum dose for sedation). Daily interruption with retitration or a light target level of sedation is recommended to minimize prolonged sedative effects (Barr, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13135189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13135190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, emulsion: 10 mg/mL (20 mL, 50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diprivan&reg;: 10 mg/mL (20 mL [DSC], 50 mL, 100 mL) [contains edetate disodium, egg lecithin, soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F214560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Strict aseptic technique must be maintained in handling although a preservative has been added. Do not use if contamination is suspected. Do not administer through the same I.V. catheter with blood or plasma. Tubing and any unused portions of propofol vials should be discarded after 12 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     To reduce pain associated with injection, use larger veins of forearm or antecubital fossa; lidocaine I.V. (1 mL of a 1% solution) may also be used prior to administration or it may be added to propofol immediately before administration in a quantity not to exceed 20 mg lidocaine per 200 mg propofol. Do not use filter &lt;5 micron for administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F214634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in  D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR. Do not mix with other therapeutic agents prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alfentanil, aminophylline, ampicillin, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, cefazolin, cefotaxime, cefotetan, cefoxitin, cefuroxime, chlorpromazine, cimetidine, cisplatin, clindamycin, cyclophosphamide, cyclosporine, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, fluorouracil, furosemide, ganciclovir, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ifosfamide, imipenem/cilastatin, inamrinone, insulin (regular), isoproterenol, ketamine, labetalol, magnesium sulfate, mannitol, meperidine, milrinone, nafcillin, nalbuphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, paclitaxel, palonosetron, pentobarbital, phenobarbital, piperacillin, potassium chloride, prochlorperazine edisylate, propranolol, ranitidine, scopolamine, sodium bicarbonate, succinylcholine, sufentanil, thiopental, ticarcillin/clavulanate, tigecycline.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amikacin, amphotericin B, calcium chloride, diazepam, doripenem, gentamicin, levofloxacin, methotrexate, methylprednisolone sodium succinate, minocycline, mitoxantrone, pantoprazole, phenytoin, tobramycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ascorbic acid, atracurium, atropine, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, cisatracurium, digoxin, doxorubicin, lidocaine, lorazepam, metoclopramide, midazolam, morphine, pancuronium, phenylephrine, telavancin, vancomycin, vecuronium, verapamil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ondansetron, thiopental.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturers recommend that propofol not be mixed with any other therapeutic agents prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F214559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of anesthesia in patients &ge;3 years of age; maintenance of anesthesia in patients &gt;2 months of age; in adults, for monitored anesthesia care sedation during procedures; sedation in intubated, mechanically-ventilated ICU patients",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F214624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postoperative antiemetic; refractory delirium tremens (case reports)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F214636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diprivan&reg; may be confused with Diflucan&reg;, Ditropan",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Propofol may be confused with fospropofol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Propofol may be confused with bupivacaine liposome injectable suspension (Exparel&trade;) in operating rooms and other surgical areas due to their similar white, milky appearance especially when prepared in syringes. Bupivacaine liposome injectable suspension (Exparel&trade;) is intended only for administration via infiltration into the surgical site (and",
"       <b>",
"        not",
"       </b>",
"       for systemic use). Confusion with propofol may lead to accidental intravenous administration of Exparel&trade; instead of the intended propofol. Therefore, to avoid potential confusion ISMP recommends that all vials be separated when stocked in common areas and all prepared syringes be labeled.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F214626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (children 17%; adults 3% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Movement (children 17%; adults 3% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site burning, stinging, or pain (children 10%; adults 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea lasting 30-60 seconds (children 10%; adults 24%), apnea lasting &gt;60 seconds (children 5%; adults 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (children 8%), arrhythmia (1% to 3%), bradycardia (1% to 3%), cardiac output decreased (1% to 3%; concurrent opioid use increases incidence), tachycardia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (1% to 3%), rash (children 5%; adults 1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (3% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory acidosis during weaning (3% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, amblyopia, anaphylaxis, anaphylactoid reaction, anticholinergic syndrome, asystole, atrial arrhythmia, bigeminy, cardiac arrest, chills, cough, dizziness, delirium, discoloration (green [urine, hair, or nailbeds]), extremity pain, fever, flushing, hemorrhage, hypersalivation, hypertonia, hypomagnesemia, hypoxia, infusion site reactions (including pain, swelling, blisters and/or tissue necrosis following accidental extravasation); laryngospasm, leukocytosis, lung function decreased, myalgia, myoclonia (rarely including convulsions and opisthotonos), nausea, pancreatitis, paresthesia, phlebitis, postoperative unconsciousness with or without increase in muscle tone, premature atrial contractions, premature ventricular contractions, pulmonary edema, propofol-related infusion syndrome, rhabdomyolysis, somnolence, syncope, thrombosis, urine cloudy, vision abnormality, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F214563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to propofol or any component of the formulation; hypersensitivity to eggs, egg products, soybeans, or soy products; when general anesthesia or sedation is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F214546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: May rarely cause hypersensitivity, anaphylaxis, anaphylactoid reactions, angioedema, bronchospasm, and erythema; medications for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertriglyceridemia: Because propofol is formulated within a 10% fat emulsion, hypertriglyceridemia is an expected side effect. Patients who develop hypertriglyceridemia (eg, &gt;500 mg/dL) are at risk of developing pancreatitis. Serum triglyceride levels should be obtained prior to initiation of therapy and every 3-7 days thereafter. Monitoring of serum triglycerides should especially be considered with therapy &gt;48 hours with doses exceeding 50 mcg/kg/minute (Devlin, 2005). An alternative sedative agent should be employed if significant hypertriglyceridemia occurs. Use with caution in patients with preexisting hyperlipidemia as evidenced by increased serum triglyceride levels or serum turbidity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: The major cardiovascular effect of propofol is hypotension especially if patient is hypovolemic or if bolus dosing is used. Hypotension may be substantial with a reduction in mean arterial pressure occasionally exceeding 30%. Use with caution in patients who are hemodynamically unstable, hypovolemic, or have abnormally low vascular tone (eg, sepsis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection-site reaction: Transient local pain may occur during I.V. injection; lidocaine 1% solution may be administered prior to administration or may be added to propofol immediately prior to administration to reduce pain associated with injection (see Administration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myoclonus: Perioperative myoclonus (eg, convulsions and opisthotonos) has occurred with administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Propofol-related infusion syndrome (PRIS): PRIS is a serious side effect with a high mortality rate (up to 33%) characterized by dysrhythmia (eg, bradycardia or tachycardia), heart failure, hyperkalemia, lipemia, metabolic acidosis, and/or rhabdomyolysis or myoglobinuria with subsequent renal failure. Risk factors include poor oxygen delivery, sepsis, serious cerebral injury, and the administration of high doses of propofol (usually doses &gt;83 mcg/kg/minute or &gt;5 mg/kg/hour for &gt;48 hours), but has also been reported following large dose, short-term infusions during surgical anesthesia. PRIS has also been reported with lower-dose infusions (Chukwuemeka, 2006; Merz, 2006). The onset of the syndrome is rapid, occurring within 4 days of initiation. The mechanism of the syndrome has yet to be determined. Alternate sedative therapy should be considered for patients with escalating doses of vasopressors or inotropes, when cardiac failure occurs during high-dose propofol infusion, when metabolic acidosis is observed, or in whom lengthy and/or high-dose sedation is needed (Barr, 2013; Corbett, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease (ejection fraction &lt;50%) or hypotension; may have more profound adverse cardiovascular responses to propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Use with caution in patients with increased intracranial pressure or impaired cerebral circulation; substantial decreases in mean arterial pressure and subsequent decreases in cerebral perfusion pressure may occur; consider continuous infusion or administer as a slow bolus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection risk: Propofol vials and prefilled syringes have the potential to support the growth of various microorganisms despite product additives intended to suppress microbial growth. To limit the potential for contamination, strictly adhere to recommendations in product labeling for handling and administering propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Use with caution in patients with preexisting pancreatitis; use of propofol may exacerbate this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of epilepsy or seizures; seizure may occur during recovery phase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioids: Concomitant use may lead to increased sedative or anesthetic effects of propofol, more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output; lower doses of propofol may be needed. In addition, fentanyl may cause serious bradycardia when used with propofol in pediatric patients. Alfentanil use with propofol has precipitated seizure activity in patients without any history of epilepsy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ASA-PS (American Society of Anesthesiologists - Physical Status) 3/4 patients: Use a lower induction dose, a slower maintenance rate of administration, and avoid rapidly delivered boluses in ASA-PS 3/4 patients to reduce the incidence of unwanted cardiorespiratory depressive events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use a lower induction dose, a slower maintenance rate of administration, and avoid rapidly delivered boluses in debilitated patients to reduce the incidence of unwanted cardiorespiratory depressive events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use a lower induction dose, a slower maintenance rate of administration, and avoid rapidly delivered boluses in the elderly to reduce the incidence of unwanted cardiorespiratory depressive events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in pediatric intensive care unit patients; concurrent use of fentanyl and propofol in pediatric patients may result in bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Propofol should only be used in pregnancy if clearly needed. Not recommended for use in obstetrics, including cesarean section deliveries.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some products may contain benzyl alcohol which has been associated with the \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edetate disodium: Some formulations contain edetate disodium which may lead to decreased zinc levels in patients with prolonged therapy (&gt;5 days) or a predisposition to zinc deficiency (eg, burns, diarrhea, or sepsis). A holiday from propofol infusion should take place after 5 days of therapy to allow for evaluation and necessary replacement of zinc.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some formulations may contain sulfites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt discontinuation: Avoid abrupt discontinuation prior to weaning or daily wake up assessments. Abrupt discontinuation can result in rapid awakening, anxiety, agitation, and resistance to mechanical ventilation; wean the infusion rate so the patient awakens slowly. Discontinue opioids and paralytic agents prior to weaning. Long-term infusions can result in some tolerance; taper propofol infusions to prevent withdrawal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Analgesic supplementation: Propofol lacks analgesic properties; pain management requires specific use of analgesic agents, at effective dosages, propofol must be titrated separately from the analgesic agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel: Use requires careful patient monitoring, should only be used by experienced personnel who are not actively engaged in the procedure or surgery. If used in a nonintubated and/or nonmechanically-ventilated patient, qualified personnel and appropriate equipment for rapid institution of respiratory and/or cardiovascular support must be immediately available. Use to induce moderate (conscious) sedation in patients warrants monitoring equivalent to that seen with deep anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: May enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: May increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ropivacaine: Propofol may increase the serum concentration of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F214579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Edetate disodium, an ingredient of propofol emulsion, may lead to decreased zinc levels in patients on prolonged therapy (&gt;5 days) or those predisposed to deficiency (burns, diarrhea, and/or major sepsis).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propofol should only be used in pregnancy if clearly needed. Propofol is not recommended for obstetrics, including cesarean section deliveries. Propofol crosses the placenta and may be associated with neonatal CNS and respiratory depression.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F214593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F214567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propofol is formulated in an oil-in-water emulsion. If on parenteral nutrition, may need to adjust the amount of lipid infused. Propofol emulsion contains 1.1 kcal/mL. Soybean fat emulsion is used as a vehicle for propofol. Formulations also contain egg phosphatide and glycerol.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Diprivan Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (50 mL): $5.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Propofol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (50 mL): $8.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F214556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac monitor, blood pressure, oxygen saturation (during monitored anesthesia care sedation), arterial blood gas (with prolonged infusions). With prolonged infusions (eg, ICU sedation), monitor for metabolic acidosis, hyperkalemia, rhabdomyolysis or elevated CPK, hepatomegaly, and progression of cardiac and renal failure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     ICU sedation: Assess and adjust sedation according to scoring system (Richmond Agitation-Sedation Scale [RASS] or Sedation-Agitation Scale [SAS]) (Barr, 2013); assess CNS function daily. Serum triglyceride levels should be obtained prior to initiation of therapy and every 3-7 days thereafter, especially if receiving for &gt;48 hours with doses exceeding 50 mcg/kg/minute (Devlin, 2005); use intravenous port opposite propofol infusion or temporarily suspend infusion and flush port prior to blood draw.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Diprivan&reg;: Monitor zinc levels in patients predisposed to deficiency (burns, diarrhea, major sepsis) or after 5 days of treatment.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F214568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anepol (KP, TH);",
"     </li>",
"     <li>",
"      Anesvan (TH);",
"     </li>",
"     <li>",
"      Aquafol (KP);",
"     </li>",
"     <li>",
"      Diprivan (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SV, SY, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Diprofen (TW);",
"     </li>",
"     <li>",
"      Diprofol (IL);",
"     </li>",
"     <li>",
"      Disoprivan (CH, HR);",
"     </li>",
"     <li>",
"      Fresofol (KP, MY, NZ, PH, TW);",
"     </li>",
"     <li>",
"      Fresofol MCT/LCT (HK, ID, TH);",
"     </li>",
"     <li>",
"      Gobbifol (AR);",
"     </li>",
"     <li>",
"      Indofol (MX);",
"     </li>",
"     <li>",
"      Lipofol (TW);",
"     </li>",
"     <li>",
"      Lipuro (PH);",
"     </li>",
"     <li>",
"      Neorof (PH);",
"     </li>",
"     <li>",
"      Pofol (KP, SG, TH);",
"     </li>",
"     <li>",
"      Proanes (ID);",
"     </li>",
"     <li>",
"      Propofol-Lipuro (EC);",
"     </li>",
"     <li>",
"      Propovan (PY);",
"     </li>",
"     <li>",
"      Propoven (EE);",
"     </li>",
"     <li>",
"      Provive (AU, KP, NZ);",
"     </li>",
"     <li>",
"      Recofol (CH, HU, ID, IL, MX, SG, TH);",
"     </li>",
"     <li>",
"      Safol (ID);",
"     </li>",
"     <li>",
"      Trivam (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F214545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propofol is a short-acting, lipophilic intravenous general anesthetic. The drug is unrelated to any of the currently used barbiturate, opioid, benzodiazepine, arylcyclohexylamine, or imidazole intravenous anesthetic agents. Propofol causes global CNS depression, presumably through agonism of GABA",
"     <sub>",
"      A",
"     </sub>",
"     receptors and perhaps reduced glutamatergic activity through NMDA receptor blockade.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F214562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anesthetic: Bolus infusion (dose dependent): 9-51 seconds (average 30 seconds)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (dose and rate dependent): 3-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2-10 L/kg; after a 10-day infusion, V",
"     <sub>",
"      d",
"     </sub>",
"     approaches 60 L/kg; decreased in the elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to water-soluble sulfate and glucuronide conjugates (~50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Initial: 40 minutes; Terminal: 4-7 hours (after 10-day infusion, may be up to 1-3 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~88% as metabolites, 40% as glucuronide metabolite); feces (&lt;2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bedforth NM and Lockey DJ, &ldquo;Raynaud's Syndrome Following Intravenous Induction of Anaesthesia,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1995, 50(3):248-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/7717494/pubmed\" id=\"7717494\" target=\"_blank\">",
"        7717494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bennett SN, McNeil MM, Bland LA, et al, &ldquo;Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(3):147-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/7791816/pubmed\" id=\"7791816\" target=\"_blank\">",
"        7791816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burow BK, Johnson ME, and Packer DL, &ldquo;Metabolic Acidosis Associated With Propofol in the Absence of Other Causative Factors,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2004, 101(1):239-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/15220796/pubmed\" id=\"15220796\" target=\"_blank\">",
"        15220796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cawley MJ, Guse TM, Laroia A, et al, &ldquo;Propofol Withdrawal Syndrome in an Adult Patient With Thermal Injury,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(7):933-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/12885106/pubmed\" id=\"12885106\" target=\"_blank\">",
"        12885106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chukwuemeka A, Ko R, and Ralph-Edwards A, &ldquo;Short-term Low-Dose Propofol Anaesthesia Associated with Severe Metabolic Acidosis,&rdquo;",
"      <i>",
"       Anaesth Intensive Care",
"      </i>",
"      , 2006, 34(5):651-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/17061643/pubmed\" id=\"17061643\" target=\"_blank\">",
"        17061643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Claassen J, Hirsch LJ, Emerson RG, et al, &ldquo;Treatment of Refractory Status Epilepticus With Pentobarbital, Propofol, or Midazolam: A Systematic Review,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2002, 43(2):146-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/11903460/pubmed\" id=\"11903460\" target=\"_blank\">",
"        11903460",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corbett SM, Montoya ID, and Moore FA, &ldquo;Propofol-Related Infusion Syndrome in Intensive Care Patients,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(2):250-58.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Devlin JW, Lau AK, and Tanios MA, &ldquo;Propofol-Associated Hypertriglyceridemia and Pancreatitis in the Intensive Care Unit: An Analysis of Frequency and Risk Factors,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1348-52.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fassoulaki A, Farinotti R, Servin F, et al, \"Chronic Alcoholism Increases the Induction Dose of Propofol in Humans,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1993, 77(3):553-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/8368555/pubmed\" id=\"8368555\" target=\"_blank\">",
"        8368555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, &ldquo;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gross J, Bailey P, Connis R, et al, &ldquo;Practice Guidelines for Sedation and Analgesia by Non-Anesthesiologists. An Updated Report by the American Society of Anesthesiologist Task Force on Sedation and Analgesia by Nonanesthesiologists,&rdquo; Anesthesiology, 2002, 96(4):1004-17",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/11964611/pubmed\" id=\"11964611\" target=\"_blank\">",
"        11964611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&auml;lvi&auml;inen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(Suppl 8):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/18330014/pubmed\" id=\"18330014\" target=\"_blank\">",
"        18330014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kotani Y, Shimazawa M, Yoshimura S, et al, &ldquo;The Experimental and Clinical Pharmacology of Propofol, an Anesthetic Agent with Neuroprotective Properties,&rdquo;",
"      <i>",
"       CNS Neurosci Ther",
"      </i>",
"      , 2008, 14(2):95-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/18482023/pubmed\" id=\"18482023\" target=\"_blank\">",
"        18482023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kress JP and Hall JB, &ldquo;Sedation in the Mechanically Ventilated Patient,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2006, 34 (10):2541-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/16932231/pubmed\" id=\"16932231\" target=\"_blank\">",
"        16932231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kress JP, Pohlman AS, O'Connor MF, et al, &ldquo;Daily Interruption of Sedative Infusions in Critically Ill Patients Undergoing Mechanical Ventilation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(20):1471-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/10816184/pubmed\" id=\"10816184\" target=\"_blank\">",
"        10816184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liolios A, Guerit JM, Scholtes JL, et al, &ldquo;Propofol Infusion Syndrome Associated With Short-term Large-Dose Infusion During Surgical Anesthesia in an Adult,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 100(6):1804-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/15920217/pubmed\" id=\"15920217\" target=\"_blank\">",
"        15920217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCowan C and Marik P, &ldquo;Refractory Delirium Tremens Treated With Propofol: A Case Series,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2000, 28(6):1781-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/10890619/pubmed\" id=\"10890619\" target=\"_blank\">",
"        10890619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010, 17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merz TM, Regli B, Rothen HU, et al, &ldquo;Propofol Infusion Syndrome: A Fatal Case at a Low Infusion Rate,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2006, 103(4):1050.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/17000843/pubmed\" id=\"17000843\" target=\"_blank\">",
"        17000843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossetti AO, Reichhart MD, Schaller MD, et al, &ldquo;Propofol Treatment of Refractory Status Epilepticus: A Study of 31 Episodes,&rdquo;",
"      <i>",
"       Epilepsia,",
"      </i>",
"      2004, 45(7):757-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/15230698/pubmed\" id=\"15230698\" target=\"_blank\">",
"        15230698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shapiro BA, Warren J, Egol AB, et al, &ldquo;Practice Parameters for Intravenous Analgesia and Sedation for Adult Patients in the Intensive Care Unit: An Executive Summary. Society of Critical Care Medicine,",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(9):1596-600.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Short TG and Young Y, &ldquo;Toxicity of Intravenous Anaesthetics,&rdquo;",
"      <i>",
"       Best Pract Res Clin Anaesthesiol",
"      </i>",
"      , 2003, 17(1):77-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/12751550/pubmed\" id=\"12751550\" target=\"_blank\">",
"        12751550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Training Committee, American Society for Gastrointestinal Endoscopy, &ldquo;Training Guideline for Use of Propofol in Gastrointestinal Endoscopy,&rdquo;",
"      <i>",
"       Gastrointest Endosc",
"      </i>",
"      , 2004, 60(2):167-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/15278039/pubmed\" id=\"15278039\" target=\"_blank\">",
"        15278039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Unlugenc H, Guler T, Gunes Y, et al, &ldquo;Comparative Study of the Antiemetic Efficacy of Ondansetron, Propofol and Midazolam in the Early Postoperative Period,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 2004, 21(1):60-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17816/abstract-text/14768925/pubmed\" id=\"14768925\" target=\"_blank\">",
"        14768925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9826 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17816=[""].join("\n");
var outline_f17_25_17816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214584\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214585\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214628\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214588\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214606\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214589\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135189\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135190\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214558\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214542\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214560\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214634\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214559\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214624\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214636\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214626\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214563\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214546\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214621\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214551\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214579\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214554\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214566\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214593\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214567\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323734\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214556\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214568\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214545\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214562\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9826\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9826|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/57/39827?source=related_link\">",
"      Propofol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=related_link\">",
"      Propofol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_25_17817="Azithromycin (systemic): Drug information";
var content_f17_25_17817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azithromycin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=see_link\">",
"    see \"Azithromycin (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/3/6200?source=see_link\">",
"    see \"Azithromycin (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14310218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning for Azithromycin Heart Risks",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has issued a safety warning that azithromycin (Zithromax&reg; or Zmax&reg;) may cause prolonged cardiac repolarization and QT interval, increasing the risk of cardiac arrhythmia and torsade de pointes. Patients at particular risk include those with known risk factors such as existing QT-interval prolongation, a history of torsade de pointes, congenital long QT syndrome, uncompensated heart failure, use of drugs known to prolong the QT interval, uncorrected hypokalemia or hypomagnesemia, or clinically significant bradycardia.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The warning results from FDA review of a research study and a subsequent study conducted by a manufacturer, both assessing the potential for azithromycin to cause abnormal cardiac activity.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare providers should be aware of the potential for QT-interval prolongation and heart arrhythmias when prescribing or administering azithromycin for patients who are already at risk for cardiovascular events.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm341822.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm341822.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm304372.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm304372.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7983183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zithromax&reg;;",
"     </li>",
"     <li>",
"      Zithromax&reg; TRI-PAK&trade;;",
"     </li>",
"     <li>",
"      Zithromax&reg; Z-PAK&reg;;",
"     </li>",
"     <li>",
"      Zmax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7983184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Azithromycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Azithromycin;",
"     </li>",
"     <li>",
"      Azithromycin for Injection;",
"     </li>",
"     <li>",
"      CO Azithromycin;",
"     </li>",
"     <li>",
"      Dom-Azithromycin;",
"     </li>",
"     <li>",
"      GD-Azithromycin;",
"     </li>",
"     <li>",
"      Mylan-Azithromycin;",
"     </li>",
"     <li>",
"      Novo-Azithromycin;",
"     </li>",
"     <li>",
"      PHL-Azithromycin;",
"     </li>",
"     <li>",
"      PMS-Azithromycin;",
"     </li>",
"     <li>",
"      PRO-Azithromycin;",
"     </li>",
"     <li>",
"      ratio-Azithromycin;",
"     </li>",
"     <li>",
"      Riva-Azithromycin;",
"     </li>",
"     <li>",
"      Sandoz-Azithromycin;",
"     </li>",
"     <li>",
"      Zithromax&reg;;",
"     </li>",
"     <li>",
"      Zithromax&reg; For Intravenous Injection;",
"     </li>",
"     <li>",
"      Zmax SR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7983188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Macrolide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7983294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Extended release suspension (Zmax&reg;) is not interchangeable with immediate release formulations.",
"     </b>",
"     Use should be limited to approved indications. All doses are expressed as immediate release azithromycin unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Babesiosis (unlabeled use):",
"     </b>",
"     Oral: 500-1000 mg on day 1, followed by 250 mg once daily for 7-10 days with atovaquone; higher doses may be required in immunocompromised patients (600-1000 mg daily).",
"     <b>",
"      Note:",
"     </b>",
"     Relapsing infection may require at least 6 weeks of therapy (Vannier, 2012; Wormser, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Bacterial sinusitis:",
"     </b>",
"     Oral: 500 mg daily for a total of 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Extended release suspension (Zmax&reg;): 2 g as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cat scratch disease (unlabeled use):",
"     </b>",
"     Oral: &gt;45.5 kg: 500 mg as a single dose, then 250 mg once daily for 4 additional days (Bass, 1998; Stevens, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chancroid due to",
"     </b>",
"     <b>",
"      <i>",
"       H. ducreyi:",
"      </i>",
"     </b>",
"     Oral: 1 g as a single dose (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       C. trachomatis",
"      </i>",
"     </b>",
"     <b>",
"      urethritis/cervicitis:",
"     </b>",
"     Oral: 1 g as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 500 mg on day 1 followed by 250 mg once daily on days 2-5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release suspension (Zmax&reg;): 2 g as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 500 mg as a single dose for at least 2 days, follow I.V. therapy by the oral route with a single daily dose of 500 mg to complete a 7- to 10-day course of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Disseminated",
"     </b>",
"     <b>",
"      <i>",
"       M. avium",
"      </i>",
"     </b>",
"     <b>",
"      complex disease in patients with advanced HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     600 mg daily in combination with  ethambutol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary prophylaxis:",
"     </i>",
"     1200 mg once weekly (preferred), with or without rifabutin",
"     <b>",
"      or",
"     </b>",
"     alternatively, 600 mg twice weekly (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Secondary prophylaxis:",
"     </i>",
"     500-600 mg daily in combination with ethambutol (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonococcal infection, uncomplicated (cervix,  rectum, urethra) (unlabeled regimen):",
"     </b>",
"     Oral: 1 g as a single dose in combination with ceftriaxone (preferred) or cefixime (only if ceftriaxone unavailable); if cefixime is used,  test-of-cure in 7 days is recommended (CDC, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Monotherapy with azithromycin single dose of 2 g has been associated with resistance and/or treatment failure; however, may be appropriate for treatment of a gonococcal infection in pregnant women who cannot tolerate a cephalosporin (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients with severe cephalosporin allergy:",
"     </i>",
"     2 g as a single dose and test-of-cure in 7 days (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonococcal infection, uncomplicated (pharynx) (unlabeled use):",
"     </b>",
"     1 g as a single dose in combination with ceftriaxone (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonococcal infection, expedited partner therapy (unlabeled use):",
"     </b>",
"     Oral: 1 g as a single dose in combination with cefixime (CDC, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Only used if a heterosexual partner cannot be linked to evaluation and treatment in a timely manner; dose delivered to partner by patient, collaborating pharmacy, or disease investigation specialist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Granuloma inguinale (donovanosis) (unlabeled use):",
"     </b>",
"     Oral: 1 g once a week for at least 3 weeks (and until lesions have healed) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate respiratory tract, skin, and soft tissue infections:",
"     </b>",
"     Oral: 500 mg in a single loading dose on day 1 followed by 250 mg daily as a single dose on days 2-5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative regimen:",
"     </i>",
"     Bacterial exacerbation of COPD: 500 mg daily for a total of 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       M. genitalium",
"      </i>",
"     </b>",
"     <b>",
"      infections (unlabeled use)",
"     </b>",
"     (confirmed cases in males or females or clinically significant persistent urethritis in males): Oral: 1 g as a single dose or 500 mg on day 1, followed by 250 mg daily on days 2-5 (Manhart, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Follow up patients on either regimen in 3-4 weeks for test of cure; consider moxifloxacin for treatment failures (Manhart, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease (PID):",
"     </b>",
"     I.V.: 500 mg as a single dose for 1-2 days, follow I.V. therapy by the oral route with a single daily dose of 250 mg to complete a 7-day course of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pertussis (unlabeled use; CDC, 2005):",
"     </b>",
"     Oral: 500 mg on day 1 followed by 250 mg daily on days 2-5 (maximum: 500 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis, group A streptococci in penicillin-allergic patients (IDSA guidelines):",
"     </b>",
"     Oral: 12 mg/kg once daily (maximum: 500 mg daily) for 5 days.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (Shulman, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of pulmonary exacerbations in patients with noncystic fibrosis bronchiectasis (unlabeled use):",
"     </b>",
"     Oral: 500 mg 3 days per week.",
"     <b>",
"      Note:",
"     </b>",
"     Duration of treatment in clinical trial was 6 months; durations &gt;6 months have not been evaluated. Trial patients had &ge;1 exacerbation in the past year, no macrolide treatment for &gt;3 months in the past 6 months, and were screened for nontuberculous mycobacterial infection prior to treatment (Wong, 2012). A more selective approach for patients with functionally mild disease has been suggested (Wilson, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"     Oral: 500 mg 30-60 minutes prior to the procedure.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against sexually-transmitted diseases following sexual assault (unlabeled use):",
"     </b>",
"     Oral: 1 g as a single dose  (in combination with a cephalosporin and metronidazole) (CDC, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7983293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/3/6200?source=see_link\">",
"      see \"Azithromycin (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Extended release suspension (Zmax&reg;) is not interchangeable with immediate release formulations.",
"     </b>",
"     Use should be limited to approved indications. All doses are expressed as immediate release azithromycin unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacterial sinusitis:",
"     </b>",
"     Children &ge;6 months: Oral: 10 mg/kg once daily for 3 days (maximum: 500 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cat scratch disease (unlabeled use; Bass, 1998; Stevens, 2005):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;45.5 kg: 10 mg/kg as a single dose, then 5 mg/kg once daily for 4 additional days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;45.5 kg: 500 mg as a single dose, then 250 mg once daily for 4 additional days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):",
"     </b>",
"     Infants &gt;3 months and Children:",
"     <b>",
"      Note:",
"     </b>",
"     A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Presumed mild infection or step-down therapy, atypical",
"     <i>",
"      (M. pneumoniae, C. pneumoniae, C. trachomatis)",
"     </i>",
"     (preferred): Oral: 10 mg/kg (maximum dose: 500 mg) as a single dose on the first day, followed by 5 mg/kg/day (maximum dose: 250 mg) on days 2 through 5.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Presumed moderate-to-severe infection, atypical",
"     <i>",
"      (M. pneumoniae, C. pneumoniae, C. trachomatis)",
"     </i>",
"     : I.V.: 10 mg/kg/day on days 1 and 2, then switch to oral azithromycin therapy if possible to finish the 5-day course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative regimens for community-acquired pneumonia:",
"     </i>",
"     Oral: 10 mg/kg (maximum dose: 500 mg) once daily for 3 days (Kogan, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release suspension (Zmax&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;75 lbs (34 kg): 60 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Disseminated",
"     </b>",
"     <b>",
"      <i>",
"       M. avium",
"      </i>",
"     </b>",
"     <b>",
"      complex disease in patients with advanced HIV infection (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     10-12 mg/kg/day (maximum: 500 mg)  in combination with ethambutol; patients with severe disease should also receive rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary prophylaxis:",
"     </i>",
"     20 mg/kg (maximum: 1200 mg) once weekly (preferred) or alternatively, 5 mg/kg/day once daily (maximum: 250 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Secondary prophylaxis:",
"     </i>",
"     5 mg/kg/day once daily (maximum: 250 mg daily) in combination with ethambutol, with or without rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"     Oral: 15 mg/kg 30-60 minutes before procedure.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Otitis media:",
"     </b>",
"     Children &ge;6 months: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      1-day regimen:",
"     </i>",
"     30 mg/kg as a single dose (maximum dose: 1500 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      3-day regimen:",
"     </i>",
"     10 mg/kg once daily for 3 days (maximum: 500 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      5-day regimen:",
"     </i>",
"     10 mg/kg on day 1 (maximum: 500 mg daily) followed by 5 mg/kg/day once daily on days 2-5 (maximum: 250 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pertussis (unlabeled use; CDC, 2005):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;6 months: 10 mg/kg/day for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 months: 10 mg/kg on day 1 (maximum: 500 mg daily) followed by 5 mg/kg/day once daily on days 2-5 (maximum: 250 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis  (including susceptible group A streptococci), tonsillitis (IDSA guidelines):",
"     </b>",
"     Children &ge;2 years: Oral: 12 mg/kg/day once daily for 5 days (maximum: 500 mg daily).",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uncomplicated chlamydial urethritis or cervicitis (unlabeled use):",
"     </b>",
"     Children &ge;45 kg: 1 g as a single dose (CDC, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7983295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7983296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Use with caution in patients with GFR &lt;10 mL/minute  (AUC increased by 35% compared to patients with normal renal function); however, no dosage adjustment is provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     No supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Aronoff, 2007; Heintz, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7983297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Azithromycin is predominantly hepatically eliminated; however, there is no dosage adjustment provided in the manufacturer&rsquo;s labeling, Use with caution due to potential for hepatotoxicity (rare); discontinue immediately for signs or symptoms of hepatitis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7983340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as dihydrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 500 mg [DSC] [contains sodium 114 mg (4.96 mEq)/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as monohydrate [strength expressed as base]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Microspheres for suspension, extended release, oral, as dihydrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zmax&reg;: 2 g/bottle (60 mL) [contains sodium 148 mg/bottle, sucrose 19 g/bottle; cherry-banana flavor; product contains azithromycin 27 mg/mL after constitution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as dihydrate [strength expressed as base]: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL, 30 mL); 1 g/packet (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 100 mg/5 mL (15 mL) [contains sodium 3.7 mg/5 mL; cherry-cr&egrave;me de vanilla-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 200 mg/5 mL (15 mL, 22.5 mL, 30 mL) [contains sodium 7.4 mg/5 mL; cherry-cr&egrave;me de vanilla-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 1 g/packet (3s, 10s) [contains sodium 37 mg/packet; banana-cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as monohydrate [strength expressed as base]: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as anhydrous: 250 mg, 500 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dihydrate [strength expressed as base]: 250 mg, 500 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 250 mg [contains sodium 0.9 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 500 mg [contains sodium 1.8 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 600 mg [contains sodium 2.1 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg; TRI-PAK&trade;: 500 mg [contains sodium 1.8 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg; Z-PAK&reg;: 250 mg [contains sodium 0.9 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as monohydrate [strength expressed as base]: 250 mg, 500 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7983186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release microspheres",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7983300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infusate concentration and rate of infusion for azithromycin for injection should be either 1 mg/mL over 3 hours or 2 mg/mL over 1 hour. Other medications should not be infused simultaneously through the same I.V. line.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Immediate release suspension and tablet may be taken without regard to food; extended release suspension should be taken on an empty stomach (at least 1 hour before or 2 hours following a meal), within 12 hours of reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7983259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS (with or without 20 mEq/L KCl), Normosol&reg;-M in D",
"     <sub>",
"      5",
"     </sub>",
"     , Normosol&reg;-R in D",
"     <sub>",
"      5",
"     </sub>",
"     , LR, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin, caspofungin, dexmedetomidine, diphenhydramine, dolasetron, doripenem, droperidol, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), ondansetron, tigecycline.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amikacin, aztreonam, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, ciprofloxacin, clindamycin, famotidine, fentanyl, furosemide, gentamicin, imipenem/cilastatin, ketorolac, levofloxacin, morphine, piperacillin/tazobactam, potassium chloride, ticarcillin/clavulanate potassium, tobramycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7983211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Oral, I.V.: Treatment of acute otitis media due to",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ; pharyngitis/tonsillitis due to",
"     <i>",
"      S. pyogenes",
"     </i>",
"     , community-acquired pneumonia due to",
"     <i>",
"      Chlamydia pneumonia, H. influenzae, M. pneumoniae,",
"     </i>",
"     or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ; pelvic inflammatory disease (PID) due to",
"     <i>",
"      C. trachomatis, N. gonorrhoeae,",
"     </i>",
"     or",
"     <i>",
"      M. hominis",
"     </i>",
"     ; genital ulcer disease (in men) due to",
"     <i>",
"      H. ducreyi",
"     </i>",
"     (chancroid); acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to",
"     <i>",
"      H. influenzae, M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ; acute bacterial sinusitis due to",
"     <i>",
"      H. influenzae, M. catarrhalis,",
"     </i>",
"     or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ; prevention of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) (alone or in combination with rifabutin) in patients with advanced HIV infection; treatment of disseminated MAC (in combination with ethambutol) in patients with advanced HIV infection; skin and skin structure infections (uncomplicated) due to",
"     <i>",
"      S. aureus, S. pyogenes",
"     </i>",
"     , or",
"     <i>",
"      S. agalactiae",
"     </i>",
"     ; urethritis and cervicitis due to",
"     <i>",
"      C. trachomatis",
"     </i>",
"     or",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7983213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of babesiosis; cat scratch disease; gonococcal infections of the pharynx or rectum (combination therapy) and expedited partner therapy; granuloma inguinale (donovanosis);",
"     <i>",
"      Mycoplasma genitalium",
"     </i>",
"     infections; pertussis; prophylaxis of infective endocarditis in select patients who are allergic to penicillin and undergoing dental procedures; prevention of pulmonary exacerbations in patients with noncystic fibrosis bronchiectasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7983163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Azithromycin may be confused with azathioprine, erythromycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zithromax&reg; may be confused with Fosamax&reg;, Zinacef&reg;, Zovirax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7983245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (4% to 9%; high single-dose regimens 12% to 14%), nausea (&le;7%; high single-dose regimens 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, cramping, vomiting (especially with high single-dose regimens)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: (with I.V. administration): Injection site pain, inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;1% (Limited to important or life-threatening): Acute renal failure, aggressive behavior agitation, allergic reaction, anaphylaxis, anemia, angioedema, anxiety, arrhythmia (including ventricular tachycardia), arthralgia, bronchospasm, candidiasis, chest pain, cholestatic jaundice, conjunctivitis (pediatric patients), constipation, cough increased, deafness, dehydration, dermatitis (fungal), diaphoresis, dizziness, dyspepsia, eczema, edema, enteritis, erythema multiforme (rare), facial edema, fatigue fever, flatulence, fungal infection, gastritis, headache, hearing disturbance, hearing loss, hepatic failure, hepatic necrosis, hepatitis, hyperactivity, hyperkinesia, hypotension, insomnia, interstitial nephritis, jaundice, leukopenia, LFTs increased, loss of smell, loss of taste, malaise, melena, mucositis, nephritis, nervousness, neutropenia (mild), oral candidiasis, oral moniliasis, pain, palpitation, pancreatitis, paresthesia, pharyngitis, photosensitivity, pleural effusion, pseudomembranous colitis, pyloric stenosis, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (rare), rhinitis, seizure, smell perversion, somnolence, somnolence, Stevens-Johnson syndrome (rare), syncope, taste perversion, thrombocytopenia, tinnitus, tongue discoloration (rare), torsade de pointes (rare), toxic epidermal necrolysis (rare), urticaria, vertigo, vesiculobullous rash, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7983221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azithromycin, other macrolide (eg, azalide or ketolide) antibiotics, or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer does not list concurrent use of pimozide as a contraindication; however, azithromycin is listed as a contraindication in the manufacturer&rsquo;s labeling for pimozide.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7983222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Allergic reactions (eg, angioedema, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (rare); reappearance of allergic reaction may occur shortly after discontinuation of symptomatic treatment without further azithromycin exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Macrolides (especially erythromycin) have been associated with rare QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and ventricular arrhythmias, including torsade de pointes; consider avoiding use in patients with prolonged QT interval, congenital long QT syndrome, history of torsade de pointes, bradyarrhythmias, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, uncompensated heart failure, or concurrent use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents or other drugs known to prolong the QT interval. A recent retrospective cohort study (under FDA review) demonstrated an increased cardiac risk with azithromycin relative to amoxicillin or ciprofloxacin, and similar risk compared to levofloxacin; notably, increased cardiac mortality (an estimated 47 additional deaths per 1 million 5-day courses of treatment compared to amoxicillin) was associated with higher baseline cardiovascular risk (Ray, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD); CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gonorrhea/syphilis: May mask or delay symptoms of incubating gonorrhea or syphilis, so appropriate culture and susceptibility tests should be performed prior to initiating a treatment regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with pre-existing liver disease; hepatocellular and/or cholestatic hepatitis, with or without jaundice, hepatic necrosis, failure, and death have occurred. Discontinue immediately if symptoms of hepatitis occur (malaise, nausea, vomiting, abdominal colic,  fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation and new onset of symptoms have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (GFR &lt;10 mL/minute); increased gastrointestinal adverse effects may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral suspensions: Immediate release and extended release suspensions are not interchangeable.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7983249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7983250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Azithromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone.  Management: The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivermectin (Systemic): Azithromycin (Systemic) may increase the serum concentration of Ivermectin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May increase the serum concentration of Azithromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Azithromycin (Systemic) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7983254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Rate and extent of GI absorption may be altered depending upon the formulation. Azithromycin suspension, not tablet form, has significantly increased absorption (46%) with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7983214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7983215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Azithromycin crosses the placenta. Fetal malformations have not been observed following maternal use of azithromycin. The maternal serum half-life of azithromycin is unchanged in early pregnancy and decreased at term; however, high concentrations of azithromycin are sustained in the myometrium and adipose tissue. Azithromycin is recommended for the treatment of several infections, including chlamydia, gonococcal infections, and",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) in pregnant patients (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7983218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7983220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Azithromycin is excreted in low amounts into breast milk. The manufacturer recommends that caution be exercised when administering azithromycin to breast-feeding women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7983299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Some products may contain sodium and/or sucrose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral suspension, immediate release, may be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral suspension, extended release, should be taken on an empty stomach (at least 1 hour before or 2 hours following a meal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet may be administered with food to decrease GI effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7983342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Azithromycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (3): $72.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Zithromax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (3): $178.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Azithromycin Hydrogencitrate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 g (1): $75.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Azithromycin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $8.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Zithromax Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Azithromycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (15 mL): $34.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/5 mL (15 mL): $34.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Zithromax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (15 mL): $70.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/5 mL (22.5 mL): $70.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Zmax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $128.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Azithromycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (6): $46.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (3): $46.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (30): $560.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zithromax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $497.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $995.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (30): $1194.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zithromax Tri-Pak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (3): $99.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zithromax Z-Pak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (6): $99.57",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7983325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, CBC with differential; when used as part of alternative treatment for gonococcal infection, test-of-cure 7 days after dose (CDC, 2012)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ajustin (KP);",
"     </li>",
"     <li>",
"      Atizor (CN);",
"     </li>",
"     <li>",
"      Azadose (FR);",
"     </li>",
"     <li>",
"      Azas (KP);",
"     </li>",
"     <li>",
"      Azatril (EE);",
"     </li>",
"     <li>",
"      Azee (HK);",
"     </li>",
"     <li>",
"      Azenil (IL);",
"     </li>",
"     <li>",
"      Azi-500 (PH);",
"     </li>",
"     <li>",
"      Azibact (DE);",
"     </li>",
"     <li>",
"      Azicine (HK);",
"     </li>",
"     <li>",
"      Azin (PH);",
"     </li>",
"     <li>",
"      Azinobin (CO);",
"     </li>",
"     <li>",
"      Azirocin (KP);",
"     </li>",
"     <li>",
"      Azith (AU, TH);",
"     </li>",
"     <li>",
"      Azithral (IN);",
"     </li>",
"     <li>",
"      Azithro (MY);",
"     </li>",
"     <li>",
"      Azithrom (TW);",
"     </li>",
"     <li>",
"      Azitops (KP);",
"     </li>",
"     <li>",
"      Azitrex (EC);",
"     </li>",
"     <li>",
"      Azitrix (PT);",
"     </li>",
"     <li>",
"      Azitrocin (IT);",
"     </li>",
"     <li>",
"      Azitromax (NO, SE);",
"     </li>",
"     <li>",
"      Aziwok (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Azro (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Aztrin (ID);",
"     </li>",
"     <li>",
"      Azyth (PH);",
"     </li>",
"     <li>",
"      Binozyt (ID, SG, TH);",
"     </li>",
"     <li>",
"      Clindal AZ (BR, HK);",
"     </li>",
"     <li>",
"      Cronopen (AR);",
"     </li>",
"     <li>",
"      Decantin (PH);",
"     </li>",
"     <li>",
"      Ethrimax DS (ID);",
"     </li>",
"     <li>",
"      Floctil (HK, TH);",
"     </li>",
"     <li>",
"      Geozit (PH);",
"     </li>",
"     <li>",
"      Imexa (MY);",
"     </li>",
"     <li>",
"      Inedol (PE);",
"     </li>",
"     <li>",
"      Koptin (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Kromicin (CO);",
"     </li>",
"     <li>",
"      Macromax (PH);",
"     </li>",
"     <li>",
"      Macrozit (CO, PE);",
"     </li>",
"     <li>",
"      Maxmor (ID);",
"     </li>",
"     <li>",
"      Mezatrin (ID);",
"     </li>",
"     <li>",
"      OD Mac (PH);",
"     </li>",
"     <li>",
"      Onzet (TH);",
"     </li>",
"     <li>",
"      Shepherd (CL);",
"     </li>",
"     <li>",
"      Sumamed (BG, CL, CZ, EE, PL);",
"     </li>",
"     <li>",
"      Thromaxin (PH);",
"     </li>",
"     <li>",
"      Tromix (CO);",
"     </li>",
"     <li>",
"      Ultreon (DE);",
"     </li>",
"     <li>",
"      Xithrone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zaret (CO);",
"     </li>",
"     <li>",
"      Zarom (ID);",
"     </li>",
"     <li>",
"      Zedd (AU);",
"     </li>",
"     <li>",
"      Zenith (PH);",
"     </li>",
"     <li>",
"      Zeto (IL);",
"     </li>",
"     <li>",
"      Zicho (ID);",
"     </li>",
"     <li>",
"      Zimericina (CO);",
"     </li>",
"     <li>",
"      Zistic (ID);",
"     </li>",
"     <li>",
"      Zithromax (AE, AT, AU, BD, BF, BH, BJ, CH, CI, CL, CN, CY, EG, ET, FI, FR, GB, GH, GM, GN, GR, HK, ID, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zithromax IV (MY, SG);",
"     </li>",
"     <li>",
"      Zithrox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zitrim (CO);",
"     </li>",
"     <li>",
"      Zitrocin (PY);",
"     </li>",
"     <li>",
"      Zitromax (AR, BE, BR, CR, DK, EC, GT, HN, IT, NI, PA, PE, SV, TR, UY, VE);",
"     </li>",
"     <li>",
"      Zmax (HK, IL, SG);",
"     </li>",
"     <li>",
"      Zmax One Dose (PH);",
"     </li>",
"     <li>",
"      Zomax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zotax (HK);",
"     </li>",
"     <li>",
"      Zythrocin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7983260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7983262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive tissue; distributes well into skin, lungs, sputum, tonsils, and cervix; penetration into CSF is poor; V",
"     <sub>",
"      d",
"     </sub>",
"     : 31-33 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding (concentration dependent): Oral, I.V.: 7% to 51%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 38%, decreased by 17% with extended release suspension; variable effect with food (increased with immediate or delayed release oral suspension, unchanged with tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral, I.V.: Terminal: Immediate release: 68-72 hours; Extended release: 59 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Immediate release: 2-3 hours; Extended release: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Oral, I.V.: Biliary (major route); urine (6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p  58, 151.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bass JW, Freitas BC, Freitas AD, et al, &ldquo;Prospective Randomized Double Blind Placebo-Controlled Evaluation of Azithromycin for the Treatment of Cat-Scratch Disease,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(6):447-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/9655532/pubmed\" id=\"9655532\" target=\"_blank\">",
"        9655532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-14):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/16340941/pubmed\" id=\"16340941\" target=\"_blank\">",
"        16340941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(14):332-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/17431378/pubmed\" id=\"17431378\" target=\"_blank\">",
"        17431378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010:  Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections&rdquo;,",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61(31):590-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22874837/pubmed\" id=\"22874837\" target=\"_blank\">",
"        22874837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coates P, Daniel R, Houston AC, et al, &ldquo;An Open Study to Compare the Pharmacokinetics, Safety, and Tolerability of a Multiple-Dose Regimen of Azithromycin in Young and Elderly Volunteers,&rdquo;",
"      <i>",
"       Eur J Clin Microbiol Infect Dis",
"      </i>",
"      , 1991, 10(10):850-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/1662630/pubmed\" id=\"1662630\" target=\"_blank\">",
"        1662630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foulds G, Shepard RM, and Johnson RB, &ldquo;The Pharmacokinetics of Azithromycin in Human Serum and Tissues,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1990, 25(Suppl A):73-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/2154441/pubmed\" id=\"2154441\" target=\"_blank\">",
"        2154441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghanem KG and Workowski KA, &ldquo;Management of Adult Syphilis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(Suppl 3):110-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22080265/pubmed\" id=\"22080265\" target=\"_blank\">",
"        22080265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Pharmacokinetics of the New Macrolides,&rdquo;",
"      <i>",
"       Infect Med",
"      </i>",
"      , 1992, 9:9-13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoffler D, Koeppe P, and Paeske B, &ldquo;Pharmacokinetics of Azithromycin in Normal and Impaired Renal Function,&rdquo;",
"      <i>",
"       Infection",
"      </i>",
"      , 1995, 23(6):356-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/8655206/pubmed\" id=\"8655206\" target=\"_blank\">",
"        8655206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan JE, Benson C, Holmes KH, et al, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim MH, Berkowitz C, and Trohman RG, \"Polymorphic Ventricular Tachycardia With a Normal QT Interval Following Azithromycin,\"",
"      <i>",
"       Pacing Clin Electrophysiol",
"      </i>",
"      , 2005, 28(11):1221-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/16359290/pubmed\" id=\"16359290\" target=\"_blank\">",
"        16359290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kogan R, Mart&iacute;nez MA, Rubilar L, et al, &ldquo;Comparative Randomized Trial of Azithromycin versus Erythromycin and Amoxicillin for Treatment of Community-acquired Pneumonia in Children,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2003, 35(2):91-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/12526069/pubmed\" id=\"12526069\" target=\"_blank\">",
"        12526069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lockwood AM, Cole S, and Rabinovich M, \"Azithromycin-Induced Liver Injury,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2010, 67(10):810-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/20479103/pubmed\" id=\"20479103\" target=\"_blank\">",
"        20479103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manhart LE, Broad JM, and Golden MR, &ldquo;",
"      <i>",
"       Mycoplasma genitalium:",
"      </i>",
"      Should We Treat and How?&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(Suppl 3):129-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22080266/pubmed\" id=\"22080266\" target=\"_blank\">",
"        22080266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, Koranyi KI, Gadgil SD, et al, &ldquo;Pharmacokinetics of Azithromycin After Oral Administration of Multiple Doses of Suspension,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(2):314-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/8383944/pubmed\" id=\"8383944\" target=\"_blank\">",
"        8383944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ray WA, Murray KT, Hall K, et al, \"Azithromycin and the Risk of Cardiovascular Death,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(20):1881-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22591294/pubmed\" id=\"22591294\" target=\"_blank\">",
"        22591294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al (Infectious Disease Society of America [IDSA]), &ldquo;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005; 41(10):1373&ndash;406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vannier E and Krause PJ, &ldquo;Human Babesiosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(25):2397-2407.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22716978/pubmed\" id=\"22716978\" target=\"_blank\">",
"        22716978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wahlstrom E, Zamora JU, and Teichman S, &ldquo;Improvement in Cyclosporin-Associated Gingival Hyperplasia With Azithromycin Therapy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(11):753-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/7854392/pubmed\" id=\"7854392\" target=\"_blank\">",
"        7854392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson R and Wells AU, &ldquo;Azithromycin in Bronchiectasis: When Should it be Used?&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 380(9842):627-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22901872/pubmed\" id=\"22901872\" target=\"_blank\">",
"        22901872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong C, Jayaram L, Karalus N, et al, &ldquo;Azithromycin for Prevention of Exacerbations in Non-Cystic Fibrosis Bronchiectasis (EMBRACE): A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 380(9842):660-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/22901887/pubmed\" id=\"22901887\" target=\"_blank\">",
"        22901887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 43(9):1089-134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/25/17817/abstract-text/17029130/pubmed\" id=\"17029130\" target=\"_blank\">",
"        17029130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8868 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17817=[""].join("\n");
var outline_f17_25_17817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14310218\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983183\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983184\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983188\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983294\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983293\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983295\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983296\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983297\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983340\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983300\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983259\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983211\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983213\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983163\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983245\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983221\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983222\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983249\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983250\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983254\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983214\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983215\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983218\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983220\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983299\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983342\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983325\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961955\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983260\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983262\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8868\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8868|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/11/21683?source=related_link\">",
"      Azithromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13988?source=related_link\">",
"      Azithromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=related_link\">",
"      Azithromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=related_link\">",
"      Azithromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/3/6200?source=related_link\">",
"      Azithromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_25_17818="Female pattern hair loss 2";
var content_f17_25_17818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87194%7EDERM%2F87195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87194%7EDERM%2F87195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5qcgHj9aa31zTgwbcCq7j0PpUTAqcZBPtXtKfc5uUVqY5XGQce3pSFutRlsHmsqrTRcUbWlSKR8zYxW00nyMzAFNuNw5BrkrSQxs24gA8g1qw3LAKYs7u49a8SrH3juo/CaO3EaquN4IOR/FmoGYfd5U4OR71OXSSLzFRo2HOCOahd9xRXYBl6kjse9EY2LkrFWYO0se12KnPH0p4+7idVJ7FRii4Rj8nzGMnKuvU/jTpJCJyuQ64A5HOMelaIysPjt2MIMjb8fdLdh6VDJ2aOSQPngbsCp/tDxzQtC6hgucf3h/ntUl1DDcgTRKtvOTkoT8hPqD2+lMZUgEjSCSXO7OQc7cfjW7aXCThre6RmA5yx7e571VtoHKFVi2zdWBI59+atwg/ZikyjzQQUJ6H1FIBzWCrbSvbssxQn92/3h7qe9UYljWF5pCfkGQq/Kfz/pUwV9hlgDKFwGP9alS4kl+W5i+RgcyKnf6daYDrSf7bbMHYLKq8A8hx6Z6g06ISLbSZtw8ZAYhhkr+P9az1s54PLdZY/KblSrYyf89q0LFlguxLFKftGOVY7VPHpRdgSsod0VEZBImUUjhT3I9qpQTOs7RyAuhO0buMVvQC116H7O0y297GflcHaM+hFZd/ZTyQmG5g8q7QsN4OBJim+4FK8jaCcJgruGVINW9K823UJyVkXDk9qp2+b2MxTSDzVXCb+3NS2c0tlehZwHycZXkCkJIDI9ldqUGGzyccYrVsRFud1IEZwwb3Paq11DGQZYx87NknPAA9qjjmjNviE4ZXK7T3PrQnYZLeuk8jWzxMpB65+Un1rFvI3iukziRM7cCt29iZwht/3vd8c4NUNTVkdB8qSdRjgmkwsZiQSxzmMIWy2FJ/nTktWjGGBZlYkgetSXSlHjkBdcrwOvOakvcxyhYm5kfBZe+BSFYgsQzX0KnKx5wzseKn8vyJ5RdoHgJyCOefUH9aggeK5uvs9wNkjqcSDjn0NPijlXFtKcEZ2ljkfj70CSNW1jii1KPYwdHQvu/hkX61Tv4Ef7SUTYCwIU9R9KLIGytXkuBIYy2yOPrkdyPanziO8R1t7gtJlXCsuO/QH0pjKNyN1mFjQjZwpXuO+aZlPLgODvyQc8lSB/8AXrbvEgbYcbBIm1ccAY6jPqawZv3UaMWCsv3lHXnnv/OglotWFlJNdAsFCE/vCewH+NaVo4mnvLqIrtGQnYKCMc+4HSs2e5mhfMfy4H3e/Pf61ZVzFLL5EYKzQlwgONwI6/hzQh2Mo27JlnVl3LhG7Ma1NLJj00+aUaI/e55B7CkgR4rKRmJeByoVWxuQ+/pVs2TycNtChQXIGNo+tJBYxroNOY5CCrFtq5Oc49a0In3QBg+P4evH0NOv41WNjEQI41DRkjqc4NUbRWwHzkHJVfU9zVCaHwMGc78cDaO20mtDSYmQqwIcONoB/nWY+DHFKQfMO58jpjOK29I1FI7fcqKW2nBYfyoT1GkQXlwDMImLMEypC4AzVW+uFmmht1TbFGNzAVK5ZYyBENzHcX9SewqndRMpcMfmJ2nPt1oYmQMohHmswBx8o60tkDE+7Ixnn3NROjSPC2Qo/h3dTzV77Mwt17s56e9LcRfWEJIXBwxHzAdMVmSuHmO0jrgD1qzcSuim3P32XG4HoaygRGV6kjjFAXNBWWJSwG5/ftVOW9YEg8LTcmRtoIX1HpVe8IVwi9O5pBcvWt6JDtDDmtX7SixhQMmuWSMICyHDGrkE53Kjk896TQJnSWtwexJ+vat3T751ZSzZFctbtswo5zWzasAox1porc7WyuQ3cc1pI/y/LXD2t00L+groLO/VlG4irTJaNpXNSK3pVSKQP06Vajx61aYmWomzirSGqSetWFft3oEW0ap0PFUBLjtUyvIwwABTKRfV/wBaKqJ5w5LAelFO4HyfGFQNKfnwflHqaDJMYiGIwx4UgcUowg2ZwzDn6+lRxwvIwG0pj+InA/Ou1vqc9iu5IBBPOajOcVoSRO4LRrk5xjrio/7OuWG4ITmspzuikiC3LB8gA+xFadsWHXIPXjikttJumOPLIrXttIuAC0q4GMZzzXFPVnfStGJTTLI4PJ6qe4+lSWlwm9objeWKnlTjYPf1rR+wG0XDNGWJyA4/Wmi1gfLSIkEn8LLkKfqKlImcrkcNsrRnyo5incjHP+FPFoCoaNdzP93cMZPp7VasIoreVYzMGkzyASv61fhnto7ja8TPG+VOWLFT2YfSmQYiaZuRpJEZ/JPzqD8yg9898GrCwRsoEc8ZmLbTDKMHH16GtWzdyWk+TKk7sL1HcN/hVe9tS4aSOFDGMM5U5KL649PcUAFi00b+WqoMDlJFDKPwPT8KnDLOP3kYTPLqo3Ln1x1FNsPsnyPDcc5w4KFlA/mKlleFpUUIiqc7ZYz8p9j6GgCpBN5FwzJJuBbYyN0Ze+KfIkkF05aXMaSB1ds5IPRfasScPHNtcEMzEjPfmteC6a6t4ra6GHVvkccF+Oh/xpXAZqkchmSS2T/R5z84UfcYdT7CqH2uUMkyYliib5WPcehrokeUwXMK7gqxeYyg4Zl7qDXP2lqYrjzvNzFICRG3BP1oYGhZSxXLPNBGtrcRgNjBIIzzWrNeJGWeSN3imO7B5VsDn8f1qhp9p5kySW7hEOCQzZIHt9PStrRL5YppbeaKMtgo7MuevG4/Tsw/GmmBzc8UEUrTR7xHkHaRnH+NWbUWmpy/OVSRSTz8ufSrt1pskTTTfaNrJk/ONyOPXK+tVntVkmSWy2bZPmHl9d3fg9KGBHdo0MALOST1X1FUkRtgQnDK27OOGHrmrFxA/mSEO0Y4IDdvapzsmgCQROJWHzM7Ac9OKgrRjLWRiS1m4QSJiVWbg+9MuZDlS0Qz1VupHvmpY0MNrPMxURjAAA5yOoqm0JyCJMGQZXByp9qGwSIcm6uIllBVc8H+79adNHFIHikdoyr5VwuQCf6VFcmeOaCFgVYncMdevSonnf5o3UvLG+3gclT2NCYmVdphufLnUNtDKGUZVz/StO3DSW6GVS0cgCEjsR0aopofJjgmJxE+OnOWrRsTPJaQ26Om1mcDsMA5H9RTEQOjCN43beFOAq/xL/ER6VDIWhZukR+4qdxnvmrzOYSsioBIHLYYeo7/AI1Db4aJpZYI23rvxyDgf1oYxrTJ9mt45lITBVgc4xnG4VW1G2+dFSUPMp++Twy9OP8AA1LebXNrLaBiWAAjIznnkA+ua15bK2lnd43QzqMm3PIDY55/i55x2NITMBreWXbGqsxU7c47/WrzpHCIi94I5oNsX7tC2OOn51PZyf6SjXCGR2kCwgHj06euTWRNbyJcSh2IDMcH1YHuaNgN62sLYWjXGn3ChpFw0cgKhiT94Z9DTBI8C/Z5d4HBlB6ytj+VQMWtLxI51V2j2qQvAfIyP1p1vA8sqOWTy4kzIpP3sAn8xVJgQbJo7MTP/rJn+QyDhBVS4xHEvkPnzOSW4JNat6sVxN9uBZXI8vY44U47Cs+5szNZxFXUhUBbA5Vs8UmBSWSbeqMAqRjacdq07KGY2oEEK7R0lkP8qXT0WNkM0eZ2UmNOv1ZqqlJvtgNzKV3NjBOCfoKEBbFuotnkaRpiX+bYcBffmqNwTe3sFtAMKx+Xb3Hck1Lqc8KaVFaQSkuXJc45ajRv9F+2PIQsc6lEyMhRjqKoljJ4UN4wjYybTtwvTFW7qN0jDkLHEi/Lk85p9vBHZpLOj/Mo4OOWqhdlriNTJINoXd83cn0o2RJFbkNPI7AGGMbmZj+WKzrUPPeM4zhjnPbFWbi3WONIw+S43NxSxqExDBuwPvGkJjhGkTGFX5LfM3tVG5O64ZVACjoa0L5EgwC2S3zDis6cvMP3YAXvQIXdGgBbJFStIi+XsGC3rUB2LCAF8xl9aYkpch3yewHpSGbqOsRRt3GMmr9ld7n4YEVzs7b4kBODVrSDsJMnSgaZ1QlEn3amtZnhk55Ga5+2mZJmIHBzVy3vA0uGOPei5eh22m3iucbsZrdikwB1FcnYmPCurZJrpLZ9xANaIzZoqznp09anj4B5OTVZT0xViM4NUIsx9B61Ome9VlNWIz8ufSgaJXPKgHvRUcI3ybm+76UUDPnex0ASSOWlbJ68cmtiHw9ahTCVAxwXySc9eQawLzX7iKG2lijSNpBuUsM5AOKp3GuahfJuMxWJMbsYGD2xVSUhJwR1H2C2iiZw0O452qx5AH9avwXVvBGFBELHjsQa4rz7kuI3IZT8+A3zKcdz6VRjll+0MkrHGee+KzbsawXMdzNqNohLNLGFB575qu2tWjoY0lIf+HK9T9e1c1cOxcLOMKvDMnBIqOOJPP3wzEwqw++MEVLZo42RrtqUscrO1tuZOA3UD8agW+eWQecoAI6Z5x9KAryxkGeJoH5KfMGU+oqSTSBJErRNu/hD5wD+dBmx8uy4iaXfiSIYYEfeXP8ASm284i2OomcAhnDdOD1GOlS6fFJFebZCrxSZjcdMZGMjNRyx3Ks67QoGUyvG4d8ipuK5o3N7Cs5cwiNwTyAxVvr6VJas0kTT2UUkv2YjBjyWQH0HpVACW7tRb+W6zINu4fxp/te47e1Os42t4iomKAt95TjDCjmGXbNbFbn7dC0lozHDKACmT1J9B61LJbJLcbmKjzAcSxMDG7f0z2p8qGaxP9oPm5Oc5OCqkd/X6Vn6Qj6U8Ukskccc0gDhskSAe1CYEjRfa7dTMpaWM5DKPmx6H8aRUzHt+0KHZON6H5PYetbUE8k1luWBWt2LI5UjKHOOvXBx3qvbW8AwzNIWU7QI3GCfcnofamNEFo0sQZJRJMjxNEJEPX/63+FSTpGJdkMkZMZGxW5yhHXIqxDGtuVuY5EidcsHDHg54DD3p0tnFcWLXMIW3OTvUAkqc9CB270gKMturCJ7SZIiOJYxw3sw960ROJRsvYo1ZFCl1Y5x2ce3rWSXELYumMrMcLJ5RCkeje1auYmgif5pUBCtyQMEdPce9O47FVWfTS/nGRYGA2PIco3rg9PzpJGltIzJHbQwwSHcwVSxz6g02Sb+zjJsgWXT2ONmW2rn9M1JOSLdpbUIHzl4gSUdcDkKe38qLkosvM1/BbyyqCjHa7bcfMPf3qg6l7tYnyDJwqyfwH6+hqS3td9tL5KSrbySjeBISF9wfSoreFrjeJj5csRHykYBGccGpZaJLyR0sIggEXy5KY3fU59KoxQpd2xMO2OZRkYGAfce9aUW8xgpJHJHGWAjYdCeuPWqT3TQzLBcxON3QKAualsq3Uhnt57dYpGJkRcgt3H096YYlt2bzVRy6FldQSwHp6Vet7aS5uF8ncWhLLgnjpnP5VS+yyW6+YjkQnc0YOeB0x700Q0UCwgmSRTI2xvkGAMA+1a3m2jFVEmyPYHUr8oHqMd6j1O332vnRKoMJBlUdVPb8Kz1RJyWXdlgCqk8U+ewkjQmbz5HtyTG+4vGwb+E84+nFOWEqqGQEMxJLZxhe5NUJInazVmHI3KD7jkVpC8SPT7WC4HmmNgZBjk+5+lO4AxfTt1ogRb0jak0n3RnnK+mR3qWyu1L20lyoQK4DKBzkfxfnTrtBJBCixCbdIFz3IbgEemDU2vxjT9SmhsoN8MIEbu/O5lHP45oGV75SNQjLyrFHHI7RyqM/P1APp6VRulkJIwyiQEFSM/OD1/HNXLBorlwswzCw4LDO4H29Qafbw/aLpJrZjMi8SRqeRx1+nFJgiK8eSR7UOp8xXHnLjpjGGHtUlhZv5kjRjZmVwGduMd2xV0BPN86QbweN+7JQe/rg8VHfWf2dkhhZnuWHzqD8oB5Ofc+lPZBa5mlDNdQSLIVRG5YDpg9cd80t5BKzfaERUEjAMm4ZJPfHtVmCOW1idwSEX7ygbmweMCqVy1s4so4fOBdvvE8k9PmpXuJqyEWZnmgljUbIdqt7qDk1FdOH1O5uIxvbjy/Yk8flW5JbW1vpEsKMqzAht453KODn0xWXdJHbQ/O6faJ4SrDptx0H1NDYW0M7T7Q3t7JksxztUAZJ+laWrIkcaLAgIgYI4J5I7D/ABpsE7adai1t/vyqHeUDkAjse31psLhQkaqHGCH96ewgtHkdb1rglGXhEPpjkfSq0rpFHE2RJKSVHHCAd6tWkSi6kkJkI2kgH1IwT9KoiKSaZpGO2BBsU459Sae5LRCrxmOSV2+YnjjtVVJJC7OF2IcHg81eeOMxxIqEF3wc8fKO5+tUryRI553tyzLH8p6DP/1qCGPnmChjKwZwmFqgrs8ZMsgVSf0omVTHueWONieRnJq1Z28Tp8+5lHIO37x9AKBCW6mWUsiqW24APYeppQU/54dOmO9SmfyUkht0UFx85xkmnRMVVRPKCR2FACLCrQsVbJP8J61PZrtUgqQR2prSI8mYiST1AFWfNjhXLZLYz9KT0KQ2ylZJW43elTy3BfcQmD61UVism4DG4GhC3lZLfe9aQze0a8KALI3fIrutOuFliUj7xrzeyXKbjncDiuz0EsqDmri7CaOuiOFAqxH61mwznAz1q6kmcY4q7klxTzTndsKi8sar+aEUsfwFTWpONzdT0pgW03Ko4BA9KKEYUUDPky6kZ2QMSSgxg9ue1BVmjTorMc4xjOOlX7RxKDlDHI4ILxjnH07j1xzSSb49on/fQ4xuByD757VpOQQhzFuxg2lEnD+ZKSBzjH+9+HSoLiELK0vIw2zyz97j1q5FjcjArIUUsrY+/wAdD71DJGzSk7CoYbs5z+tc7OhPlI4j5ko85SwyC2O/0qceWszNjgnIGM/SoMH5MdG6Hv8ASrVtH+4nYsFkRR5eepJODipJcriRSyhseUQST8wyc+wq7bsodbEyeZu/eFgOVc9eagmlnSARPcSuu7Hyv+gosIk81CWaInGX27sD1xS5gsW7c3ERjZpfMQMFXd8wOfftRfpEbyVFQEB8ZU96sSxNDKZFdDaSvlT/AA/iO1XpdN+1Mbq2xGsq58liCwPf8PrS3Haxm2CIt7GkgcICVkIPtxzUyI8tyyoSWQFsMBhh2q9LpqWlj9ollWMRlVOHXEh6jr1IpR5V0DchcqpPmLEcFQenHcU+gFa0tlt5gt6gckHaBnLEnjmql0jQlFmO5YgVDKMnIPftxWxawmVkt5HLkPugkVsEAAna3rWe9nL5Nw0beZGoGFI6MTzR0AvxRQrpk8ySSGJ3BA2/Mpb7w/A81LbukwSKQ+bJAP3x28kdmP8AeA9RUegT4kaK4t2aB02SEcg+hIPce1OTETpPbxk3UHzxFOQy5wy0IbRKYI2SeTZIcBgPLAZecfMPUdKv2kV1NpYkW4YyRgIvyY3Mc/lTL1Ipbazu9NKQRuW+X+BWb19M4P0NUo45dOl8+Jygm+WQo3C8+vv60+gIjnkmYhLu1mdgAFlhfG0+61JafLkwujxLnzE5G31zjt9K0JI7TULd533G7ikBJ3kZ45xj1znmoDaM9u01rLsaNT5Zb7yex9Rx1qSrETrLJE0m5HjVgJI+pwf5+tUbyF7S8WS38wxp1RgR8p4wPardrIsc8bOoCOpWSJR69CPQZ/Kt1kDac6RTySJGiusu0Agn1Hp+nWqViWjm7BpoUeKFyYbj5oW3Z2uOm4ehGRVyR453VhCzs5GJI2+4TnKkH061E8DwuLgxo0aHeWi6cHoR2NN8s2gl3yvJBI4JKqTgdQfqKluxUURXKfZ7+ZZQRID1X7p+lWJxAXj+zTeZJEC+4YPXgdai1S1nhJTK/KFYFCTuPUHPoadHFBJp5LRbJiw8xsYDY/h9hWfMmaKNnZk1hH5M4cESMMhwOA5PY+/NMljAdJULSRZwYuD5B9/Ue9NjQNJH5USrtYksmeD2NbUNgLQGWORTcghmZhkbD1Uj3q4vTUTiclcMbW5uI36EDLAD5s8gGnKkGPKjYMrYBR+GjJ64PcVZ1uHzriH94u2QMxbo0ZzwGGOQR0rLkSaeSOJxtTBRgO+P60MzRO0MUY+xvlNx3Bm6K3Y59D60s9tK+qzG3RQ4BzGx7Afr7VCJQY7e2DM8aOASTkDnkAf1rUs7R4S6SSv5aSFN7ZzjOcY+lCaCxA7iN7Q2UrrAvKlxjY2RnPtmpVnmii2sWLmVpGVuQHPUk/yokjImWSWJZ18wxj+FyDyMEe1al1Fato+7Eq3JIUDd8vXjccc0wSsYalrPz5VILpIqMi9ArLk4pbJEs4xIrO7uxfhtpVOoP5VLEPMimifI85mAm8vnK46jsSa0bFMRrby2581VLJuUDcf7uO/FC8wtqVrqS4R8yxpNEQCJF4OOoBI6nvg0biZpJgxZvvq2eDu7e9BUWdzHE0ypHKqttJxtJJ6/Sq1nG0RufMiJdXwcHcTjnj0pNjj2LF9NHFPiFSqPCFk55LHr+tZ18hYu1sHV0K7QRzgAf1q5JH9msFaZP9LYs2G6oD2+v8qbcESWpvg6tcO+1tvRM4B4/CkmDi+pIscrX58xfMMrbSMdjySfasqe3CEyFJHBJCsOORxwK6K1Mdk015GjbmRzkvnJIwAM8e9Z0u2eJJY2d9owCTyqk8mmthSRpR26jSkjdAbhUBdiucJ2z+dZ0lrcz3NqLaMb2AYjoqj39fWtTWIREY4oFmCgKDzlm46fy4qOOVUjnt3kcTKD5pA6J/dHuTwatbk2KOpbU+W3SObzmXcwHU/woB6d6y76+e0imimkU3J5EcYwqL6e9X/OhF4z7d8hQnh+AQMcfQVQW1iupDNMAuRn5s+mRj1ND8iGilbM8tt5kkqhYvmcHuB2qhFcxXUkivbAq+cyZ5rShRWttsrnkkqoGfmI6D1xTJo4LbIVWikZAWJYfL9R2NFyeUom1twiuQWRe45J9B7VLHIihWQhT94HqevSoLkoEQQZw/BOevrmpLe3RYXeRsKmNrKeAD2+tBNhLqaG2nZowXkY9OwqqJB5gI6txg0+Yxyynyw3mNnLEjA9BipLS0AaMI24jJJ60wsW7WcROGRACOORU12ibVkQMyvw3sabIGJXbEQq96ZBJ/rVlicKV3D3NJjRMhXyCX+9H6VDExuJMKcouBx2NEz4gVNpUucn6UsUgjjAhA5PzH3oAvQsyT7c8d66PTtQNtjcPl7GuW045uXaTqelakXzAq/3V/lQhnfWV0s8O4H5iK0LabA+fjArjtElJdgjHZx3rctZjNNtb7qnAwetWmTY6CHErBs/L2q+hrPgYZ7fhV2M1SEWVPTFFNj60UwPlyJ7iOSOVeHjyVI681PHJKZpCzIrMMsGIByakCGJmkePDkfIR0bPeoowssfllNrE5B9+4NZykarQnWQu7AfKBhkK+oqS1MwWY72EAB+bd/Ko7OQxSOgTBxkkjpU20DEu1mUgZwOV98VA7EEiq7rtZVJ6Z7DuKvxRBZXhfG7YcsOegyKglMIdQkIGwENICS0nfJz0/CrelEyXC7vmK8Ek5yvT+tJspIbA2yIKYQwJyy/56VLEFlm8rawRuPmI+U/WnLZK5lbz9jL8vMfLHPbsKltdh/dg3CTuPLIdcjB9KlIotwCe2tXaSNHwcAgbifwqyL3cJPPtZN4O7CKUHPfHpVN7I2032dLg5jUlmY8sfQCp7e1ivITIGkW4hwHQtxIO2M9x3qhhHJI0FwBNHMzYKxMq4x07/wA6jEAiKghonc9jn6irsixZtJnEa7lLA8cEHHzfQ9qWSMXMOzahVFDKy5yvcD35pu72JsWbmEyr9oVUdEKoG4GVPQk+xFVi4a1YMqpKDh0yFDn2PrSW00cRfbkJcIEkRsFW+nvmpEvoZFaC8JRS2JCVzgcAbvUU7jsU7j9xp4uo55Qq7kC5yyt6E/yNXtKuoxp5adHhkiwRLg5APPQdaqRW8UdxcRMDJA3GyN9wb0IzViO1lW1j+zSkrJIAVPH/AOqpvYaiXQYfsjRRTbJUJ3tKmA6sc/KOgGak09Vu45LS6hjYgBBIg5H+8O4PrVWwVSkkc0gikEnUY4x1Bz1FGnvcafqks7yMUk3CKRT364x7HHWmpJg00SXuly/a4havG/ybCuQSCOnH0psPm/YFaBGKq/EZGXDd8+g9qviZZZvMchJFkBdwvGf978a0LmC3EQuGSR5pPkKFsFqllxOZnsIpZ8sTGzLuT5tvUfrVzw/JJFqoiupVUlShGcBuOhHoasXCuztEluyNFwFkTqe+P51X1JUuHgnjRoZY1VcqvDOPX8Oam7uNxRW1B2sZZfsoSJHbLxnkrz0+lI89re2oZ5jDOpUCVVPIOcZHpnirlyxvHS7CqjB2EiEcbv8AA1HJbx/OVXyVlGCg5G4HOAfzOKepHKTrfw6hHBEzLC0RCnAyWz1wPyqG3xbRgXCsYixB9SOlV3QWWoHKCQ8EBRhVkIGD+ufxq9LdCYNC23EWxFPU57nPfmoehrDVjrNGOpbUBW2yVYkcsT/FWtdxI9qwvHdp4wFEkK/Ng+vqOOtUI4ri1DTxRhWBVgNuQWq7DO9wl1IF3xsu9iDlwc/dx65/SpjPsaOJzs9rLM81xFvZosoCVzuGehH9awpI2W6IMbRJlshufrXTzzTPZXskYKPkMNvG4/xAfhzVSWIS6WWhj82dApEnUle+ffNarUxcexixxi3WKe4gZYyuzjlm+groLu+W5ura4EYSIhU8tc8N0JP4d6qyDdFbGX5o2bbJEw5Q9mFLZq2ySPGN5Kuc4XI6AepqdgRqXdtGYoGRVL+aCrjjcVOMY7VSukljtZbXaBKvCBh8sysSSCffsfaoZb0RRIUVlVd+4443cc+ucVpWTs0RincuAAYwBn5SD936elHNYdrlO2gMd6tifMDJ8i7j8w+UEg+uBU1rGY9StRNGWcZQOvUk5GcUalFJa31v5rMFkAPnx9TxwQT346VJZ3cUEg+0xfaDy+QevHDexzVXs9RKOjKX2IXjXUTlC0LbY2I+9g/dPoaJIX09ZnizG7upVlIOzAzyfUntW7cxQyxy30GA2wHAPUk4Bx/e+tYkdu873tnKXQIcoob7xUZz7k0mgSGTWo+zRyMu8OC7F2wUIOTn8RVe4Qf2fKIcZZUlDjqOecVdNm125Tzd0aDe7E8svfPvUMe83scaoZYYhuREGdzjoT6j2qW0Oxcl1SRrVvIYx7tqiMqGDDGAD7+9Vba1+yQTiSL9+XEyIo2lV7qR68g1akd7ZZDbKBLwS4GSh7n8ParUaJCkS8F5lLeYTjkjH9KtOxDjcitZbi6uV8rKvMxYzueAMdPasN5fLs545ZHZpCSXAxwOgHfmuqfT4bW1lmkkEYj/AHZDEjdIOwHpz1rlbiQtZxtO3yTSF5JSMAAdFFPYUkU57UtA8gVl42IvQBcDJJp99ZpNdwRQTbLaNQ7SNz26YH8qS9sZJpY2LMId4VWLctn9KmmUxWf2Lb/qwD5g4zIfX2qkZtdTFuLqKOYLaq5jiY7pG7sepA7YrObbcXD7lJLttGTzx61euoSLpreFGld3JIxwPf3ourZI7hBCpfcQQF6E98UNkGYsO5zuJ355H90VoTxeZasIRuiiCqWx1PNSSWyJqQiClmzjy155+tF8dszWUYxGrbsIe+OhpisMRWhgOyKNS64DNgk/T0p1rI2wR4QJGDlzwTz7VXZWijQjh14Pc59KfFbyeRJIVZnOFOB0/Cndk21Lsd2I1dtm6InG8ngn2phdpH342kcYbjiopEby41kjKQo4wD/EfWq8+6aZmDjKn14FAMSd5Q5MxBcNjA6AUsBy/JCoOn1qsp3s+45RRnPrToQZWDnlB0zSEjR3Eou1gCT2q2GY/IHLEDms2LIkUjJX0xWrp44d9vJGORSGX9KJW3RY2IYn16V1OkZMhx07Vw1hc+RKwyThq7DSL1CivkA4zVJgdTbt+8AHWtOLmsKwmDyBh0NbULfNWiJLsY5HNFIh45opgfM7ys/ltNkoDxk9BVny4nYGRWBccKpHzD1FKsPmyLayRCE4LYJwQe9RyBrdFwCF6gdciudm9i7dxR7EkgVgWOwqzZOR3NRWcTu5CybZRwvPBHpmm2szXSiCNd7clQePfk1ctoLe4mWKSRoC38RGR7fWgZUa0Zg+3KOgyQOePp1qeDcmWTZGxTyiw/iB7n0qa4eNpU/0sOyNhnCkZOKdtY+ZOipLGBg8fKT6+9ADdjnH3kV3GCeADj+VaNhDO880Uj+ZMsbbVYn7w9D61Ra4JWKNVOAo+Ut8p+tW7GdEdXkZ5cMCWVug9PepaVy4siBPDoZXMZ+YHhh6c9+avKhnsbgzEq85D+b0KsOMnvtq/IFFuFhhV9pB2k8nH9cHqazXXbcXEUVyihxwJTnAPIUn1osaeottBM7IlwN+zLAqc7s8Zz+FWrUzQyQ7QwaNvmO3LMMYBNQ2lusemNbyyAzOdwQHkY6hT/SpbWRoYCY7h9mcKsoIbpyDTTJtqTXIhggMtzJuiY78IAW+o/lUsMsE16V0+2jM/wB5A/JcYyQB6+1VEtVVmSPzGUDcdxHDeqH+lJbWZHmtGvzxMHilU4IdTyB7807sTWpNFI0+FeKKIu37pVwdhz09s1bgl2zTadfnYw4BUYPH3h9QelKwj8l3MGyXI3YzkjHP4c81DbwRMVEqLJIuAGZyP5de1KWqKitbFy8T7IoiXErvhVd1yHJHBI+lQF8xN8oSZYlOOvzL/PI4rUgIklMDoZFQElixxGwHBB9aokxjyLhJFlKvlgV5Ve/HYVOzuW1dMWELCyRgmFGUMI2BI3nk89hjFaErQLIilGigL5JVTlHHp6g1n2Eryie3dGwCS8m3iPk7SP0rVjiae13TSEPldynnDZ46dMjpSchxQt+zXkiLc5ZGjxnggkDhgfXisi6hYPaogaRZvlCj0HQ/Ug4NWoHS2v2i3srRSEqzHK4bg8d6aJZk2xRIIPKPyurc4PofTpSTY2kQmJpFkdAPKhUDcvRe3X26VDemR4ituMySModXHAB65/nV6/ukUSwxxxszliyfdD7sDA/Lj3qrDpyojzAysJDsaF1+77g98d6GxWuT6faqhWe5ZDNGeZcZIToCR6dO1L5sr3qq+1/OyrAAbePf0rRtbX97bvMwZJY9jgn7pAP6dKW0soQYWljBGTI5zknIwCB/SplLUuMCncvKsMbB8RA8bT29wfSnaXHJ9rOWIVCcmMcN2yT7VWRmivZrWP8A0mLmNZDxgdsirmlXXkWcjKwIUndvPOBwDj07YrNaO5o7PQqahG0cbeXCFkRWJI4JHTNZdreSJcSQOFEMfCnAJ2ng5+lXZtVMt2hk8uMtHsYYzx2x71Xlt5CjXLFAx+4wXG4ehHfpWiZlZ3JHVjNcmGMSQouVDdcj9cUtlC02nSsF2+Wd4DLk7W7A98U/RYzdwFG3JICVd1bk9+n41oPA0ane4jhYlfbGM5IovdD5bM52ZXaZPtCv5sbgYOMEEfrkV0dh5F5bQJvFs9uM+YgzuPYY64xXPEM25ZIsyswO7GRs9j61cs4pkW5jXeO64OQvPQH0xT8yVozS1HHUgSKrglCcq27gqR2B65qhf6e1hHFcEcbTt7rgH7v5U7TYxDfyTSElZBsAc5yRx0rXmdI9HuvOjaYFlKxkcjOcAGmnoDV9THm86E25EZjWS1ZVcHg856etPDCaBLiI/wCk2zbZmXqc/wAX1FRNL5cTRlnRI03K7Hkk9aRI2wphCCRm3+V/fB759aLiI1dFk8qNDulJJz1PPI/HrV+VjBc+THj5VO6ReDj0HoBVLSoHS6SRk+QyMd7HBQ9/0q9paPPdlzlQ4ZScYwD05qSkWYmigVGZDLbsxiCgc4bHNOvbcRqy3Dq7oMBM8nnIHsMcn6VPFcL9mt8RkRb3x2JIGMk/rVfVtruEUI2TsBjckvgZJx6Z4oTQNGJrFzLeKhYYXPzgdM9sVnaom57OOQeZ5YVUiJxlupJ/Ct7zGdt8yIsjSIAuODzisnVItsguTHhkk8qRmGdhBIxj6c04u5FSJdig2xSS3UZdYm3xx4xkgdT7Vi3t0zvPIQw81FcRrjgnt9a21fz7OeBrhgrSjeyIWcjHA9MetY93Hs1BWiUxWqbS8y8nnjK1rHQxnqzNngKQ/aZS3mgYEaHBPpn0qHTxNO7u/YYX2+laBVGuZ2t3xbs2VZgRx0BA/wAaeLOSykt7QbnuiDI4XnaT0B/Dn8aN2RawtjBFbRrdvyDnczHO1yfX1rMhW2nuGmiVl2sR85wCc9j3qe6DQzwWqvkiMKVzkZwScj61DZNPJbFVuPlB+dQMbeefpVdRWLd3bPCY5YWADHdgDJB9B70y/wBQf7KWkURs+CcYzx3bFPaaK7D7d8VvERscNz9T61kX1uUuXkSRJIjK2TnqKq5LKSOXn3ySZ/iBHeq8kkm9tyYLHO01djiaOfbwArfKfaovJNxOWJxzlifSkiGLGluq4ZpC2BgAYGavRQ5j2qBux97+7VVkd1VEA2/3xV+GKSVI4INzgtwij5mNPoFhYWELlUxISOfersZMVq8jSYP92syDdaSBlQGRSR83amyzBi3muXY87VpAX9OjMu89cnOa27IJCFBOSao6JJFFGBLHkZyRmt+KKKVt2FQY+7TQ7G5ppCbCgyv1rbR+AQxH05rl9MdhMVUEqPet2PcARuAGMjvVoRtIzOMjAFFVbVlMfUu3pmimkFzwgTrNbi3l2l16OOdw/wAaYoB2qyMQRgAg8HvT44yPnu40CLyHJ2luewqzPfeeiiVQU3ZXywOD/Wuffc3sUhAqS7ArK3Cho+lW5wAAWABPZeCB/e9jStCzqRbRPIfvDDZAz1qOzjMLyNc5yyFxnrnsKaETXNnkLGsRa43biyDlxjg/41FsuPJ2qjLHnBwOBjtirVqhj3Brht6nDBMhjxmgYcSlSzocP8uTs+uabQ0ir9mDwsXdQFHDngj2qawKs0hHBjAUk55yeSfSn4E13GrgMkkYAaLj2qssv2eUgspizsL5+8M9/ek0NaG2jJHtIm2DbulRxljzwFHcVX1KOMxCaB2jEp3shOcAVXuJGeQGGM/KMfL83PX8BVq3uIZLfy22nkswcHoOcDHrUamidxksZ85XWUlFRcAHnOKt2TpeEoFd9rZYsOeeKIoEkkZkfyzMxb72QM/Tmr1gn2d2jVFJeMoSxxxmpvqXy6EAhxHvRh5jR7JShJyAcgj0I/pU9lO7XqCF87xydow59PTJrOlnm8qRI/vp0lJI2+wFXrO8aaNS6xDDKxyOp6YqkyWtTblngkSKR4EaRFA8zkMvXAx6dvyrLM6xZdLZHTuSxY+vHvV2JYDJCmcAOdrFu47e4plzB5dxFJAI2eNhhQRnk9+1O42upbuL7zLpWgVpGUKp4+UEjoB6+9Q3kEV6bjYqGSIEg9S2McYHWq7W8qXWyJXjlb5tzg/MM889utOnhVZP9GdlniRmG7jjvgj0qb66lW00ItPG+/Exh80OoHLY2sO2K3hbLEZ55MwMoA2AZyw6AfzrIMgnkjkZwuEAYZwWz3B75rQ+2uLh47qUS5O5Wbk89DUyRcWhlzpM1veLI0iTK7DKeq9yD6irMccbXUtobcvbgYdg2Cyg5zu7AE/jUKSLtjkd8lnDtGvQAcc+lSNmQyi32qpcbjuwGU9eKlSsVy31Kms6TErQvGkLb5AoJyGHPNQ2sM0LOl25bcSysx3YXnr6HitW5hSTZFHm4QuC24cjA5wapP5ZkcoVAdSj7unr19aXqO1hYCfN3uAIygDjPOc5X8feo7F7jMh88SMFLLv4IwDkEHvWpYw+fcQRbnaL7pfZ8pTuD71WkhaG8uULRNHBKyMV5B6HOD69KlFbEbyRor5sQ4EB5XL89S4I96g3xSQsyucgGSNVHPuG/HpW5BdxO0LwSOZi+DCF2AKR29qrzxRy3sUQV8cAYAyCT7dqaknoDi9zFeCGSSBljTzGJB9AfXPqasraNJO26RIGBKbCPl6dRSPan+01SZT+6yWRRxgf5zU+xh5myRGgc5XcNwxz39etO5PKPtrGUN9nxHH5nCFGAxx61U1G4ZrqK0nTzH2BANuCeuGz3rSj1MFY4zCFZNpB7CNQf1qhqEq3bQlyrPESynHzMT0wR6e9TfUbWglnpQubhlxllQEndtEfOMCp4g2nSSRRLC0twHy7HgAYwFHb603T2+zXL+QryIcKQzDcT/jirVjvklkuLuNVMQO1SAdufX+VNO24rXK2o2sTvA0LA3LYaRieFYc49++feoftjLC2yXepl8vyiPujHyn+fWrcqTQwkg4jYuQvBVOOn41QMYJbzss8sYb5ejHPHNVB3IktSSa0E3nxlSHXPyn8vz71TkhktYY3jChkYAK33w3QHPfg9KsvO0l8jSOVWRcGPOChHT+VTJE4vknuVeSJpCSqHODjGf1FJyaY1FMm1NUktHRY9khfzenGO5+lOtrYWYEdpM0sTYO1sfJnk/UcUyKB5NSiWFgoJwQedpwRjJ59OKv6SyWsNw9yMnB4zku4OPwqeZlqOpDrNs2YMBDGAJCIxz9foapXcciyRXEYyi4V1A5DdTtPsO1SwBprqedw6x+cqKu0/L6/yqxqcEUN3bLFcE7zlVJOd/TnHeiLu7CkjNI+1ly7LblmD4IzkDnI96znjbULhLS2DshxneOSM9SffOK0o7NEvCyj5gcMCfuc9Mdhip7BI7T7XOm7d5aoGB9TwB/npWkWloZSTaMNpUIvLeZo44UTzBt4YkdWPr6VnQyRrah4izW6gKxx8zZOQD2FaltaDz1muXEnDqVA657fh1rO8zjyCFRZMKrjj5s/exVcxDiW9NiYkTQR+XAzBGDtgFep57/hWVJdbppRG7GW5c4cAggE9j2FbGp7mnlsPP8AIsbciMEHgt6j3J6/WqUtugMKxhzKuVVG5Bx/T3qrmfKVLiyDbxINu5QEcKdwdeRj15qHV7hPKMNtCI2ZRM7Zxlu4I/pWrcTZiNzJcujzAIVAJ+ZSAcY6cc5rBjit/tb7oZBCeQzZLSnsv0zWm5m9DJuQzwnqIxzknBNaUgf7NG6qFuXUFmI4kH07ED86lu7eKOPzXt5RM7DKtlsk9hxgCnSsNjvIrMX4Cpx5XH60Ihq5hzxmW4wrHzODjtjtVv7OAgUksOGLEYHHb3NTwWcpj2YKgnLlRknHTnsKltwEgd5OUBGechB2/GqRLRTW4l3OoULGDxuXmrGm3CxzOzRlSvG4Hnn0qM3C7XbeirnACjJb65pIvmheVGVX/u4xk9KGIqXDMZPLHCg9c8mpLSFhKjAcDkmmJCwlKspYckHrmrJleIeWifMevtUjNC1DyN04z1rbhkkjyFbnpisG0lERA5PH61q2sjGUEjB75qkFzo9IhlERYffPX6VrRSEAiQnPSs7T7jHRetaJjMwEh47GrJuaVkwjIBwM80U2JfMUEdVHBoppiPE5V+V2dkJUbQO9LpgBSRJVKRM4ZiPvfhirUV8q7fKhClRyXG4CnpfRRO5gTMcijKuRgN3+lc6szpFSRZb6N1aPaGztzhSMd6VSGL+XHLtbIXHJH4+lRy3rl9hAUOuVcenTmr9jB5Fq8kUjTjGcA/KT/SmnYNygshhx5LSOx+ckEEj/ACKsSNNGIprbmNlzlVyc+jf4UyW5dYxJFEhdTuJIHze1VJ2/dedaO3lucPGM/Ie6nPBHoadw2NKDyZ/Od12sdpAQdW7nHYVnx6dKksiSGBg6n5N3QgdeOlOsGFsTIsSOCCQrHBH/ANenRyPZrJKWlG9M+WyYAU/pxQLcLe3uNr+RCZFY4cqeAQepqSM+TyRvXcQ2BjcPan3F5cs0UuIw7DKFOBjsSOlWdSDSogjJDyIfMtXOQpA5K+lJq5UXYmYRxzRrtUq4+9j7/uD2PtV+4jZ1jTcn2grwQQdy+/uKoQzs1nBbO8LsMJwN3v8AN7/SrG3yY8oVymX2++cYx1ArFqx0xd0WJNPa7hllVnHyfvOBx6j8adYQwDdA42x4+ZfQeoz3qS0kZbSS6miYsndehz6/Sq4UPavIsv7xOUcdfrzRew7JjbGBpCUdlVkYNG+dobngYq7qh2XMizFI8naxzxn/ABrOleRnR4o842g5GB9a0TEl3uaRVS3kO9huyGI6E+npmjzBNbFmGCbZA0eWkkTjLcMv49D7UxCXv1xD88SjKtnOcYII9MVdtGiht4ZIcuYiwCHJHPX8qcpa7YypHtfdneQcP6UnKzuy+TSyM+ERh1Zlby1B2iRcYI7AVfV4jHbW3kRvEAxB75JyBnqelRyotzdKsibH4V3i7H1IPrxVG3E8N3IZiSwcoUYYIx2+tF9AaSepsyW4acqYtnGQiHA29Twe9SGFEKoroLiPG09M5/Spbe5hkcNazOmIiCZeSRjHHvUF9bxGMLDJGFwGYkEbT9al7lLRDDm2kYsQiPlDIvQnOD9MVYnthBPII4BLaYIO0425HGf8aqWamaEKsquiDy13DBcnoTVyO6A0/CxsdsmyTB+YkdFH+yKdgW5JdTJHaJJbwpIwwXjEmPrtHeqVksKXM00QaRghzvHyjnjI9c8VIyJ5h+UsrLuDbQV3Dj8KvWuli4tEuJWbasgTYgOCT3PrWZbRXgthdTERlfNC4ZmXnPb2qO3EkF/5caCN4cndIcgkjpWqlkY98ibnVcjYQRz7HtVGximSW4E7Rh2JkGRllX0z3PalFAxs8sj3kQmA81dpVo/vBR944+nFUtUjmidRDAxSVy6qg4bA/n7VHqU8izGcglmwu5f4F4A3f41avPOe4tmgkOFyiBX+RT061SVmJu5l27NGvlO0jqwyV6FSeg/CrWm2gN8UyIliBwzcKeOeatTWMelXMTSK8jEHK/eByOMmtK2t4ruxVgpRXj+QKuSCPX8qexCTehhWaRxaqwYiNY0LMdpyNwwCPatKO3SPTLcNvjy77pGG7LY4J9abqVu0csN9FGSzjDcEbEB4zVnS3Mdm8YQxMWzhvuqM/pmk2noUlZ3Kd4gkjithGRCm1iFHUjrkevOaqXUMdjsjYpIrghzu+YEnI59MYrXkRGa52bhIwJ2j+8evH5VlXNg897OJyqoyhIvkJwcDk/yoirbCnqRGL7VebzCpmC5wOp9AfQ1PptzFElvG8TeVloyX/gIHQ+h71AiNBL5gZzKo2SYB+UDj8a1XmtZFMSRq6lFLk8bj1DH396ptbMhJlGd5pbkWG3FwZt4LDBY4Her1rbedPMPOSRjkE7cgsv8AdrJ1FBcXf2yxnBvHOdkmV6nGAeh4GMV0NvZvFFuOCjfvEIbOwYOVA9c96zasarUpWs7WbGJ0MjSSguynO3tj3PoKgvo4or1TCzs5ZTEc4YnOAf1NRmUNgWoUNHMpUZxwQep/GkNo8z2sryeaInAHOD1ycf40luNrQuXFsl1LOLeQxIwKsoXBUjqSayoNQWOeaMrmPaYYmVScsR96tlIDHakXSACd9xEZ5OOxzz071jp5dpaSzbXaQrkbl2hR2AFat21M7dDGtoZVuNgQ7Czku5xkY/zxUf2aGGaOSaWQtEu9BGMl24IU+g9am0pBHdPczFpI4jIEXdwWI7D8alktpbaWKSZGRwNoKnliecZ+nNNGT1Emtw9tHc3EahIsK+eMs/OAD6VHIz3bXEqp5aRAAeSNo2ehJ7Z7U6GzeVN1zOGAdnCn5jk+3TJ/SorlJ2SczzPFEjqoQn7oHY4qk7sTVkVZzG1v5ZUqpbLscnI/2T1BrMkuMiEBpUSNyq71wfm/TFWNTnJlka0jJt0z8znqfX/61Jp9rcB0uJUVyQHaJ/4vYfoa1TOdq5QRrtopRFGsVvyrSk43EdSM1anvEtbOGCMo8p+YlxkIe31JFWZ7WQSCSORblW+d0XG7r90Dpx7Vi21s91LcXDo6xpyoxwCTxnPpiquQ0WHnlykFw7Et8zIpI/DiszIeSSONWRAC4GD1FXyjm6leWVEnxlFzgux6c9hVWNEs7iaaYOzhSqgfdBYY5+nJqkQyKKFbRWllk+/yBRHOlxutyWwVO30zVZp3lUkSbgDhUYA8VOBJ8qFNrMeAF6+9G5PUkijFsuGkwx7KeVB65o82PzAU5HoetXHsiFgdyESThQOXkb0HpSXEqW8zRWVukTIcO4O8lvQetKwFm0sZpR5oQogII38Z+lWFab7SRyD3z6VSUXJg8y5mKvnGGbJUeuKtWFwyYiEvmr3Ljj/GmB1mlk+agxxszW9GzbQo6dxXO6T8pLHAycHniuktdqkEgn1q0JmjAAq4opsZB+7+tFAjxnzUWdQI0LuejccVC8KG4zCqow52HoTTbi4cxxSEmQ8Z3d+eue1K0Lx3IZNzIRkZOM1gmjpaLIkhnYSFfJIHKqox17+lW7CaOGSaOIMI5R80bnAb6VTLAgneVZ0BWUDBI9CPrTPNMVzl1U5XBIGAT/SqvrcXQs3FtE88axv5SuvysTuQ4zwfSqEquJm8qIjOQyjOCvpj0q2lyqb4LhQwfDqyjn6U24gmVYzHuntuSrZwV9qTGvMS1JaKcGEmVeQ+OePbuasW15Is5jHQYLAcr09D2qNZlSLZFI2+UfKf4sgc8+9SXDzTzJc3J2SmIFYclQ/HDMPw6d6Nw2NBHiisWdEQQsc7WGQD6qeo+lN8gJdRzs6FN2AC3zk8d/T/ABrEju7iWWEndnuQOCO/HatKPJlj86Bgihi2Dy2enX2qblrUgYtHLcQRucbwzK4xg99p7iukspDBaxzkRG5Ytuz1I6YJ96zpLCCGWE5EsDjKheMjHT65q9YooiQSs2d2Sjpkg9uazmzamrbjbiTbbLGhYoD5pHYA9sVZUxmONpxs7qynP5jtVm909kkiDbVEmPmB4+hpt1FAjSRXDCJvvMqLn3zUXubWtqZ2pq02yKIkIRvKgEAjFGjmVYnSSWOGJtx/eD5WA7fgauKJb238z948gBKSN1Ye/pgA4AqaaxL2Vm0SlrfcfmXGGPUr9fatOhnbW5s6VYswVhs8tkO8IclRjOcdq03WKK1maVHGxAquq8ZPTNUvDU0UWqCOIloXiIG8YwR65roLuKRVC3C7oR821ekn+fWokbRMZxDucQImJUBVH67h6fXrXO6tbXNrcC6mQRtIMIc5y3r711F3EsixiUARIu4ysu0jPYd+KotMl3ItqkJ8uP7sszZ2jHX29qURTMkGOezhtkjYPJJuZsbWI9B681Nc3ODGkgBjQk46tJ6Cr0ugXcSvqCeUTDyFQksF7t6lu9S2FvFOwWSX7uHRQBz6mqk9CYJlZN92Ge1R0OAWVUAKL6nHUUy1QW928ZMmWXZujyQ3HUHpXZWVrbwkTW6L+8BCBshhjrz371QS1kW5EMGAqsJBkY+XPIHvWba2NEne5iS2myUCxVpVBDjJJBJHRh26VrRlmgS4beijlUQZXP8AdPpmrbsWi1D90/ks33lYHLdBz7VPbW0QsIZCxw+Vc9yCP6GhrQaMm6upbiymtRaljI5Cur8fU+mKyplkjj+1+YsjJxHhtpz3JFdvbWjWttcSCAGKIbWijI3KMYxjqRzmuQ8RSG4WE28IZt4jOBg7c4oQpMjGx9hizNCVKyNgkMSPlP0yetWYdMmhFujuZJouWjz8rjHYDpV2xkh0/T3sVZWeIFRlcbgRnP8AStF7RrSx89Wc3WA+5WyjKeNv+PvQwSRjQxSXOqPwJVRQm7oFz0Gex7c1OtzPb3jw+T5cBO5CgztK/wAJ9s9/erGjlMzBJFzIoLjHMb88MO/9K0HswYDdIu5wP3o/H+uKnYpLuRxQJ+/dH+SXIkDjocZBHp3FUdbglgkSSJGlhZRE6g5wOwHqOPwrae1Q29tcW2JHuF3NGGGCue/oRWDrIv5LFZLSCQyQr8g2nIGfvex7fSluwaVrl37LFe21i0ZQ3BcgkjaUPfcfWqVxHLa2EjmRPszuA24ZkPP3ge1VIJ72KT7PceWrykB8/dLN3z2q5daeqWzPcmZ87FDFuAM9uxziqvYm10V0sjd6z5aKdgBWZ3baGGOPxxWfPCgFwsYCxBvLAI+VtuCRn8q6uBWd2MKAsVcquQSADyPrzSw6aNxcSxuGcME27tpPr256UpPXYEjlXtEuFFxEqvGzbAqrja/Xj61cGo7okinKOV5Csu0Eg9M+nNOurS7snYW6J+8YNEnKqSe34VFNZGCyllu4S0omCgOu1fXA/HvS3K2G31hFImWSSLzlZiX46DjH41PpnnTwSyQCE7WCruToByT9aZaMbicBl85gAo+b5VHf61YjjKTTTS7vs/zZSIYU9sjvnGKm47GepaPz7i6uDlISdzdGyf59q5qRrmR0hui5g2KEiLZZix4/Sugt4xqWrRxWbgJGoH4jJI9PSp5LaOzuI3meMjczMNwO5v4V/Cri3cl2sYGq2aaXdrDIkYk3LGqlshMdc+pOabqBM8lztUiGIAuznqe+PSobuKS91MS3ku8LIVRVAyzc9++KlNlFLFIPnuJGYqHJwMdOn9TWiZi0VDKdyP5eSBiNs4IGM5x3NVNSLGNkRisMagyLtwpJPQepqxvSEBSzZiXyQ2M845bP6VA6/JJM+fIdt0agZY46fSqS5SH7xnRwJBbKpaSWFTvKY4Zuwx7UlxcTxRmFyImdFPzDlQeuPrxVhZv3qquJLnksWAIGf61kXjTLdys0m6YuCc8jgev+FaxXUwm+xLOnl6dbBmxcSzMyIxxgcDI/Gq9uZrhybhnEYzjcM7mHTj61JcRIYbLzC7SAEnBwMA5zVKe8nA2xlIwx52+n1NUZsZdTu6EWqZAJDSEctzTGVWh8qeThsYwew6ikjBV9rnCYPAPH0pCXLGQABEUBQeg9qdzO1x5wjqbeIMM7QQM4btUlq0zeYR9/o85ONo7gGnWk/lHLxxI0owCpPUd/rVK88zaYpBtGeF7fUCnsIsmYQ3PnrOrmNiYkUlsDtVSC6KPuOd+cAj9TVeGOQn5VICjrV+0s1SNmDbz3x1BoJYCQSI+S3BzuY9auWW4lWPQHNQJGIj+9XKnkg1LHK24BQApPGKBnV2NwzxoM4PU109hJvQBz2rkLEj5VUEngAD1rshZxWV5FbTXW4Jj7QyJnyj3A9cVaG1obEUZjAV1ZfYjBopblpYbxo55vPO1SsmfvKR8p/KimTY8HYOgYEZA7Z/zxVl53mkhMamWRFGRnGfWnfZmnX7QsiPEBuwflO33FUZ5hCfMMbnDbtm7aPYEdxWFje9jX8geUCg227sCPOfofr2pkdsUkZjKJmTLNGF/h9aq2+otP5014wkLHAQ8DHcD09qvbBDYmSIkLKVG4nJCnkDP14oZRHKHKK6RsAMcEcj3FSW00luQzSSD+IwYyW9z6CoAAlqyvP8zNkMrZxj19KdKCzo3myEvjOz5iBikM2L1lu4/OhRIblFxJEoC4Pp+XNZZlNxmQbEkK4fBzhfUjvU0zMqCSICQt8hfd8z+hPvTDHIyLISpVRlgmFCn/ABob6gJbkwWjfYZHDldp2nqD7HoDWlbrBPHbb5AIyNqtnBGOcN6/WqRwoX5YxJgDcGABweN3pxT7q3KTFQo3JHkBTlQDz8vrSZcexqRWMyzBFdFXk4Zs845xVyGRZ328hCAMMeVOO9MtnmmtwwINuqqWmxh2PZRTIkmW5MTDy5FAVY5DgkE5wKza0N42ubfkzNBFHOGZlIZTjhfaq+oWSSlpEBLiMMcDnJPK1qW808kFuI7d95IL/wCyO5wOuBWkkaxCSe3APmOEOF+8Oxx3qFpubWuc9opZbaaOYtHI2dit2x0IPcYq/oaW8FxPYXCGa3nctE+CCpxw4H1NXEs4UvjArKsMh2DJwFY84z6E5p89vc6ahZjJIm/ehjbcSuOdv0pxbuJx0LOm6dd2E6TGIy28r4DNg+Ww45+uK1NXimWEIhZ3fblHxg5PYjoOOKmsrlHyhBdJF2Ry+oP8R/l+FaFppj2sgk2i7eHG0k7xnsCMY/OqJSRz+q5SOcfZ5Yy4yqkblx/j9al0i2aS12W7w+fKhlcN8xYDp7BuvHat+502WRPtNrK8m4EkE8F+mCD+NUtMtbexuomv5fKeDJYg4GzrtA6bs45PShtvYaQ4aT5ekcW+RKpmWRpDlVHB49ScjNVNO0OBHnlmDwPKP3cacfIOx9CfSuhbUTcJNIrhpZAOUbI4/lj24qlZf8TbxBaiDBmLN58qvw5HJZR/dxwKnqMgj0VbcRrEMluo5bjHTB7/AErNmP8AZ4MJRym4kKTng9HB9c9q7e40yylvJkhuJHaEGQTs/wAy4GNuPT1rFtNPll+0Pq7NE2Vk3xrld3Ve3HGOKW7BSRhQ209xbRTRJJFG0zMXcYUL68ep9a1Ws02LNYtB5zgJOvVGXkk+x9+9dNpDfabm6tXj8iby8ybekZB9+OetPaxNu008UUYXJUruBYkn+72FNrqg5rOzPO1ae2uLgb2ljkcLFgH15BPWn69aQ3haeBJYGI5MfALg8AfrXUeI4lt7tYrQorLiTyyMljzwT65I6Vm2ts8mn3MkDBNjLLcW54fA6uAex9vWgV7mTptjC0H+kwoZf9TtJG4secnP8NboiMmn/ZX8qPyDgPCpYknoAO341tf2RC9rBJp7ImpqWnyucEd1bPoKpE3kOyeAr5MnyNLEAzqAcE464OaW47nNtaxxSSNDcbophlD/AHWH3lPuea0LF5rmFrO2gDRwlWmOck9jjtjNXptEtpzM++KO2ELyFASGZgc7lHQY4BpNJtpltlE0zYgTIeNfnQnkcDr7ih9ilLqOi0R7afEJUAoxzGeccHGM9arTLJCwVWXawDtn+Bf7uPrXUhViUSXXy713Fo1JCMBkE46VXskjuFSW9UyR3C+W0hG0BOx9D9aizHznEa/AsUVxbJ5bAhPvHlz1wB2qmk8culLbuPKhYlgr5YuRwB+Fb3iGyi07W7qCMK8odUjaTORHtGST/WstLFtOd2Eaqv34nfnDMMlCPSiO4nbdEVjLJFfp5KbWjdSrAZViB/XPIrVsALSCYvHILm43FUyBgqSQR7HNUNJuns8vdxRDzCWdE52D2rd0+UazYzNF5cjxASbDwwXPX1yBipluOOxma/ZytYfaHaMEohUKOFOOn1qnK6Xip9qD+SQpZQOS4bAJPTv09q2NcgnfTbbyIyyj5TIrgqCc8/lUMUNvDpQcFmnJ3lX4B5wTj2pbFbkFtEsdy+nxGOOSGYsH3AKcjt78Vh3NndQpbxzzPDAWdjP0Y+/tjFdBaS/YwvmRQu0mMmRcFcuNp/Sq2owC/wBVeF3cxqkxCqVHyjPzY9qewn1RjNfQJYW8giMZMhBGAGf5TgsfU8Gsu7kVtN8mcsXLBl4+6c9c1buLMFJ7Yqm/zAEV/m+UcF8988GqtjaFgzfaFSMPndJ0B6ZH8sU9yVorFPTV+zxCS4IMqEiGNhz82Rn68VRhy6NHEzLEQQJD1+grXniZZRMjK5h+VGEZHy9zz15qmZ2traK1kIEjHO7G4Lu5598U3oJLUo61YWtnb2wgcz7gDt38qcncCPWshDdXc7rbZwqKNw6Rj/E1e1HUoFY28aKxQ43lsHqMnH4VlPc3C+fAUZIyu1Y0PJycgmtY6u5hPsXrkeVarF8m4Hc82M5JPY+lY9xMBeiWGGFVJAwy7ic1dlnHmqN3lRxR7dhbrj+fNUlcGWIxojlstkgtjPqfWtbmLXUpazMJAjAylw7YZuM9sVl2sf7nzJ4zkHgH+dbl1Cs1ozqD58Epb/eB/ljrWbM88sbAyggcIMg4561XWxlLuFzh2iiiXzFiBckDA3Hnr7U+3iMtnIoXLO+WXPQetTwW8aRKjie5ychVYKreuRUTTZXckYRhkKUG0Y96pEPYg1AQRgi3+YRgKufpzSXKLFBZKMm5dAzHHQE8Cp5jNu2JEjtjO8jkEiob9JI3WaeQlygGT/epkvYWcmR2h3BWxnbjmoo5Ps5B4HGcZ70aakr3DMxLuAd7noB9aiktTI+Su4HowORTuSWPMa6BcuGxngf1p1qPnBPBHQetVIm8lztOCOPrU0e8vuzRcDq9FUyAFs5Bzx2NepRWcl2EurrQ5pJ3UFnSUIsnHUg+teX+GZQNvzAPkHnpXpVzHb31/LcDWbUCQAlCzfKccjp0qkBU1n7Qb5muYxDIQo8odEXHygfhRTZYlF4Yo5o7hAB86EkH86KYHjFy7TBYghCx/c8s8c0kqNOWjULLtHzYYZP59adEmLlGR2RTkHjqPf1pbeENJMIApZvlYlcYU9xWNzexW+yhZQrIyuBwjNjHv70sMssEm63aQqRgqx4/KgGWBGjjkcN13HnIH1q7BIXjmlW7UueGUqOc0CSI4bgpCySwoUY437eU/wDrVLpIZcjZhG/hyM9e1QCEyGSGOVWQjcMnpjtVvTYzcxfL8zhivHOAfT8akuJovCwjjeaMSKVKBkwCRn+If1ptzZFLdPLbHBAx0B9/Y1t3MAkty8REcoULuHIJxzxWfO0ttaNDHj512yAjGfXipubcncwbRZfNMbOqrvGVIyQfrXVWccJmayuWiJKkrOpOFyfu56D61WglggtEmmXfIo2qDjDLjNWdOeJ7OSd/3CluFK8YHoeh+lAJE8elvFKzGcCBQCB0/CmXsQhvIbjc0m9fnbJOB1z7VsaUYLm2dU+SUj92snII78+lASULLYywtkIFGF3Lx1AI61LZqkaOlT3Bt43WVVx0ZlyPxPat3TCBfp5UZlIwxIPAI75HY5rH0qdJL3yfLS3AH8Xc9B9a6GJUt0VTL5ORtkeM4w3p+NZvfQ3i9B76cLtneZBiUMWVsbQPQfj371JpdutrI5tpzFGq7UyARx7HtTrfV7IRCKfy381WAVuArYwMn9an02UXDWlsJAXnJQRSD5gi/wAXtu7ZqkTJo0I9Ls2aRrS48m8kUp5gXdACDnbsHQ4zVubX7dbaDOnx27QttjVSSZk6FmB7Z9KgvdcttOaCHyUtZoJWXyZTkscccj+I+prLgvWvr3em2Mx/vmklIby2GcKnqMmqvcyst2aejSw3FxPbNIYbhmEjJuGJjgkDJ7An61Y1s2K2hVo5GU/OzHBDj+LHcgkde2KxGeJ/tBvbiJAxEoj8slwR1O73x0qHUp7a8js2M8pS2XYWj+b525yV9Og4otYa1J4Lq3G4zILdJX2RKF4Y/wAQz2HtW5pMt4zmJ7GO3ddyBkC5/wBk8dAPauZ1K/bUIbKKZVx56/NGdmVwAM+h611sFtaahqojsr9rOUSbT9iwFxt7Fu/YkUJXBsjt7CKZZjCv2gGQK0gUoZFOCcZxnnNdPFMReLHfvLHCygQq0QG/Izz6YHAqOTwxZJCkr3VzLKdo8wkkAnjJToemKv6nBb2ZuVRNpmWOKOZtzrJj+HHY5z0oasYuom0kcnYWE4vtW1G/dkSFQYoh0kYsQgY+vArTstOkFtvuWS4kjjSSFc4beT0z3z6dqwbOWW78SQ2YneCEs4ELNvVdvIZh3J5x6V3Gq3UUk1nJFDHcb2xbpGMFWBxkk9OO1Cd0VNyTVx9va2d1AyiEM8UbFWKbnRmJ559PSqd7oX2nT44yytcW4y80KbS0fIK56kkdvWrNrfW62m8S3EtskhhaRBtaaQt8xK45x6+1XJrryJZkQSl3OIuchw3BcjjAHTmkYc0kzn7COXTJLgTpJPbSW6lWJ2KqjPBbu2AM1Xs4LXU0iMJJkIJkZP3ag/wqwB/WtnUR9rS2ht1TyJX+zK7uTG0eOWA9c5qpa20bXl/JdhEhmcRxRvhEkjQjkY5PA60+W5op6eY2LSZX0+4ivlG/ATMJHy4+/kEYAAxn1q3HavbalfNKI1BdBG5bYrAgAj3NLqN9MUlCJJO7ZgkiV1CxhhkDJ74xWT4Xlv8AVLhb+6wZfnhihJBEAUdSDwDxUtIE5atsupFc28EixiB1LNHtWXcScckjvjiqm68aOOGVlSSVQR5hVklOcbY8fdx3BromXd/Z8dqlwJyweZ/KC7lU87yfu5P51W1a6srGwLGI/JJuO1d7CQHJUjHAPr70mtAjVbdupw+pQWy6rqE8rGRCkSbCcyDcSDj2BrGvpm/4mFtdKouPLJQqMOcjCn8MGtiaG2eRZjuEk586W2LAFQMnK46Y9PasbWPKbWbuPebiMbCjEks8O3Pyvjg80oxbeh0ykktSvLpRha3csPOEaBCGyHBHWnQmTSYjdxZJ3jepx8wYfwn6Vjy3X2a0Z7iZ5gU228p+ZowDwjf41o6ZdPLIltPaJt8xTjO7y1K+3rzWTWtzVPQ6FrgWkIQhNwjEjnGDsOQB/XNW7g2psZZoVjjkSX/WEZOw5yB681lxwm8uQzwLHEkIh3Fv9ZwcHPfoKp2s1/NpbAsqFpAyjAGMDqPTNKQLVGjt86zSSaRYxKmM7cs3zYLfgAKwjaR3N0Z/MywjfBZcA/U+pq3BdFRcbZUZwMwxkZYEcnJ6CorG5gglhnvJXKGVy8RIAIK9MdDUqWpbjuc2bmeK+m22piuGUxyN1UDPyL+AHWsp7wWtykbFXj8wkgKeT14H1robp3Zlg06KTzTgmNmyMgYBbPf2FZ6wSsfLiAN35qyPJIR8pzwOn4VT1ZOyHalK11JFEZjiMsnlrH9wE54rn7qR1U72eSM9OQCv5/zrfkaaeUR3TLHDvC+YvLkZxgeprI1UW87yJBCEhVfLjQcnA7ZNPbUh+RheUtzpxWPLOr7g20Ar9T3zUU9nNbywPlpJWBZnYckg9PyrVt5jbxPDamLEh5QZLccDkj+VVFabcs1yCsgOY+CFYE9a2UjBxMxEthI8jruZiXJbk47gCs7UJZHaSaJDEoOFQZyOOv8ASte9dprt/sqhF2ksduBx1xVa8BNuqyknIC4HQL/jVKRMomdYM91L5cwJViwLdDjH60abFCzRQwIJmVSwyNoduw5pNPeSNXiDqZXBRBs3ZBPX0HHetLTo4oIZ2ZZVEfzEDHXGPwraO+pzPVGVPC41CeS2QNhsM8QJCN6e9JNp7yusm9YoAdwXnI+oHetfzWa3g8pEiaNRiOMlYyzep/iNY8zCKeYrIzIDh9rYB/xqnZENA6ztdHdGxgwEP5fzoVEEi/aAsiA4Cq2T7UxpId0e1nwQDljnFUbtsXG9XOzOPcfSglk1yxVJoB+7TsAO9UrCaePcM/Meo9avX0bJetsYN0yD1ziq7nyl3Ip3Z54qkQxGiTIZhlzzsH86sxlI1z7VT818/KNuepI5qbKovQvn1pMSOj8L6t/Z1zJi0trkuBjz03bfpXdaf4iV4yx0vTgT6RV5nYD5lG0A9jXY6WoVQH6kd6pDOmtJDcXbXBjihDAYSIYUcUUkawQKv2e6M2MEjyyuOOx74oq1YDym4he3hVpOcDIx1JPb6VVhkkWdMRlJGX7ueM+vtWpcBWctOcEfw+lZsaq6ybjgDo307Vxp9DtlG48eWbgJGCrMSD5nU8dqjhspYZUztkUgkk9scUtt5f2tTJvdB/B3P0rSM8ADLKxfOWjOMA+1UjOxTmsYhAZF/dzjkHPb0qPQYJhKxilZGb5iR0welabGPyHVpVeFhgkjB57AVBBbyRtsU72iQupU/N1xj3oKtrqbKiWJjGOSxG4lvvfQ9qvwiGRZI7oKjZxgjJY+mfWsm2uPN3pLC3lHhmY5AGeSKnvGCSoEkSRcARlBynt/9eolodEbEbWkdzqz2aRhYsBQVHIB5JH1rcTTYfs/kiVXCAqUUHagPf61Q8t47USNu3tjBx1BPXParlrcTRWS/Pt+bG0oATk9SaeyFFJNlqGXbstZChmxtURqBxin2to0ysd7iYMVOx8FR7e9VtouoZy0YjED+WB3Ydc57fWr2mRhGaOFvlVQS7HG0nkY96TTZaaJbPda2ri5QnygBuJHzKT7966S08i/MaIwJZApBzyfrXPrcSyTbpRbtDGxG4/eyeo9q6GxjghlBjZ3iU4dI+rtjgj2qeUtM2bK3t7aRFCAybCgyqnnoD9KdplnFpVxMl0y2xtlEskh+bzRn7o7jPT2qBruGNTJdh9oTfE3VVcEH5vWsaFbrVdYnlu5VaQYkmYqQrL2HpnPamhSLnie+iv5n1O2EYbcIB5eQVU46jv796o6Yl5Z6w10ieZEf3QR4huPy/fP8PXgHtWpFLHJexpJJteImVpi4+VT16dTXPw6hNeyQ2htXawW4ZC4YB2U87XH92rtYzbudLYs11Y/bL+VoN8iwoZEyAeeTj2xzVCQ3UN0G3WxitfkC5OAGydwA54NE3iaR71rRrWPAIjjA52KCOTjvgVW164ttQuGlsrdollZh5sbtlE75P59KGroFKxveD7Aanp1zqE6wtIsgmELDaZI8YLA/XtXSeBrmzXUGuL8o1vOHwXHzRhTheg479a4mfUrS2WLT9JuQ0Tr5LM2SDn7uBx1b8q7PRop9M1eJbhInTy1spZJGAXBGSW98DjFC0FNXTOjfVjdXV9HdQKA5UQmEliFU5XeRwOev1rP1AtqllPGbnbdSytucEqLdc4GB0LZ/GoYdR0zSk3wiO38ubZIuCYp1IwW68HoOfSs69vtN0SWC8uJmljW5MzxyEANnsmOG55yfSkRFW2Rk6dYXFpqMiSf6RFKhX7aPkdAB84A/vY/nXR6XfTwrP8AZ4hAsbqIjNhnkjXsATwQO/euJ1jxM95rkkcEBaW4lDyHgMgAyCB2OBXfxzyahp1sU+a4vY1Nubog7pCME4HK8Cp3Lb0XMTw3YfULe0ui8UNzI727yD5/JxuPsMsMfSoBqElwjX1/5rmaJoI4ZIz5ZAbd8w7cAc1i6jdT2VxDbO6XTWpNs3OCS5Bbn0FU9U106hqJt4Y3VLNnjV1bAJCkqDnr360IOTqdbda7Db6dYxW0ZkhkkzHO7kqJFYfIBjj0FZt1rtvZWq3g820tbycne6iSRccNwc8ZB9K4PUdY1JZbaR15i2yK8Z3+SG7KOm/HNa1vdSy6ZcWcdo7Wm9p5rycBd6hgQjN26EcVQuRI3YNcebT7iezVXa4uPNaaUbOSeFH93AGRXT2Mca6oJrSEyKkPybG3GbABb8c8fhXERyM2Lu/s5LQ3CNPEsS7yFz93g4HHBY1b0ixNjDcX13O897Kwk3LMS1pEeVwRwSe4HalYT7I72ORLPTruHEtxNEGlJIwfM6jHPPJ/SsVZrZLiLSnaRpb2BpXkXgyOy4JPvkACqEWs3l8TZz36CFJBDLexoEYq/wB0jPHB61c1W80rT30uzE0DXKgBEc5JXnOCOjEgc1LVyYx5XbucjrzzvqIikjhE9ysbJJEh2rIAQAT3LZOR7Vt6JNNrFjb28sPlxRQyQlJFAZ3jyRGT1HBz9Ky5LRomulmzJKiLOfKfhow2SBjuAetX9HkdLK8fTTF/pMyyh5nJjRSGUDPXcRk0J21NZ6qxx2o2E1/GthYRG200yNM8m0PsA42j2ye9bPh2wurewRY7eRijojsmCR823p3J5qxpVqJJ7YwTQNas01qzzjHAUHcRnrmqsviCGw0m3gTyftK3Ed1CArbCGTHzMOpJGazT7mjetkXxHDFrkiz3DRJLDvFtuwLZxnaMnp6/jVWW/t7mytLYSxpcySJtESk/IAdxY+pJ6VPoNlHqhEl2vnTSK7jPeRFyB78/pUWoagEvIivlAi4EhRQMxkrzt9ucVMtiob2IdMiNpa3LWu1fLnId2bPDDjOewwfzrCvbZLq2c3Sxowj+QZzl+xH4V0lw0FwZFhfETyKpjxhc443H25rno3xYzTTI0MqTYj3dyV5x7VCNbnOw61J/bKGBTDdxBdw2gLuUDv74rRRHtbq4uWQW7ljIFkGSCfmNUUsYrzWZ55ozsaXLleiqfb6iqesXk6NNNcs+CQQobOeNozVWvqQ2a0rwkPKNyyiQtHnnaue3pzWFrUAsp4pFO4SfMxJ4I6ZFXLS4XyE80BZHGFO7IHHQmqgtp58snlswXcMjKrnp1p6oGk9jJW0CTRqGS32qzZzu8xs56VNqcghgSZwxDM0ShBnkYyat6kqyXDW10UWWQKVOMHJHQH8KqXUVskTSsPMlLAJzw3rn3rSxiUFIa8eN/N8lWJPHLcdKDAJ/KMaEQby0hduQAOOlW7E2zReYZjuBJfcCp64wDUM92GDlZgsceRgdSe2KIaMU9UZ10LS3u1a4gCNGFyFbGPbA7nvSLdRSSeTawKJLhizSzPnC+w6VWQm2tvNBDK5JJOCXb3qnGojmYlgSVJ9Nv+FbKZzyjYjuLqaS8SNZTtQlkToq1QmI+UgFwx4IGAK0reyhicuztJ8uQy8Kv4mrAWznhkD+a+zJhGQoJxzTXmZtGJdIEhhyGAZAx3dcZqSwSOXdKzfIhBRWH3qdqAln8vETyIqqq7snp2/WkFs0wmMxWJ9nIPy7T6Yq0jJlab7VIzmIoTklmXndRavJ5LySr8q96rot1FdAAE453L0xTr2R/OBHKN/D0qkZsabuPzC3V/apImZ3DO3y5qi8LZVgFCmr0C+YqoCev4UxGlbzBZF2sMZGT6D1r06MnT5dRuYdPQLD5drYI6lxO7DJk/2uK80tLDDKoxubAAJ65r0mLTLSxspI/MvJrnTZolaUyYUE8sI17Y6A0JFIl1RDFq0kSRiIsiM8S9EcqCy/n2oq3d2Atp3WJ2dWCyoz/eIYZGffmirsK55cJ1nhSK5dyxyEY9vQZoEJjsTE0btJvIftt4+UfWqDxvCMbiVYYDdcVpPfusEZmQTxYVW9Qcc8/wAq40rnfzNbmVg/aY/s4LDB+v41Ytl3qVeU+YSX2j09q0re1gaF7hC0kJG790vKkdsepqWC1+1hvssG5AAxPRo+PumqSJtdlSeIbd0aoYiu4DPD/SmxXKLOpQMD0kUj14xVi7haFpYjsAJACKM4HfnsaLC2RGE0YJhB4JGWY+lFivItwlBEiwuJHTO5SuCB2471Dc3iSXCNGFSYAA7UyFPfParH2RflnzJtJJEg4zjjBFNjiiWP7WwRpgfliUbefU0r31L20JxfXLyJCyFg3yO0Y5PvjtirM0sUcWJpCJGO1S5xvOeMdh+NVrF5FMs0SjeoCSlW6E84FTpte4RrhAsOzOX5BJ7n0qlqHUfpM0kqiPOI2BaQh8g89vWtYQGKRjPdGGHbkJjBf05rKRoI7t2KyOsaHylVMbz2P0zWnpdlc3UchvWLSgZbLcYxnn09qHawokLwW8UxOwXEsh3KitkA9smtX7fdW01r5UbrtAX5RnPcjHeqlrA2nRpqMcqGN48RRJ8zuM8g1NYpHeahJI7tEI1DxIDjZkc8/WpsWtyS7uprwzCdEW1XkK2QEye47ZrZhvRb3BDq4WSLMkZOM8ALx3A9qdp4tLrTYGlEcl3noxywU9SewFSwTNM8hQB4irxkEcgdsfjjpVKNkNu5UurK6UyT3V7GjyxHIV8Kw7fQDpViTTbbS9OTUGDTxXoGUZiquuOSSORyalttPS/s5I3kl8wTbJyVUxoMZAHf6mqWv6iWsYrK2EXmQIPLlwdpGcKcHjFNEMy538+xi2MHeOc5bG0sAMEEjp2rqZ9GhiuLeWORZfPiE0caMdudvQn+YNYcJaHSZ0ggL7T+8EigksR0BH449jWsbua8ZzdHyIEgRfKh/d4IBwx9SOmKoVrMw4Ip7aeBLmSOZoC77vL5HXBGOn41qQ6ysdvFDeySy/M0iCUjJkOCqsepGahtruFLRZpkH72MoIvM7cjLd81A1gl7ohms2Md3bDcUkHAUn1PPTFZyjcq53hvL3WtCRxDBbxTR/vosAI7DO4YP3T6V5vq9zDFd2kX2rFswAR5fmKg8YHpjFW7DTmaC6N1csYlKPiJ/9Z65Y9MVX1CH+zdbXEazw7NiybPkQkdOevPNFgNbwpYSXWrs9kscySjYHkxvcN8rMfReTzXY7YluLs2t5ODbqttCkZIZSAcbiegPTiuXspn0W3tosI8isZZJcZDoSMLlenPT0pmr+K7m71S7IIhkkk8m4xhl7bQG7HFFrj23Fg1EprE1mrL5TRB3bqVmUcqCeuc9ataRqrabBM13DHKbh9zGXlEONu4gfUAGsu9sbSG6mewM9z5yhhHgBicfe56DPb2rS8G2lsmofadQ8oHd+8kc5j49vY9qLWBu5etbGM6PPHMp+0S4eYr/AMtSTlQg6qABjj0rpNF0hLNtPOqPM1jEryRxMu4KpI2tIvcHmuchmtoZSbiFrlkZUgZcsJctuA7bcehrVF9/Zmrr/acVyYJRuaGI7sKexJ6DPQUhPV2Ol1XVbW408QizE/mgwNbKm3AAIHzdkBrNkgjttPh83y0iZ47aC2ij81IgcfMT37DJqTwuft8N61ukommmK+ZeYDSKo5CgHgY4zVaDUpJIkht9PTc8pVXBO2BshVDc/c/xoJt2Rla/DMBbSRxmDUbcNC0KNvMhUkKxU8AY5JNc5DpGqSxXgjthItq6yTSI3PfGM/j0r0q8gt7Uahcajc/aGvITax3QXazSgY2EjgD6+lYPh+0k80jzBcyzsFkijIMYKry3uD0xSZUJXGeHbJ01KKXUibSGePyFjtpMqAy5LE9efWqeoTR6MJQiCO3uJmCJgtuxkbiexz2rUS2e2hgItmkEcbzqVblGzgqB12jsD0rE16T+1nTzESOzjjRgsYz5h3ZIY+pqdy0nuYdzrFu8F3cR26jU3uEVIGj3KAV2de3POKjks3i02VNQmFzLJ5NopA3eSd5IVc9MbTyPWtDRLRLuz1mS3RI1MZ3M4w0bk8YHc+1M05Z9J13Sb7UTBJapDkxryHZs4OPXnmp0Hrc07K4ksbhvIyk1ufJjkT7uOhBB65yRUj2L217dR4Q/vEdX6EKVGR9M1Qt76OFdScrmVwixZbLEFw2V/AGpGu5oYI7/AFN282YiHz8hiVCnaoXt25rOSNE9Ta1COSHQ9kbFBcTZeTj5NmcH8Sa4HxLNAmkQ3D3cjMsoYFWPL7Tx9OhrbuHlu72OQlvISNmJf5lYqozx09q5LXlingUyurHAC7FwOnTFJId+iI9P1R475YZIt3mpuL7jkcZH61Z16aKX7J80YkXO9ARhsYzx61V0xovti+dCoDxOVYk5zgdD1zx0qG9uobgWzIAZSepOSvrn8KrZE3Ni/EKR3DWiQyQokT5UYPzAZx6kHrWDdwPbXoS1lkWUgZAOQQegxT9wlNxIszRK5ZtpGRtHUcfSq9qfOl8yTzMyKzpg8c/d59KT7gn0J7mRb2e0YFpbtYhGyN8qLIpOcH6VRuUms4ozGzErISVYYUZ4wM9a3Ll7eSyt1tYHikigxcbxlC4Ynj1NYN5dzXKvHLI7eWuQjHjbjtmtEzKSBZpY4ZVmtyNvSPoRz1BqO8sngEU6ozI65w57HrkVUsLq5eaOMLuDg/JnjaP0xT0nFwGklLTISVwp2nNWo2IchBbxyw7UOxmbCrjp7VTvNNDXjh7lVSBMkKpPHqR3NXdEv/8AS3k3lYYV5L5IHYLz1JNZLTzfaYpQxMcjZxgYHarVjGTbEuoBchIIZlilCnMb8KR659faprKGK2Yyu0brECcBt2WxjGKjR1aC5M6stwcrvz0qKG5gSOSMFwf4hjrTuRsVmllRg/3YxyABgg1FPeGeYZRQxG3cepqw0wkIj28twBT7qGNbj7PGyhkIBf8ADmqiyZIzZr5kkMIwTjoO1UnkMvP3iOMirN3CkDuobcH53U1JYkY705UfLg9TVoxluLFCWwJOF7g1eUQxYWLn3rDkkuJWJPBPYdqtWjsF5PFAkdLYRqxXI3O3Tnoa9bs7HVGtj9s0i2uJZtjPIZwvmlR8pIB5/DrXlGgIshEmM8glT39q9ehW11OT7VFqMEUbhcxyZDxcfdA9u2KpDKt9a6mlz9rvotu4gHYQVHovHT6UVtyS28yahLHISLjZGiHq23GZD6ZoqiTwCJCk29mDEZxu6CnOR9mBt85yN4XkfiKc0Y3jzxuJUYUHkUtssduDJIi7JCVAU/Nj/wCtXEj03toUobyVliCTOro2Ao4AOevFadtqYSWTZGyvuwXVyMfUd6zo9KlkkM6Or4Bwynnrxx61YuNP2iKWInD/ADFf7h7ir6GSuX5rjzIpDA0bhOS6jv2HqKs2t0mlWKuyyfaHGY0JBMI65x6n+VZ0cUhMkaIpZwM7epParV2VubyVZyN0Q2sN2SP8fTFKLNGQ3+uSXTYVGRSMDb27n86dpsUs6iSN8lIy+HOe/X6j0pstqsswWJWyQBHGDzn3/wAKvSyQxNCbeIJPtAMxPB7H5f6073JaH20C2MREZeZ5c/KvHB7k961IYBd2wSdRHCMBnzhiB2x6ZrP+0MsP7tfmK9CeApOOP8KmtbjyLaaNj5uEKKSQQD1xSRZUht7y3YmOQvHDn5ScYXqK6W0nSGORt7K2QRgg9f4m9fTHauWX7XHZu7B443yqoR94fWr2jT+XGguHCnbtbPpnoad7iTsdLDLBHLbG7UrCzY344BPQVPqloiXcTGIoHBG4fKQc8E1lLO12jRRzB4YsFWGR/wABGf51WvruWK/aMTtIzgEKxOCR2ye1LqXdWuy3BatYzmOwMjqQGd5BnPqMVraNduxnt7pnSEfvPlXaWxxjPtwax57hroo3mPvlIE4Q4ZPb6V0kxSNI5riWM3ChWyCFBwMD9KttslJdDQs5GnsfMjU5VhH5sWF3IeSSe5Hf8a5vWGBmkKyeZNECsZC8OB/d9RipbzUmgSFYI/MWRndoomyijvjHeuW1jUpb68VoitvDGMgn7wbHT647UthS2N3RJp9Uvk8+ZVtLyUApJxuAH3mx268ZroNfC6fqbGGUSafIA1sAcLLgEdevFc94bdrS5iSeONJbhMxSNg4PqR71q6q15q8w3GI+UvlQkDCnBySPTnmqBdx8kKQxxxXMcNxfW6mV2zw4ZchQw6/zFT6sJoLeF7fbcXMsCszqeB0OAfYYHvVLSrGM2yCeOaZ5g3l7XAHmf7XtnkmsyZbiSNbaNFlD5WWNc5Ug4JGPQ0rIDXstTgihknuYZESVjtSZeCT1B9+Kg0KW4vZJi6uYYlZYFPTdjG5l7+ufYVW0spLqD2k0m9YhsSRmztOO3qa0TpgsGiuFnkW5yUmtv4Wi258wEHr0GDSbGlc1NKvpJbaMOIIoWzBviizzt++T36ZIri72SSGWRQrMlwquqKnUjvg/TP410F7eDVo9PihRrZQoll+fn8h09cVLc29o+vqLRo41jQlhkk89Dz0zQpDkr6FzS3mvNEtorqyigukjLM+/BZOnHpUeg332K4naRY8xn92Zl+UNnjOeCKTRWe4nvbT7TAsMcYSRZG+dupXa3oP1rOmeAKwESOsRZSjMW8wEdvT1FSylojqrW/li1aK7lEXnCVTDEn3JSwIYkjr6VFdTyR63LHPBGiupWNVLMV4y2R1IHauLsNbmsdTaFVV4omVoyy5C45yR69q3vDOo2891eapE7IgBZ5ZCSVBP8OeMDofrSYJnVW+t22n6SkAkkEhykAT5TGWwCx7jjPsantNR0W00JmTfHecOzmZsblO5cr6HnFc5qcmnXjMmmzk3boGjwGYMMZCk9F5qLTLeVmFncWayJCBLJHHhXZh/CXPUdaQcqe5t6prdzqeiabGssjQyiTcoQZJb+Inp3A9af4ZsZNKgfyGNuQmxvJOXyw7iqD3wm0y8QMIoUU+TEOcgdUz2x61F4e8YR2Flc2V5M6zSODBcKu5lyOTzySelGrY2kkdDrerSte20ES/uVj8sDGd3qM96y/EltFB4duZo53+1kxgIoPyHBO09uKs6ZeW15OwiPywhmeaRiWy3Zfy61Brd/C8ggubhUtJZcsByFcAgH1OOKUkVFmPoWqm9029igjSGZ/kcFQDhV5Le+aoz3KPJbtMptkijMUbRLuaRl4LYPGCTis+F3aVbQhY4lkMYuI2wJSfUd81D4s1RnkQxLBbwaexVNvG5gMf/AF/eklYUmWLO4nTS7iWYnyGljQuX5znoAPSta/v7aVTLExSKPyyN553ZPCr37VzdjNbvok84dgQVEkakbmZumM89a0NNsw0CPJcFkSTbA8fX1JP8qUojizYur2e2urmLVVaNHtT5TDDbt4BwSO+a5TW4pGUXCoEhhUZQg/M3bmtq9k+274pSEk4QITkkdck+lZur30KeXCIX+yPhHYjOSDggVHW5T0RQsZtl3ifHkY+VTlTkjnjvVfV7dbeAyW20L5xDccnAHArWkjUATyjYyLkqw5TjnPvjHFZGtx3dpctBjesuHUBfu5H/AOqmK+hsadbxFYtsYPmxEADkk45J+lVZbGO3iukhBYLtYSDopxyOe2e1XNJvPKv4hGY45ni8obhnGR94fjmrLRG3spwGjVnUBmmXO73B9c0tbB5mdcLI/wBmlhbyzEu45OFcZ6Y6ZrndUaRrxjeeVu5cBePw9xXSpGI4jE80cMeFcLJ8wBPv6Gqmsx6fdHDuz3G0Kdi5VB7CtIozkzlLa7kt3ikR0j8rcVwuSA3UcdBTLJJ1nAt1eSUZYKibs85qxcW/2G52xM7gqQxYBQq575qlPqVqrL9k+1RQqfvowJJzzg8fhWtrnM5NM0b5oLVhEMIQRI8XXEhH9PSql3aRiKMFyqKu7k7ck9qfazmeS6VCtxvVZIzMmJMfUdazLhgxD3AeFAx291B9+9HLqDloXtWk8yMklUIVQAp4UY6YrHiXABeEgHcSSeoqVoJVhFyifusk+aDuBPpxSySI1tFmNht7g5Bbr+VVbW5m3cqNOfORtmEDAHB5AzV6/ETX148BUhmOA3Uc0yZoV8rAILMCy8c89qrzFWuXdVOHYtjOeM00tCXuQTW7M/AwAvT3qnJF5CeYxLHrxzVy4Z1kXyWO1qqTF2yjLgVaMpbjrNo5CX9qVUAzk8ZyKZCmzGEYKe+M1djjLsFKdemBQSb3h6YFkRvlXIDGvbbe4e2+3ww2duq2ojeBfKBLx9Cff614xY2iqyBMZOOSe9en2j2el3kdu93qT3NsBH5ikADjOBntzVIo19XyNRZjhdyIwXAG0Fc4/Cis6eaKe5aWKSV1z8plOWJ75oqhWPF7kYZpNxD5zz0BqIu0hUKpYevT8K0b2JY7idZ+JtxUNkFXx3Gf51UaV0YGOKNUGFLEdfbNcVrHo3vqEsiwyxufl3tknvU6z3AZ57dyYvQ4IGe/NNu5muGj4TCDaSAP0p9wRbRJCowzDK98+lNPQTWo6a+ktrVUiKGZzgMowB+NZoiZothLbi4J+br7fnVh4XNkjAoyiTYxB65/rSwJcKJJZIiE+78pxn6+1PUnRmppkv8ApEOGxOx+U55XqOtMuAbGRJ5dzq3yqSOVbPQioI4nMUlxE6oVHERPXPdTUk1x5lkCz+YCACjfMMDOSD2otpqVfsWXuMoCYsNGQVbOcn1NV7YKJGPlu4cZYJ1yect349qs6Bbo8QaRC0T8hT1XnrV+/tY7GWYocyEEDH6ge9UnYNxk8iXFsyGZgyYVI84J+op0DqtpOt0ghLLkoFyxA6nNVLEIUuMB2cLmLcQc+oqJpLtZmkuHDqnEYPzbV9xSsO5q29yBFFFbqzLksSh4I7A02fTd7faoJlRpM5XPRv7opdJlt00+58oN9onI2JGOBzjJ/wAKrnUI4JTD5YT5h8vUsR1NOwr6Fu0a4hukuIBucxhuudueMMfWti5voWtvMmDzXhwqg88/3SOwrOju4w4uI4oEgk4SNE68Vnsch2SdvnJ2qBg4HHLe5phcme5M1sLaHMckT/MyDG7PO0/TPSoWtbmxmha5hhMiDKjOQXJ6nPfFWILSS3tXd1EwGCoz8yHqT7/jUdsFupXlaV8l9ik+p6/lTQMl0o3V1KUtyUKFgFLD6nHt7V3dslvBosxJAAwWUqcMcd27Ae1crbEWVqzwyKrl9xAIZye5q1qWsve6Y2nxS/unkVyhG0Aex96TCGm5WtNSlgICwtFKHK7ucEHgnHQiqz3UzLLEZfLSJi6yICN3fGevJq6YjcwLc3c0Suf3ZRx8scY7KajuJ40tYeNlpGrbsjDFumPXFJblNaE5g8qw09LW3G1nE5m5ZpWYjqO2MV0Or2lvPaPezySxfKBgnG3JwaxYruW4tLfeyi1t1GFGFcj0b8hinTy3ssMKp5UiMWeSM4YjI/iHtUt3LjoJcXlqscB+zRJPGwGwEsJBjHPpS2t7FY3k4MEd2Cn+rdsFGPTd34qvFpLT2RlY5xhBt+QZ6njuMVXsnjgsZZolaZmk+XPVsHAzQ0CetmbOmQQxyC6mkCpMP3ygkeX12oT1Bx2qleFLi51Jd6IsO0IobBPHUEdcYFRf2+9s0/koIvtZ+ZNuQXHGfTOO9V9DhZtSle9MnmsDsQKGXd+PsaLApdg0qJBaXM8rI5K5JLkkMauXkbWljBcwvxKplVC3ytwAwI9OKp3k+3UpLeNylorAFwoLBj14ou5GlNqHVyURlK5+UgHPA7GpeqGrIfLrrRPF5Qm+WMY3KNoU9/54ro/t8kqpexzt5cS/MjsGVUH8X1zXOXNrFc6dazK0fmzHnBxj0zU1q8MOmoiRKY5SRIFPzORxn6UX0sHK73NmGKS5kiuHuwttcSAyxIPn2DqxHc45p02kxXYluRdRwWoJ+zuUI+QHhiOucir3h9rcaRJezqiGJWjDZ+YgHjI9O1RJJ9htftU4wd2UiVgFI9COx9DUKeppyXROJ444medA0OAd6vjeT6rjPPtU62QaG2vrwiN8NtBIxnPB/PHPWqenXLtpsktwpV2Yqq7+MEnGT/nFXbiQrYOp2SeXtdd6/cbuOe2cVTYkjm/GF2sXl2EJhWUyGSSVRnnsQfWuclsZdYmnJwYtpZN/cqORV68t4L+7aWSQGRI3l2uefMBB/I5rUsmsxYqsMimSQks3TcWA+TnsDmhXsTLXc5+wGy3T7OVFwMIMrkEn+I++K0LeaawtkSTdG8mT8r85x6ehpq2wt7pxKVBU8KORkckA+tVLp55ppbmJVKvuBkwdwBH/ANalZkp2RcthbXUU090gtpsKgDOWb1J9qz4ADJCJxJkMXCt155U/pTbG6RIGjkMbsI8BinzHjqP/AK1ZzTsb/YqyOqqS20HBx0GeooSvoPm0OgXV5LqYq/FxPzMhx83HJx24raKwraBpREZUyGzz1xjiuW0J8xB4o1kU5+UnkH057ZrVvJkS5uXuAHumBUKBhMjqNvXOD1pNWGpNlaaeP7QGjUGKEsN2MFTnpTNQS5CyRi5b7LOvnmfG7aR2H50X1xm4hijijDKck7CMHHSpLciZ2jjUIsSbDEQQGPcntS9Ru7M+KBY9MlUDzCpVQSeeOckH6021ljhbzLjKSgHazHjI9femahFmCNoXaScEAHPOOyn1qiYbiPyXeHehbcVfkE981S3M3sWNZYXQWf8AdZPIV+n0OPesGIgxzRpHmXGCCAFb8e1aMiSGJwbqQoMPtAwASe3rTJZd0JhnhWUBcrIvJBz0bv1rZanPMoLYSiya/hfdGJAgCjAB9QR0AxTb5ZLqESSqfPLYkbzMb/Q4P5HFWbK9SWOS1SQQ5bo4IUDHK8e9KpiltpCzrLMBtSOEHIGcHJ6CrSsZNmbHIkbIY75Y2K/6sL8ufQ9qnsY55d8kEKlm+WRFIKuvfHpUltpv+jsHRYpogFzkDgn7xPc1BHE1pKGkUS+WMMsYJ47k+lVYm47U0iijBjhMVw3Dqx+aIf4mshpWbKohEYOQV5LVs3N3NK0jXdqlwuMtIP8AWKD0z3xWe8flSQzRESW7n5fqP4SPWkJla+SSS6ZYzsVQAT06ChYwi4ZhIT+Yoy80oW6fZuJwx6CiGHyZGdjkAZUg4zTM2LDbyKWAYkHp7VoW9uY4/M3Et2FVIJXmQ7VO49asWJmifa/zZ7dcUwRtaF+8lBkJ64I9q9bu/t63iw22lQyWyoohd4C5K47n1rzXQbazkeRr28W02gbSIy+4/h0rudF+zFsp4huHJ7lH/wAaYye4im+1uZ4UhkwMxqmwD8KKfckLfMI7hrlAB+8IOT+dFUB5b+6vrVy8O6dCM9iR6isV4Z4ppIphKgU/dY5H5Vs2ml30n2nYEMkMDSElwMbcHJHXpVAt9qikcSFZMZZOo47+1crdztskZ6sQxyQRnAx3rSeBAf30gVkj+XjOT6e1LZ2rx7JWVORuVm6Y9c1ejtYbpZQtwpUcuQpOPx6Uiitp0Y+zTzLG7IEG1MZG7Py/Xkn8qfDcP9lltsM0jkkscBcjPANX7OSOFkjWTGMOqyDgHOAffis2ykMauFYGMyEjcchsHng03oC1KSTCAJ+7YuSGRtxIU9xjvV9kQzqAxERIDIowqk5LE1X2LNMyqcYJZe2RnoKntYppLRpI2JjRiWdR93+9nNNaohuzuacK+XFHNC4Mh3c9Bgc81HLdNMiNMTmU8jGeM8Y9M+tOmkFrYykp5vlKN+OmCf6noKowt9qhPUTZIAxgvk5KgmhIqUtNBltAITMQ23Yv3c5HX/PNT3YLhXhKoHwXKfKp9qqNamFi08TR7Cckfd+oPvToluHAKru+XAz91fXjuKqxCkaENxHDax3ERDMzbHU9AQRgf/XqWeCOW+3wqCzZ2KT055yaz/JWGxmGWJeTIDDAAHXFRWzyRDfFlt74V36Mo7Yphc3IHt4ZpFZ3dGyBtUYAxjg0lhdRwzu0sbSqQvlqB0SmIsMMBSZS1wwHmhRjavBIFMnC/b23FfJiO9GJPK9QPyoHctz3vmo6WkexJCTJGV+VMe/c0rXIhs4IBIqEsCqjg47j61WngEhd7iYwBlyoU/KoPPXuaaxTdAkQxvXCnbuH1Poakdy69xHLOhwN8uV3AZ6dzjtSqv2tCZZJGBOzaoKheehPv/WoYpo4YY/KjThyqnJyfX8M1e0qC+kingfdKOAzjs2eg9Pc0SY4ItG1P2tEmj8tBtSKMfMMd9o9sdadLJbBoRIYp42cgojF2xnp+P6VmahHqAhELNzHgI+c7c9vyq3Zwppcds6Rx+cr70fOd7FSOR7VKXUso2zNJrab4m+xliwjyQwGcDB/xrqda12OUxx2kSvLsaAKi/MM8ZPuK5mLy5LhZEjlBzgJk/Nxkr+NaWnMn29Lpokt4XBUgthhjt9aW+rGnZWNCW3mg0dU2CF1XhQcZwMcn+lZOnRPDYW5nRo5HuB0GAcdfwq5caoJvtW6R7ktgFXG08c54/nWbq+oIFsridSbeLJMCfeAbncfeqsJtLYTUYnkKxpDP8oLeYT39h0q8lwz6esTNGJEKkArgtn+IH3qjps0t5NJNNIiRzsFROWKgDBYehA5/GrcrRyRRywbpA0gAfb2XgH34qWVF6XHJK8stqlokYLA8EE5YdWA/wAap6u6J5xXzC0ZOAeWIA7Y6Hmpbud1sbSNcyTHhXIwQTnHI5B71JpTNd+bI5DPa7XzgYY5PGD1JOKkfkVkgubqCz8vMIjHl4YgMT7fTvmoFSf+1GVmxJC4jDHoB7e2TXSMyRgxhsiR8uCpAyfvfSsOV4k1O2nEqiJnIKuMjhu/4UJasbdtTrLOKS6t7iFMRufmUfeGOpyO/NOhvJWIt5oEZo4lHl4yUyRgE9/WsZftbSySQGUxwDoGxvz0A9hVm8vntNJMcQZJQRJuQgnPoT19sdqlRtqXzF7HmvKlvvlhhAMnoPUemc1NcalLBbeU8ZJCvscsP3i+mOuaq6EJYY0DNGZp1MmNp+Xv+Pesi/Ie5hGWnMimNMNgHIINOwN6GPE6TX0s0qllKhlznqeq/piraiJbI3F25EisAIg+AB2UL6CqKbIVSQZBCu0gEmAgA6/Q+lRSRiW0t0ZGVmGRheCTzge5PrWlrI573Yt7I7XDtFcLIwALLG3zEnqCO1NitluLcw3XmxuSNyKPmJA6D/Pale0DT2jQxCIF8Mx5zkctn+X0raexs2h53kxF/O2Ny2BnJqL2KSZnYtxAswZA8Lc85ZT6KKqXzMsjB2xJK4XBI3v3zx09KluoodPjVQ3Mv75ok6p6Gs69ZZJYH+55blw7Z+bjB/OnET2JoL42s8bsoHQIMZGAe59a3rKNJY2QGUTMwYN1yx5HJ7VzloJGd2KBgw37AM56/wBa6C3mVra3mt0ENyr+Uyqcqwx19v8A69TNNlU33I75n+3IHPlS3REue2Rxke1TyMITvmkCPJk+WFweByc9BVTWbyJJbRm2IsJ2gMeTn0+vpVS/iEsH7qXfIR8pYEbfY0lG43KxHcagZiN+2Ik7YpIhjcR60kjNPCGvHkQg7SS2OPf0+tV7mNY9O5Yg4LFSvBHTNRz3CRxlmkfBVV+YZyAKrVEPUVvMFzHGsjwxqM7XG7cvb61FAyXN40MyRwNJyJUXGQPX8qrTTIbKAxTKJIGIHUnYe1JbzQSZdpmGOc4+768VpG5lKxR8gefPJBHASHYkvIcAZznFLFqy5Ix5QQbgYU++2e/etFjDJbKbm4Dq7/uyiAAjtk1WltkKNLaxxPv/AIsdPwrQwY6C7jllaO3KobpfKY7TneORj0pJlmZI5bQgsuVkMZ+YY7kVlGVra42SxtLbN825RtJHf8QasXIjhOVneN2bcJoeQ/bJ9D60yR7FpZFmuVbn5S6HBXFPsr0STy2ZLeRhnaRh0wDyf0p0EkUcayl5ZJVPzsqZVueCf5GqNzeRtFcLuYvM+5yQAMDsPxp2E2UGc27DzNxJH8QyCD3BqQ3OUVAm5hyMmnRJ5iO0a4ijG5s81XifzmLBT+HYUiGTw6hcRk/IBnptFa9hNJcFchV46gcmsdclcqM4/SrEMkkSgFu+eKAR1WiWFzqVzIunpvWL74Lhev1Ndjp2j6nEwBtgAO/mr/jXmdrKqTxgAksQB+NeliHRbKLUIzZ3dw1gY0mczYLbjgsB2wT0qkxl+6lewcxSqBcYBKg54P0oqxFpVvDeMYkxEVRowWJypUEHnuaK0SA83sbkrcB2QvG4MRKgjKkcZP41VdZYZ50jRtzZ6x8gA9z3FOeGRZ4I7dGcTEHapwcHoPrV5rR4FLy3MkZIOeeSd3KqOpNcljuuRxRq0aPqLKBt/cgnA+pHp6etQrLFHi3Z3UEbtwThWJ4GO3FPa5S/vy7M0FwQQu9cgY6Y9gKqXEkdvcEO5eRslTjhSO5otYSdy3fQRw2trGXxMcFm9OSR+OOtZ5VxdzhlKAdB7deP0qeKIlo2kUlpSFz16kk8fp+NUb+1d5XmujjcSQing89MUMlaEzobRiyAO5UnfnooA4/WrelwXKxKAAjuNxB6MCMYx9Kf5b2duhWNTdKqqEbtu53H8BVdLu4mhklYs2wj5gf7xwMVSVmFye1mW0ubiOE7xId2OoZW479hUSW62sBilieYE7C2cYPbA7+5rQSBYLuSRY3YhFijZhwmeBx7nNVdWV5NTKK4ieMKojbJJ6BjkVTRJBNd3iW4jaTO5ldsD5VA4GPbvV0A+RDEZAZZEzJ2CLnoPX1qokDvchL2TKjMbMT2Hp9KpXjzRzyOvzK4G0nuB0IFKzHexevDJBKUZEkiWTau8ZK+n51HHaTSTndlDuOA3H5+lSTMs73Dup2gK0fH+sccn8KksbwNG88jbScKqgdCOufxoEaiSfZG4UXLR/6x5RnazdD9MfrUEjILN2jjJjib5c9ZATyMVV01bieciOaLzFbIYnO4561qFDe3VtGrKAGcyAHGVXgn6UbjK+mRS3UE94IMRQN8qF85ZgeMe1NYMUR1McaoV285OB1z6HNE12IpY4bWV1t0lctIFGSR1OPrilnk84rJKymaNhHKjADPHB/z3osNMktXea42W6GRtx2nru/wreiv2sLGD5Y45lDFhG4Ikck8n1wK5U3iWuoNBAj7EywbPQkc/wA6eHkZ0WIiRgmJTgMvP9aiRUXY07RrqeG5jeVwyHMhIABDHk+1XJ0hSG3kKEqHMeV5yOx+uetU3RG05kRXcz7NzjqcYO3Gcnir9wQ6NCivDGp2jb1JzyPbr1psu4y0uvPnZhEqMj5ST7ijb659RzVS4uUW+SfYZI92WOQA2e2e4qtq0ot4Ft4Z45HyRKi5YkjnaPbHU1l21y+o4uLmQNDbx4IHARucKB+tTZg5JFvUTDviniZA7nDFMqA3T8eOtIi/aLxkModic7VPDAHAFWYrRbqVpPLCCBTsAxukJ559qitBLbyfuEi+UBpCTjgenoM1SJeruaMqed5cFvBKfKXbKw4xzkD8P1qUxi3uBGdkdqMlnD/cJ75PX6U69ums7ffvJmbGV3ZzwDjPeqE6SajZMz7oo0ATysg7eM5H+NRuy9okjaj+4lhZFIT7r4IZ8nqPT0rWs7cyiR4ov3kLZDk4VRtyFPqR/WqmpPZy+HIlii/0hGWLdt4A64z361LpJMUMiySBrdIyj/MdxOOOKGuw15mhqQ8u3F8JGaNkES+WDgE84I71zJcNuuZSTF52xicYA9autc/arTyxJu2p8pX+HnAJ+gqpFGs0aJGQYkUgjn7xNAN3VjdinlWL7MyPGgCr8vJbnP5EGmwKsNtNtyWVyEV23dTyfwpjm4tYz50ORJtIVTkJ7/pUFozOPLhRAD85djg9ec0kir9DXkka6gaeF2gticBscqAuMZ/P86xbqd51Xc2yOInYhUB0yOOPwFW5bi5SxnWOVV2OpCrnCKeQPwrKnSW1lkubhUkkEnluWGQRwdw9KdhSehHdyhryVcjzCQGVVzzxhcHqOOackTSRRSRoRIedkjkfKOMj8Kqxs8t/LOScuz7WPRSeR/WphdW8MaOWPlt94LyShwBj9c1T1M1pqMecw38UbBvszqIlx82BnIJ+h71vxx77GIGTLPOThB6LjFc7PqRmuCsq7DCdpycKEB4wPyFSz6hLDBaKZNsbMSW/p+H9aXLoVzq47VkdLu62xmQoQZmAzkEjH0qLVId0IWUYlRQYyi8PjJ59Kc0s80d1JGwZy+/O3GR7/T0rLu57l5YftHzyCQMcnAGPvA/hUpaik0TW1w4jMUCsz5LbRyT759KI7m5ZI9qDcsoeSPdgfNx+lW9OJWeYjbj7xUH+H61YvpIIEtBBjzygZgg5Ynqh+op21FfQrX6COXynjz8v3hz83XP/ANaooZ0tnmmmaZwFXaygEsMdWHTiqcbzW88ioyyRzSFsv0T2x2qezDxfaRbpl1yXQjcAO2T6ULRg9USW80M8KwowkLMXfzFIPPQfTvUDbEj2uqhV4KMgA2+p/GpbWJJxDM3+jPkkgeinn8Kh1NIJr5o2fbEU4wceUcZwfx/nTsTe+5m3dqbK+BhKFMb1YtjOfTHbFC/YJZx9pPl7hncjBh+IPSg7Wj8l+VVv3M2D8p7jPpWTPsETLKGWTPHP6g1cTKe5rW+mpezwW2lx3F1OzERJkYGOTVVhIl7LBKht5Y3G8Y5THse9RaXc3um3cU1tKYrhCGVkPORT9cvX1jWrm/vJUN5Od8jE4DN/tVVzN6E8Nw9wZ1SNpkQEtheAPX61TUJnzbVjvIzJHjg/T3qCO+uVdtsrwykYI4AI9Peo0W6YsxdIpBwGDYBpoTZo2z5u0k3kLIrFAeCexUiqM1tCrowyqscEdww7VXupZmRRcKDLG+/cO4PWpLi8KQsQAT8pB7k+tUQ2WrsRov2dGI4y/bdWepdNwj49fenMPtSLLuw/TmrC2z4XIbB4yOakkq27up2f3jVxEw4BHvUZiaJwFGT0ye1OEbhgQctQNG7pdvvHzce1ehtNcW2pQpqDWPnTxpDcB1yu3qPMx/EOORXm9i1wYzIquFiwWYAkKc8Z/GvT9NsrfXbgXt5ZarbTNgyxLDlGbHJBPTNUhm7i4M8puwgm4AEf3duONvtiirNxIJLkjyWg2qqJEw5VQMD9KK1uSeT6bamySXU3m2eWSYAvVmA7j2FU5XlmuJJ0lWRlXc7EZbLVNeGUx20ecxbSz89z1OPpVQKIdRkn8wlYyRlOFYEYAzXG2ehsNhu3jt3Vt7Owx5iADYPc9aoRh3fbGd7sc/JyB69atXlsfsyyeYSjdFjXJGOxrOSVFl8tvMjUjGeuDS6ktnWaDMsumylWCzQv5sfmfxc8isqzlhEokkYM6EyCPPRh0H1yc1XtpGFzZmKVkTefmHbH8s0skMU1nHdxECZ7grNxgJt5+X61epLehaivkMWoC72uzYYtjgPnHJ69Kk0XzryW5WK1kuUhUSjyk5UKRyQOigc5rMLbkkUlTHcOqgsuOfU1qaPc3Gnrdw2ty8T3EJimeIkeajEfKfYgVaTIuTy3TlbmJ5ndt6kMTyFFQXMsk+qASRRMVGAwBG1V6sTSM0s2qtMY/LjXhUx/B7/Wia5EyRwooSMM25VPzMM5yfx7UrlFKYOl2I4WRmZSuSePx/Cp7gwqGmdHxbBQVY8Jn+FfU+oqvBCtzdDL4aTjdyNo/qatzxtc6rHFJuWGCLMSbuAxGdxPqRj6UIlkRZ49SLEt9nRdpjJ5XcPu+1a2oW1vETsy7EYO3orcZ/Cs6JMzi4LLHvfILDcR64B/mau3E48xpIU+/kICepJ4H5U0rIaGWcJgjm8pdgOS7DofYelNsHnkuY47VDskwm0DsR8xzTNSeaSYR7imyQK0JPy4XGWq/JMkFnb+RIwWRiZJW+XMY7ew60kh3IbUKs93LxJEo6r0AY4wT/nmq9hFuuFTf5wIMuM4Hpn3q3ZmF0SGyG2Cdyzu3YDrgf1qBD9nkTyJCUV3ReMFlb1PrQgEv3SK7lmmTYJX/wBZjIAIAAA9T1ow6RLEkShNxG4HBdT3NUdWR3BJJc7ggQtnbj27VJAzPahmk/ebVVQeo7ED+dRoxmvBMVvUASJY4k+bPO4HAyD24qzeERQyzQkh8hguT93PXPpx1qHSBbG0unkZg9sm95wNwweAMfXg/WqUxuY7RTKi/u5NkiNzx1H060M0jaxUYfaJHkKiJOoCk/ic9akhs1MqKQzRxYbYOMHOc+5q3APJiUQbVkI3tLIMlQTwFHQmqyl90ghlYKMAnYclj3weaXTQVr6ly1lkG/eCzSt1ToTnoT/SnySh5LmZ7dSzgwEK2NnHPsRVZ1S2sRJlxOMyD5f4h3NTWcd1NFskDP8AIZGDjgZ5GRT6jLtrDFdalZ7nyGVdgU+o/wA5pLr7VI2y1jj35MUhIwCq/wB3+QNK0QSSVXPkEW4jwgyVbg59qZZ7HkfHAiQBQQSvrn8aEgLcFqUC7y+xXCrGg3bW4/Qe1Vo4XW5lgUAna+5ycYHvn3qy077FyrI0hPLNjyvU47ZquBH5llNnzNxC+XnuDjJz+dJKxV1shtkt263CA7SE8wIBy2OMDjkAd6k0Q/YXu5JeC8gjUt/B3Jx+lXbi6SDUbYRlFB3eZt67QPWqrLFEbtCG8x0Z4i3UhgMGluF7FlbrzHaHJcpHJFG2eGGeX/Oq9iXudNuZnG2NmSLeg545IFZ1lK81iZI43YyHaR2AzyPxrS8krpohDpFCqAxybsEKSSzfnxTa0EnrdllLyK7064RJNm6TZJPtA2gLgYHfiub1a4aOKUMAAQQiAknjgZ96syiNYYIIPlt1cSOf7wUdD7k1mWjh3M910kbewHG056e9JbCk9bE9iFgUvJId8gKrGT/ER6UzS28qaNplysPLc4XJz8v8qrxTst4rHyofKbdyuT6qT7VLbHzbFv3auzqXUZwQ+ep/wpsi+pYKRvN5MibApaR8k8kg/MT/ACFWjIiWYjZSZeEAPbgHd7GsuJmkknSVDGzDBA5wezH1+lW3Yro0ikA3YkEhGMk4GCc9/pTWq0G3ZjfNeW4mWOU/aHUbn6BFxyT79BWddN542wxk5TJUkMHf1qVQ/wBna4l+ROI2bOcdwTijT4I5rpjKSpjBOegXvSs1uJvmL0SJcWix2z+XJkLLu6ZHbPbjtUeqRyxXtow3M8TCTpzsH86j092Oqk7WKyoze+RyD+VbslzbNOrH5WcEG4xj8uwHrQldl9DNE6OZJQqkFm2A9/Wq0pmtfN8tsSSLhnY8OPT3FVFkkhu50wjNuKq55wc9sVa1K+M+6OEK0ACpu24AI7iiwubQzbeUSRsXLJIvyvjj5f8A9dWLuN2ZJpvKj3jG8HKsM4qtJ5JWR3lYbDjKryT/AEqEXjx26xBA8avtCt1Bxzx6e9OxnzE00A+zTGNJETdkBjnP/wBamJB9oi3TuArHAVFByPXnpUlhqsJTEjMgOEaPYG3YyeCfarF7cyxFYyV8kjCxk4ZB2OelWkiG7mXOLGCWORvtEYBO0Y4YCoY7WG4klmhmZiRlg+D+WKttax3Nq3mAmUvwxb5Tj37CqBsSGjkiidQOPlBwP8apGbZBNI0EqBJTuYfLzyppl7NdecPtMhZiOCetSCdxdlLqMOmecrg1Dc2kskjSmR2gz8uTnI9PaglixTBo/mCnadufWnTQjZD5aqV5BAPNQ/Z/LVtiM6OBnP8ACe1IzDaYymwk5UA9D6UXJECPA5VjlWGVZqvWpkQAI7MvvxiqILq2HVkzyCOgNW4VeRGCNjB6dM0ATzqv3icsKhjWR5B5W7PtV2x0madsuTg+ldTpmjRQlDgE9yaLXAg8PaVdSfJJLIkEoBeNTw2DkZ9ea9lt4Es5Fhm1u+DADIKfdOOhOa5DTo1XB3BccADtXcxQi9Vbm405zM4B4mCCT32nmtErDuM1SxBE0ounmlh27y4wcHoQe4oqvcXks32uKSDy7iUhH5wEReigf1opiZ4l9tG2USIggC/dPJ69AeualS5truBIjFMgA4VVBX3z/jWTI33vKO4M5JQ/eU55/wD11JbxSt5wIEeMAIzYyCa5GdykWLhI3cws5TewCgDPTvxSfZYyXLF5rgHKErjC+9PkyrIEAjlkJy5/hA9PSqcdypICIGD7gGyR5h7U4oUmTwJ5dvbysIwxkxkHABz+pzTrlnAlTeiyearM0Z6A5H3elQ2Fx9oNssqLtWUnZjGOmDRcJghsARyBpMqOTk4GfpWhkDQSzxwySgiNcrF0+aTr834VpW0LQ+VGo34UvI2STk/dOP0rPtYzJDNM6SKUcIiqcKWOSxP0HFalrKxuYo8yyyIRIkadTgcAt2UZ6VQEkolj3xXMjjY3zBerccZ/Osi58s7Qh8wq3zqDjkEcfSta7lEYUwlneYsZJ+CA2OwrHtSguVikJCEhjtxzj1+tSwLEW6BUED7p2O8qRwq+maS7SQpGikeZMS7B+CB2H16cU+Ha93NKZGBjIGByOvbFR3T/AGnVZp7EO6xufKL8cetCQ2ORUiv0a4ZpQhVfL3Y+fHIzVpZJLm9S4WMxhZC/yphcKc55qKQRwW8hWLbJJgrM3JU4w2B+FNt7aSa6to1mkZeFVWyd3r+pqhALd7ma4nk+6++Qh+NwJ4zVppbgWqW5mMpKhQT0Tvn2FaUyMdQa3KPGscZV89NgIG4/qcVRa7gu49Qmt1HyTDy4iCMpjGT6kYzikNEG6SIiMqk0roFcqcEj19gTTjIbe+815QHgOzgDaHI4P4Cq/wBt2sbkqm1sRqB/F6fhVNWUvCJdxVWIxjgsepP6VFyi0Lb99O9wSpIzjPBY84/rTtyShsRqI4W4IH+sfAz+VOjwghM7O0ADYBPBPQfX61bs5FUoGRFjJ8yR8ZPXoPw60JBcmEaxW+xJdnnOplDnKt+A7e1Q6rFdXt68EYTeFO5Fb7zjP3h64HT2pk92lxemYiSS4Ykwoi/KOwbHrj+lBSaB0luFVFZmBGcuz4yS3tSY79CexhlkXerqqcOQB7fzHWorqDz3jljZyhcgtuPIx396fbicXNqyEncokG0cDavT9RV2O3jlsGkmXdcSZZwh+WOMcfixOcUWuO9tilHKTbWs0qnylyUXPXvg1qPdSMqSyhkebkbuC4HTnrWTNeefCRbqwOwpEOpI4yTVvWbprWzt9sMcj7VbDZGB0z14PHSjYadyxZTbDOrgtI8ecOQxLZ5APv8ApUscS7QqsYwcCQ7uFbOdv0xWcjPfWTPI8MDbh5caKdzk88f41oXcbW2l6eZnDeZKdzLjG84GMdxjHNEbjbIJC5DupR0mkIlwcsFHCnHoDzTFU3csqhTsXKoWbhRxkn371o3ot7eN18xMkmSNR1B9GP8AdFZcojjjtSQwuGZtyrypBUH9eoNGgbEqyt/adwo2Kv8Aqtx6JH3P5USsvnvtYSRlfJWbp8me2emRVRwLcSsAhbKKsQbnHv6nnmnatJJZzW0O3liG2kZGcDOfakgb0IIryTTbmO3QcXDhghOPl6YrQciTw8spjLL9q8sRhuWUdF/M1iXJMs8DsjEEERc9/wDAGtbULiGPTpoFIQFQiYGNpAHzf1z71VjPmKwt90c1rJOFVHZ3IOTuI5Uep6VTmukj04OiBZLeNFWPbnBZj19feoIZSs8Jd/3uArALwAemPU+9JrBNlDFOGVoriHbgnqwY8n3xTS0E5a3CGOGdTK0pG4ZldOSSOMAelaFpNEm9mARAAiDby3HBHvWLpltK0UEdqksk0p2Fs4APXj2weta9n5f23cxWUwDHsG6dan1CLLK2rQ2jXLmNNg3MDySx6L7+9PiuVe2kcgJdRkKAcD5f72fwx9KY0slw18p6Pgrnkgr/AAj6UzZBIgMhcv5ZWNgBsZe4Y+vel6GrM1klk82VHJtrghWLDhSxOAR3Oe9MsLowWtwj5/fYU8ZZVBw2P5UxbiW3At1ZngZSWjb09R6H0qTSYo5QIZJJFR9wYgHcCe+PTpVWuY3szViMNs7iWZCN6qZB/Cvf8qtX6BI3gdsxFSyq/G/OBn2zWLaWK+cd7hi4YBuMKOmW9PX1NWEnDzOrspEZ3KxOccdPXFTaxpzaGbDbNI29o5Iem5s8q3JHBqHyZfNfzSAZMqkrcIGHUfWptSeWa7LKGkhBCsyHoetOt4mWZWkzLb7tzwk/Mo9cf4VSRm7EYSMF0YOSVwjqcqSR3/GqdoPMeWF3VZXPyl/4/b2q9dSptCLG4gKfJ5b4UgdCR1BrLinjaVG2CFBjcdw3AexptEkv2WQxJ5gADSluMcADGP51Zi1KUysrRwzwAfLHJ6dgKhlieWWcxyKu07FDDG73x/WqV2oiUKQVlO0gqeMUkrbA3c1IbyCRNlpZ2sbsxOZ2JYH054xTrq5vnuImbEShcFYwPLB9RisCOaR2leQ8Y6AcE/SrlpeNEoZVXnkgGquRcfPfMZFNxDE5xjzCMH8amhuXc79iyR4wVjHGPTFQyG3niEgZCpOSScN+IqsVazmSaFyCORsPahEs1FRI7aVlB8uc7VUdiOTWZJBufDjDL0bH6H1rRN3Dd20ROBJuJIUYyfcVSlVPNOHwlNiIPKkUYLZXtzU2nhju+QkinxqQyEKwzyCP51fiiYo2xgwbqrcH86QWOi0doDbB5HIHHtXQ6fALgAIMEnNclo17bTKLZt8cytgo3r7V3mnQ7Y1KDBHUetXEbJFh8plPRVPQ966yWzXUbp7uK7hMUmCA77THwOMe3tXPyQSXDlYYpHIwSFUnFa9pYXCwgm2mz7xmqJLWpSRzXhaI7lVVXef4yBjNFWNWTbe427f3aZGMfwiimB84W8uLu6jCnzkkJj56HPIqG5uS5DN0HUj3NFwyrql6VJz5rjPqSxwB6CqkUzo29xkxjOMdT2HvXLI6UzZs5EKwiZuQSuwjJGRw1RrJvv1RICxQ7VBb+XYCq1o7TwtPNLshdsfdyzH2piucrBbq+9pMAsMliB0/rQhtmjbQxPeJDbTGXBAVm/5aMxyfoBTZ2lFurMrAhtgI4yucnA+taMkA02yWKBRPezjftzu8hD1Y+5/liq8SO0QgVjNklFkznAI5GO1aWIAaZNLEqxyqtspLjacGQn+HH1B/KrtjdQWkEkpuvK+RlWOMHe56Hk9Mg9fSrcqQw6TaXGZBHHI9vGBgGR/4j9PeucR5GmleeM4I3jAyCQMgfnimBdum3TbJ5AjFFkRACVzjj86gUot/JLIm1WXES45JP/16bcTPHBEs7K0xXBkxkDBJ/rT8R3KQAOpdHDx+uD1z7cfrS9Rl7SYzBouq3JRxLLJ5cSjovck1QjlkFtLDbuziArlyMDcfT2rQ1u4jfQ4YY7gr5s0juFUggADGcVTizkWko8tzGHkA4OQMjn6U2uwErRXcUcE92wkVssiMN3zfQelbkMUunQiY5hdjkuTljxz7AH0rEiaRoGvokJkB2gScIieuKWaXz5I7eW7muZWwQAcA5757AU1ZCN2/cETxOQkbKGyvXpkKP5muXgdUhmdSZGZ9u45UKOOT/Kta7RWs5TK3lSIv7oKcrz97HrgD9azNJt4EnM96Ga3QBtichv8AZ57n1pPUaHval5njmYLAPl458vB5/DmmXXlImUbMMZA+5y5z/wDWFXLuR2Ez+UiuZBK5K4VVPIUHuBVCVHN1IQcRFywLHA246/4VNh3Lys1xEWn4UfMkePuccZPapYbc3uwRhot6fIV7DjP40yxcMJYw5AKsQqpjJAyBz/Wn2twyoJFCC4+Riwbgk+56EelUhFmygMGpWcBZm/ebdrDBQLn5j9fSotVQs0ALb7mZVjRgc7Qx5z+GaILkNcETzhriFm3vu3fKR0GOOOefeorpDb6lLPABKwUqhOcrngH2+lKw7ksW64Y2ts7xp5m3zTwNqj5h+RFWYZPKsbi2jaNI4QpMg6t3JB9ecY7Ut7bpptpaWMTq9zcOzFyMgqQN34f4Vj6jukt3mt8mIsYodhwuRwzH64p2AnQtZTQq0/lrIS3yjlVH8J98mp7JGur3c8YMUacs7fexk8is4pFeXTvKwW2hUKpJwZXxwAPfFWbG5iXc90GWRztUDk5PX8e1ZuOpcXpYto7JbqbRHmvn+5tHIDHGMdif0o1uTatvaxPmS2ASRQc4bqx/Pig3ifYneyWQTMpJuLohSmDj5QOM+5rIeYo3mqD86bP9/wCp64zTByuamrRzS2VskS5jFxtlweckZ49qikuNiXTMCY5CYgO+U5AB78GrOoyvp+h20MBZ7rUVLRMP4IwCDn361X0uOO5tojEqg2+5QW9O5p2sTzX3NfS7cJbm8uQUlaNSZAoKISASCT/EBj86x9WMkc3mqSwjBkJIOIwSASfU9BitCa9mu4re3t96w27EAZ+Ve+T6nufwrE1/zLueOJTiSdVIQPkgE98d8807A2Tw3q+Vpad4JJWxjop5x9femlsWshVC6SxfK7ngHoT+VNnR42gitRg7yj9ye35dal1B4xb3sJwRHAp+XkKc9F/KhITehn2RaUMEYZiKLn0AB6Gs7V5HnhtodpwpfjH49adYeZ5QjPyb/vr/AJ9qfpzJci4jJ6SCQjGcgDnntxSIbNe2uGsdLtbZTH9pmjyWY9EPA57YHNSWd79gvlvYo0n2thlZNy8jH3azLSQ3fmvMgMpAVcHnGeh/Cr0sxhvUtYjlx8wK9BxxUvU0Ww8yytcCSDCQu5b5emT1A+g7UiOq6dlgwjQEBGxySeo/CorF3W1Z3IMm9twPXGMYx+fNaOpGztNMi3geVGN8UJOS7nufYVVrDvc5/a6Th5WwIQuUJznJ4/8A1VJaTRx3JilPyglknQnO4KRiq1mqMk7XBzNghEXoXJwPy5NSI4m1a0jdl8tp/LVtvIGfyPNBmzSfUZ72F4JyNsWHIZQMA4596SJgYUneM+bkrvQ/Lz6+9UZ5Ct/fN8pZG2IcdwfSr+nx+UirJtaRgGJ3DAGc0NFRZW08yLO8SNuWVSny8bj1zRcu7m03Eoyr5bMox+B9at2MkbXMksgx5alsovcnA21QnkjUQsJWk8t3ZiRgjJ4+tCRLIL3ykvHQSMVACq44H+0D61WSwhhV9+N6HJjJ5OehHtVi/gW5iE0UqbMlgxGMmo7lY5LSQscEBVyqEjGetPcS0K8skjonzBmzkdsZ701yqs4VQzD5lH0qKWKSFlQDkDhycjaaZBKPtSs+4FRgY659aQrk8pi3nI2hwGU9lpIIYhNujKqGHHpU0Ua3+2JAFmJwATwfxpt3aXNqo/c/LGdrjHK81SIY28jaGH9yoIkOWIFVGlEQAbIDdR1xWlN9r8mJzEfIU46daqyRpLICAAG4IPagkuTwwRJA9qd7FfnIPc1FGUlUxqBG/oehqg4aA7ULYHv0q0mJQFA/eYzikNss28jjYsn8Hyke3ate0whVlGVPasJGcNtk9MAmtPTH2t5M3y/3T60DNS7sPPAu7TiaPk5rq/DeprIqYky+PmDetZWnSRRJuySnQ0y9ge1uEuLYbVYjK9KpAd3bXcxuD9kmkjZjhthxnFdGl7dbR/pM3/fVcp4HKSJd3l5GZhAoITOMsTjn2rroxBewyS2SGOaMbngznI/vL/WqJI2Z5mMkjM7dyTk0Vb1CNIrrZEoVfLQ4HqQKKAPl3UncaiqJAzP50jMpPLZbp+VLFHDGZEXM0pI2oPuJz39aZPeLI86Z2+adwkB5AJztz6ZpifaI1ICMNww2OQPp71jc3sS3dwIosFzI2flUDAU+1aOm3qWgguvLRlQFAGGd3PzfT096w5UZ5TEzKzsNo29sd/rWhAgYxW5kVREVkkz1WNQSc/U/zphcelxcXOqXMW9Fklk3EsOnIOAPatvSLdvNEqo0kvmFIlU8s2M8DsOlcpazzNeT3KjbLJldvu3pXR6VcPZxyKsnl3HliMFWwwU8E/XFNBc0tSlJkt4ZJmItwylVXdkk/M5+p/pWZNcTpMyrJvj3YQsNoT/Z/LvUr3dxawSuAVMrsNzLkFCBkZ9Dgc1mpIokaOUjywMhj8yn60MBboxQ2yorCdmLFXVuOTzj296ekrQQ2sQ+62WYfxyZOcsey1lBlaYwr8qA7f17frVi9k8y9uHjkYkEcjqoUYC0CNqVxHtbaZJMsIwMZz6n0oihiit53vWBkmGeTwvPT3NUoSLe1nnBLOOIxnnOOtRTyq90sl2TI5QEJ2DU7jublgsl4txAJpH2OMK3yqygcjH055pdDs0kMsgxI0R3yZHQEcKKm0S0ZPNmuWjhhuk2kZP+rAyVx3JPFQ6tdC50a3toIjEcYkRDgr6biPwoAbq9421NrYkXqGUct6D2xVVJXnurZnBZSOFYcL2IHpiqN/GzzhY0YrGBGoxkgjGSfxrTi1Fooo4WCtKhMpbaDtAOMYpXAh1EO90sM0pZVwOed3Hp7CmukSG3ZiWQElic9ccf0qN5ChmldmaV4y+4rgDnmq2os8djbxDJeZS52fwrnv79aAuWtOkb7aPNZj5RZnxzxjk/XoKfZQXN4soIGzcynnAU9zjufSsiPzELJblmkdfLUlfvHv8AmMV09jDEui3MkrMLmBjEcdWJXAI96EBHBDBp80jmWJIIAFdj/Fjk7fXtyaW3nmuGt3kLCJnM6Bhg4XneR36YGax2mne2e3MsPlx43bmBc56cenFaU9z5aTTzFVMsKxRAnlFx1A+tO4Gm88V7DI6RsZY5Wbh8HG0nj2H9axjMYYjDNsBYDdAi8KD6+hz+NVrS+WK1kTeWAhyCOxyOnp1pmkKkrGW43Aud4GeAP/1d6TbYEzyS3NvCjFHlWQ4AXof/AKwq9bi2S2dwzvLGTvftnggD3PrWXBIVmJWMsWPyjOOCOtSXSsIY3GAGG91Xrz0Hv9KTQ07FlZGvLV2lyFLHCoM7h1xz9KmtrcpC1xezrFvH7tHBY8DnAFV4Z1+zRRQQhSW2mQ/MRx29KmuiqWUc83DqzKmM5Iz39aLDb0ILm+DuoeSSRQ+ASuOg5xn8Km0oyS2jwWx25I3bV5C+ufXNY6RySkXFzvIeQokZGNwP8hjvWkpktrq1tfNUeUPOkEZwAPT3xTJual1apb2sdxdSKYZAQFDZOFOOfxqKQAzJPHFtuYwzbWfJjB5U+g4pJLy5khjVpJZWdgI1zu2jGWbH16VasbwK1x9qihmmnjxsXgnPqBxx70wK73jywWwMjBN4+QDBY8+lYtzDcBo0lUpks7knggcAVvwvCy3smySHZHgEYZmbpgZ4APtXNvcfZr1Ygm84wpdsqD1JoBklqsialI3JEeZMZ6gD/Gk8MjN+rA70YOW3cDaFOarxy7fOcEs8gC7T1A/wqfSysV66oePLf73TJFJCLcczw3UyQxbwCrqTz8mOPpwagtYkuZz+88vYSzPnlvpUblDPILVj5RA3HrkDg0y1cQTfIEfzImj+bonPGPekmPodLpxtZHlkit2aCVgN5XG3J4/HOazfEbxxlkUHbDkDPLA/WkjEkCXAhkJiwpYnIG4Y6VH4ndb61hli+SR4gNvZlHf6027oHoijDbOieYEJWQb0Ykc8ZqG0Ch0L9EVnBB43D0qRJjNMgbCBWysY7DGKTUGQ3UEbEDgF1XBAHpQIijLXN20xZhv+bJ6EV0MEyF7JI0DMCwOT8vXgVjaVM6NIixL5Z+UKeRmtGYNBZ20BT97jMjjnq3AyKLXBaMWdxF9pWIL5xcybQcqMH7oP51DayR3FjMpjjWZNuCV4AqZpLdryLygXl2MDxxk1mR3EkF75sbJ8yFGB+6cjBz60bMGyWKW3aN4kjeOb+IDlCPxojnSPyQ6+WhyMxn7wzwfqD2qOOOWS5MaMilQGUgYLfjUtzAssLRuEUjnCvnYe5FURczbhJIfOWRRIrgtkAjk9DVORWW381MZPUkcg1fikkUoVmLogIwe49xTDcCOKQvEjKwP4n2pElaGRkjjYk9c59627m5lu3S5Mw3YCtj+Me/vXPwYuFWLBDA5X2q7bRyRRXIbdyAAfeiwieWE+YyxmRd/qTilj+zGN1nErHuQMAmmQGW4hlVSfMU9/Smx71fy5mL8/d7Ux2F8rCbDgqehJzimw2kkUmXY9eCKuqVcEOgU9OPSka2umuNifMjD5T6VIWFkiuJvkAWRQM56EU+OzuWjAZcDs2elb+n2EnkfMxHqPWum02yhkhGUxjg5HWqUQZyOgyvFcCO6J2ZwCeBXWRxJeP5W5WA7irepaFZrZliq46kE1keHUZdVMduu6NffNPbQR6T4atpLSJJLKMu+3DhUyCPcVdt7G9hujNFbTo+cqVUjB/wAKg0VpLV4mjLFhwV7MO4rQuVuwyssdyke7IBycD0zTHYbdvPLclrpNkuACMY7ccUVHzIxYsSx65OaKBHyWtyxyrHb2OABVqeVvLMkLN823JHY9DWRznjrUsUxTj5iBycdq1qYZrYcat9zXhQSQQyRs3mDeWDHk5449asRXclpG7NFDOXxGjsPmAx8w9x25qlprPd3OVk/fKpMa+n+c0ku0MyxoSyA7nVsgnvxXM4tbmiaZchuU3loIPJGwgAgkipbYyuiMIiACWd3HTjgZqjaASYBJRU6uW4XI7+p9qmuGlZowjoMhQqh+B6Z9+5pDNC6vgjiDYZYyiyRoRwcDoakuLm2juocR7NiK+ADjPXB/Gq4uFmvTgeZ5QCoyYySP5ioNRke4uvMjnDfMG2sNoyp6E96YDfMZ1SVo2cs+5nPXrzj2qbTYYz9vlaMSLGowSe55I9yBzRaMsd058xYyvIYvgL68d81bmdGghEiFQq7gyAA/N6+uQKAJdJVZdLuTnc3OB0JT2qncO32mV2UNGAg2qeR04FTW7La3FsVZRGIsnHfJ9frT5U2xoXAysjBsdGyBjmhgaD3ONOkVZN/kAFTtyUzn5RRpTo8SXkucBOEYZywOc/nVOxdVgEUY3rcAhmftg5H61PI4gtLqYbIoseQqdCw4LGmh3KekqP7Vt2kcz+Z80gHcls5/MUMxa4u5HIkdmIEY6EE459KhuZBDdMbWTMKsuHxj5c8LUuoLm+1DylCCRgoKc89T/wDWpBcmkSNraLMjSBIgGY+mST/hWS8u2eRjKS6JsjA/z6VdLwLFJHDuBO0nPOMdB+fJrLeQyHeM5LfMQOpPpQJs0tIVZDHLJGylX3qQcl8A9Pxp001wkSWduSm0lpCTyHY9T7+lJNcLFZsVjMLom1VHJUk/eB/z1qC2y8SJECMgb3bkjnJLfTtRYQ8xwwTBGVWdyFdgO47VLerIzNNqIEMSqAsI+8+OOB2qGbaJZJUBCM2VHQqPX6mnmQ3Lx3EyiMMdi7j1A6sf5UwJIW+z+ZIyeW8vKx4ztXHH+NQrticx7mLuCXPop4wT60Nds92VEZIzyF68+n+elJeSW08TpAXMjYHX0/pQMv6rMILWIW+SzwqSQPu84xmoZnnhvIw6l44UV8KPvcD+XNQXEjERshOFQIRnjileTcIZ3LupBUoDjPoAfoaALhWSK1iaKVnR28xyBhl9AR1FGrTiPTrWIupCEtlupxyePrTQ8jXESoA7BwQy8FABgBqr6o8d5eSBovLiVCD7888+9LoBXs3aZ5LiUn5Rncx9R0ArV0mGCK3m+3u7XExDBUGflznBP8PvVFCr2sccCZG7L/KfkUdD+NXHWS2tZZooDmQCNGb+InryewoQEUd3JJtUjYsz/OEHLIOgJ61t2sSRoHD7ol5LMeZG6AA+grGsITJM00oCIPlDFhjA7D61q3MzXEVmApEMakBlGOfShDRJrMz/AGDyml8yV5OSFwFI7Vy10E824miUL+727WbIDc5I/KtS7k+0WbrCSzIckZx1NZ+pgRqtu67mRSxOT1I4/SmJ6jbQhVeVMHfGihiP9nmnIphsY5cjdPIIyD2Uck/niq80zR2NtB5mFVRxjoR2q7F500ohYLKtz+83HrHjoRSYhLSOYBJETERJbgcsBwfwpGuY5PNkWJIgsgIX19WPtV60uNlwzRxsiAGPk8IO/wCdc1LIwvZUVysAxn3FDVht2OltSJrco7OsITdJJnIHfiqcZa54uV8sSIzQk8YGDgH24q3o8scltJOUwACvrnjAAFVWuc3WXhyFURDn1GAaErIG7mbnfaLO7gsp+YY5GOx/GmTPsuYyw2syLu3dMGktg0m+DBwxOfwqKTMqSu5+deAf0A/SkTc1PMZYJIYGOx8Ydv4j/wDWrXsWA0y6UJ++CFYs9x3Y/wBKyUlMVrHNxutiG2H+NyOPwFOiZ13bWYyTgo3PC92P0qkFx1lORboHLK7hhn+uaiuUgG1G+Z5Fxge/epreaGaeKOP5beNSEHdzjqfxrPRi5MrjfLkrt6AUxNil2MIto2O4bo0G7KnFMtQ0ksUcrnepwGU8KPQ1LpXl+VKjttypK8chh0NIYU+z/aY3xN3Qdz60ElaGT7LeTecmI+Yyp/KnPHIts0bk5iG7noQakDJqEMpYD7QXwy+vvVry3mtpS4/eJIE+qgUCMMspmXYdp6gVrrM8VvCrPkNk5PtWTHEXuGkYYGSavEMdNSQ9EYqBSYItQb2ffEwB7j1q1BbtHIrS4YHnNZUMMwRNudxrbgieeRI4wSQPmNBSLNtCpmEqx7lbjJ6CrsMP+kFYG5znA7CrMRjtbfytu6U9h61t+GdLCu0snLEZ9hVIGPtrNpHg4wRWvHYNuH3lPsamki+aNlH3etaMUyoq7sg+mKokw9Ts7g7Ej3fMf4q1vD2ix2SeY43SNzk1bjSSefe/Cg4FakYwo46cU2gL2j/IJ1idY7hlHls3HfkA9jU/2XVA6ESSD5s7jKMfzqCyiiZJprhWZIgPkU4yScCpHgiuFaa03AxL+8hY5wD3HqKkaE1AI16zxEHIG5lHBbHJH40VLfRJFc7Ihhdin8xRVWEfGBGKQHGfek3UhIr02YIngkeLLxn5hirAl83Do6KisD5RODn+tUo28tg2Nyngj19qtxW8bSJLbuHjU72R+GQD19fwrGpBS3LTaNO6hWFYfNkVVYb8Ab9znqfwqvGwEbhF8zPVgefwqtPfOlxIuEkg6iNxxg+npTrfURAC0NqkKnqwJJ/DNckqPY0Uy3DttYmmlwpYfIhYZJ/pVMMSGBUgA7hg5z7VfaRLwPEABchN6MRx7j61T2NFEGKlpWOWJ7A8cfSsXCxopIkWTzYwGUM+R+X/ANatHU4JlhsUt03C4iUxBT94KdpFY+C6ttIG3nPTJroNJnS+0/ynTFxExeN/Qcb8fTg4qR7iWNuz23kyLmSI7Se49qS8cvaxYI5491IPBplmXj1GW3Qby4Y7h0Yjkmp54GOyQKxh/jGeM/0NNjGTGSzuiuRuYhivQ80utzYjEQ2yH5OcdM8mmBVkkD3DEyAHYWOS3pT73i1xgCTYrBuueSOaSAr2ynLEfMEfKKTz9feraXJEBZVEk5JlLHqPoPWq9sRHGA5YMQeM8VWluBDe4iX5Sowp4IH/AOukJuwt1M0qkQqWVhhgOMHNJZsIbVisasR8ybjkAjpn1qtETueRBIUXlm9Cex/pWkrAQp5gTZgucDP0FAEc2XcNLJlzh3XpuJ7ewFRSXZkuMqRH2KHgN7n1qMymcNtHzMQWZegz70NEpCbfvOSpOOoFNCuSxyPKCgbajEYIPapdUPkGKNDhwB75A6cdv61Eq+XG7FTuUgZA4PHf3plvbSTyb1WSUEgBedxPYUDTJ9ssweCJAhf5nkPDbcc80ltHBCsUrnMrOAIyh6VfiilgkeSaEx5+Z94DHPYVmS3E1w37wyrIc7Tt+4ueaLBcmM3m2r71KbX2Mw4ABp8HnSwuUXEeVGWXpjof6VVtLdppJl8wMkqswznJK80gnZ45Ixu2zAAnPOB2p7Bcka5eASTIpEu0qzE4IHqaW1kvL2FTPM/lKnG5sL7VDfGQpFbMQGnZQcj+Ef0qFyZ57eBjtRTkY+7gd6ViTegdxDDBI7+XtDSYPMhI6ewFTa6weK2ggHyBQMcnZn+pqKSRYrWLbMNxycY5J9arQSytOm7Y0gYszZ4JP+FMs0dPWFCY8YkJABPQe9dBZR+dFbRwN5dpbbsyHueprGto2klE04AjQgtjoB2NT6jqKXSuiO1vZIMAHjJ9cU4pJDuY8jyTNLsG1AS2/wDH+VQtEZLmXYRN5mBvY4981I0rz2LIgMcCsRhf+Wh7ZpbEw+VMzlA4UqC3AB9B6mgkyr1fM1GSKQkDcHPHUGrXnbDaiJ9oSQBhjnFU9Rk8u5V/KLBogmD1471Fp7NGS7HcXyOGyR70CvZmxeTR20E8B3Hb+9Yg8knoPpXOsfLn2M2QwDEentVq4YtCSd5YLgOf4vaqAEkt+iry2AWpbkuVzp43U2wKvsjBDKg4x6mprq5hj0tPJSFppJQQxPzDFZ5nP2mOPZmJV2s3aq0aIqT3Fww3R/LHH70BzDLV44pJ3didm5sD1IP+NVFIWQRruwBnHvUaJ5cbtIcM+N3sPSrduA1wGxlW+6P8aLCuWEkSB7PzFZwr5bng81cKtJdTFcgSNhcjoKhEYl0+1uX6AsAv97nOaIp3hSaRgN0nUE9qYXLLRmIsVKkRIcOvRj7VWtxLJKXZQGUZK9mqyt0Y9PubVVDStGCT6ewqK1hLW0czsFfHTNANlSSR1lMibQ45A/pU8m1rXMA4Zd2fT2qrf7UG7B/Co7ObbbyAkkZBGKBFfTdwvt27aCcn8Kvw3Lt5hMmCGyvHWs+z2Ey5zuwNpNW7OQlwjDcWVh+NACuFEcskSkBh8yjnHvS2vmENF95JFHHvSFjEvmocMP4cevarkMaq3mx/cA5H900gG2byo25ycfdC+lbOnXBR8RqMnuO1EGmGXDAff+Ye1b2m6C7APj3yKaRWxY0yw80iWbJJNdZpiJBFg8DtVOziCQbCvzDt61pQxNJtUr0qkJst26idicYAq2lsGYFuRS20YiUcYz2q3wBxVCGoMcDp2q0gwKhiG4/1q0qjsaLlIltZ3t5CyYwwwysMgj3FNspHjkM0bbXYk/8A1qs2MIk3s6hwCFVM43MegPtVqF2eWSEi3kRAcIE2hsddp6g0kJlaeVriYyuFDEAfKMDiinzRCOYqpJQgMpPXB6UUxHxaUbuCKTafetqZE3fdX8qgdFz91fyruU7mbjYyzkcZ49KaNynIOD7VoOoyeB+VMcDHQU3qISOZJYxHJEpcfddfvfQ+ooEE0zMZHJRRhif4fwpOxrVl+7Ae7RHJ9ayloykVbdIvl8uTM64GTwAPWtSdPMtEaYbC3G8cbiKyYwBFLgY+U1qqcvCDyPLHH4VhUWpUTLvrZiVEEm5ScYVcYqSGSe3I+zNtaPlcLznvk+lWrT/Wt9arSki/kAOBXOzVI1kBSWC6hj/dTHMnzcRPjB49DU8dxssktgX8tzy2DjdngkVVtD/osg7eWTj3zVWdm+wycnqO/vSZQ66kVLhVBzscMpPHXqKfe3LSSYGdpl4U+m3j8M1Tu+VcnrlKjvidkxz/AMtB/KkBtBYrmKAn92Qm92z0I4P51mx7rm6ZcKC7naQcYHfmtDRlDeHpCwBO5Bk/WqVwAL63AGBntTJZWtVyJTG5aNQNzY++egzVyWQzWbuir8oKnHbHeqc3y2TY4/f9voamt/8Ajzt/deffmgaJ5FjhtdkI2oNpJxzkjv8ASrN0qLCEV/ljA+YDt/jVW4J8ycZ/5Z/1qzqfGnZHB8wUITRFLFJFZqpRlEhAVc/ep1qXa4jiL7SG6g9/8BU+SVgyc8/0NVbX7sX+6f8A0KnYkr6pdSmSW2ZAqlw/uBj/ACal0qKRJIhFMQN2T3yOpqs3MuTyS56/WtHRgPtD8dj/ADpdR3HLdp9pQmNCAQeVAPvSRIi3jo8Ue2Mk4HcdqbZgGa4yBxml1Pi+uMU2NMp/aVa+klkijKxqTyScZq1avNJbj93HEHBKqqAce3eqEoG4cDkrmtl/9fD7A0IlO7JJgLbToSSrMQSxJ4C+lVLJHvXM0qHaByFHX0AFM1n/AFcA7ccVa08kPFgkfI3T8aRTLNuZplChle3RvnbOMnsPelvWjmkVDEy28S4w55d+5PtRpX/IQsF/hxnHbNal+AdOhJAyd386tajOYublLZcAhlBwo7Z7VBbTrHEY5ADg5HHTPeqjf61R23VJc/8AH1L+FQtSWxupylrYBMHZnnoRVW2fZFCG+UgNz6k0/wD5bSjtsNU/4h/ntVEt3LluzQQpIrhmbqhGV/KrMRtprpfLU20u394M7lJ/pVO36w/7pp1l/wAfc/8AuigRfljMRMbOGYA8L05qtcKIY1QDe+Cxzzz61YkA+3HjsKo3pwlxjj94P5UARMQZI0P+rj+dj/eNX9PVp7h2+7Eqlj7istvvP9K19P8A+X3/AK4r/Oga3HXExIiijPGGwPRaiiGHUFN0h+4PcVGP9e3/AFzqa26g98daALRiEEBuc8Hjb3JqtCzbAztgnnb7VNcH/R1/3aoj/Xf8ApCLV5i4CrEQwaq8sQgVoYxyerUtj/rR9Kddff8A8+tJ6AVbdcS3OD90gA+lTopiePAydw5PrTIv+PY/9dTUs/8AB/vCmASoElly2H3BQuMjFWbJlD467vve9R333/wFJY/69PqKQHf6HG7FTj5T0HoK7W1hVYlEa8kciua0P/j1Suy0votaodyMwtwfLHtntVy2Udc8ip5fuH6Uy3+4KYiyFGATzT1XcMCkj6mpo+lA0OjTAxU6KPemJ0qUUmMtWkgj3I52K2CHAztYdDVsKqlnxbxFgcyLJuxnrtX1rOWnHqaaQrk1zJ5jlo14ACop9B0zRTR3ooEf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17818=[""].join("\n");
var outline_f17_25_17818=null;
var title_f17_25_17819="ASGE guideline droperidol";
var content_f17_25_17819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the use of droperidol for endoscopic procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Use only in select patients with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anticipated intolerance of standard sedatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anticipated long procedure time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain 12-lead ECG. Droperidol is contraindicated if the QTc is prolonged (&gt;440 msec males, &gt;450 msec females).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients should remain on a cardiac monitor during the procedure and for 2 to 3 hours afterward",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use with caution in patients at risk for development of prolonged QT syndrome: HF, bradycardia, cardiac hypertrophy, hypokalemia/magnesemia, on other drugs known to prolong the QT interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dosage: in adults the initial dosage should not exceed 2.5 mg. Additional doses should be in 1.25 mg aliquots to achieve the desired effect. Maximum dose: 5 mg.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Faigel DO, Baron TH, Goldstein JL, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002; 56:613. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17819=[""].join("\n");
var outline_f17_25_17819=null;
var title_f17_25_17820="Percent of median classification of malnutrition";
var content_f17_25_17820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methods for classification of the severity of malnutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         0",
"        </p>",
"        <p>",
"         Normal",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         1",
"        </p>",
"        <p>",
"         Mild",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         2",
"        </p>",
"        <p>",
"         Moderate",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         3",
"        </p>",
"        <p>",
"         Severe",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         &nbsp;Nutritional",
"        </p>",
"        <p>",
"         implications",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WT-for-HT, percent expected*",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;90",
"       </td>",
"       <td>",
"        &lt;90",
"       </td>",
"       <td>",
"        &lt;80",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td>",
"        &nbsp;Wasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HT-for-AGE, percent expected*",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;95",
"       </td>",
"       <td>",
"        &lt;95",
"       </td>",
"       <td>",
"        &lt;90",
"       </td>",
"       <td>",
"        &lt;85",
"       </td>",
"       <td>",
"        &nbsp;Stunting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MAC/FOC",
"        <sup>",
"         &bull;",
"        </sup>",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;0.31",
"       </td>",
"       <td>",
"        &lt;0.31",
"       </td>",
"       <td>",
"        &lt;0.28",
"       </td>",
"       <td>",
"        &lt;0.25",
"       </td>",
"       <td>",
"        &nbsp;Wasting",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WT: weight; HT: height; MAC: mid-arm-circumference; FOC: fronto-occipital-circumference.",
"     <br>",
"      * The percent of median method is also known as a modified Waterlow method.",
"      <br>",
"       &bull; This is also known as the McLaren method; it is used to assess acute malnutrition in children younger than three years of age when accurate measures of height and weight cannot be obtained.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <ol>",
"      <li>",
"       Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972; 3:566.",
"      </li>",
"      <li>",
"       Waterlow JC. Note on the assessment and classification of protein-energy malnutrition in children. Lancet 1973; 2:87.",
"      </li>",
"      <li>",
"       Kanawati AA, McLaren DS. Assessment of marginal malnutrition. Nature 1970; 228:573.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17820=[""].join("\n");
var outline_f17_25_17820=null;
var title_f17_25_17821="Diet and stoma function";
var content_f17_25_17821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary influences on stoma function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Increase odor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asparagus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brussel sprouts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cauliflower",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cabbage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eggs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fish",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Onions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Some spices",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Increase gas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beer, carbonated soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brussel sprouts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cauliflower",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cabbage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corn",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cucumbers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mushrooms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radishes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinach",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dairy products",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Thicken stool",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Apple sauce",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bananas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cheese",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boiled milk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Marshmallows",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pasta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Creamy peanut butter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pretzels",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bread",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tapioca",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Yogurt",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Loosen stool",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Green beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fresh fruits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Grape juice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Raw vegetables",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prunes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spicy foods",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fried foods",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chocolate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leafy green vegetables",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinach",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17821=[""].join("\n");
var outline_f17_25_17821=null;
var title_f17_25_17822="Contents: Substance use disorders";
var content_f17_25_17822=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Substance use disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Substance use disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Alcohol abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/22/2409\">",
"           Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4361\">",
"           Ambulatory alcohol detoxification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/17/42265\">",
"           Brief intervention for unhealthy alcohol and other drug use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/13/15577\">",
"           Identification and management of alcohol use disorders in the perioperative period",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/8/17544\">",
"           Nutritional status in alcohol dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/48/19209\">",
"           Pharmacotherapy for alcohol abuse and dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41847\">",
"           Psychosocial treatment of alcohol abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug-specific abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32970\">",
"           Cocaine abuse and dependence in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/24/22920\">",
"           Methamphetamine abuse and dependence: Epidemiology, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3784\">",
"           Opioid abuse and dependence: Overview and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1191\">",
"           Opioid detoxification during treatment for addiction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/33/27160\">",
"           Prescription drug abuse and addiction: Prevention, identification, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/24/25993\">",
"           Screening for unhealthy use of alcohol and other drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29514\">",
"           Treatment of opioid abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/55/2936\">",
"           Clinical management of substance dependence across the continuum of care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41177\">",
"           Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36521\">",
"           Dual diagnosis: Severe mental illness and substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5562\">",
"           Impaired healthcare provider",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/16/2313\">",
"           Motivational interviewing for substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/19/9529\">",
"           Non-hormonal performance enhancement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36535\">",
"           Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/58/5033\">",
"           Substance use disorders: Principles for recognition and assessment in general medical care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29993\">",
"           Treatment of co-occurring anxiety disorders and substance use disorders",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-D354C4241B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f17_25_17822=[""].join("\n");
var outline_f17_25_17822=null;
var title_f17_25_17823="Apical 4 chamber TV prolapse";
var content_f17_25_17823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid valve prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view of a two dimensional echocardiogram shows a prolapse of the tricuspid valve; the arrows denote the superior displacement of the septal and anterior leaflets of the tricuspid valve. There is also mitral valve (MV) prolapse; tricuspid prolapse almost never occurs in the absence of mitral prolapse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_25_17823=[""].join("\n");
var outline_f17_25_17823=null;
